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ABSTRACT 
 Human Epidermal Growth Factor Receptor 2 (HER-2/neu) is a breast tumor 
antigen (Ag) commonly overexpressed in 30% of breast cancer cases.  Both HER-2/neu-
targeted DNA-based and transgene modified dendritic cell (DC)-based vaccines are 
potent elements in eliciting HER-2/neu specific antitumor immune responses; however, 
there has been no side-by-side comparison of these two different immunization methods.  
We utilized an in vivo murine tumor model expressing the rat neu Ag to compare the 
immunization efficacy between DC transduced with replication-deficient adenovirus 
containing neu (AdVneu), to form DCneu, and plasmid DNA (pcDNA) vaccine.  DCneu 
displayed an upregulation of immunologically important molecules and inflammatory 
cytokines expression such as IL-6 that partially mediated conversion of the regulatory T 
(Tr) cell suppression.  Wildtype FVB/N mice immunized with DCneu induced stronger 
HER-2/neu-specific humoral and cellular immune responses compared to plasmid DNA 
immunized mice.  Furthermore, mice immunized with DCneu remained completely 
protected from tumor challenge compared to partial or no protection observed in DNA 
immunized mice in two tumor animal models.  In FVBneuN transgenic mice, which 
develop spontaneous breast tumors at 4-8 months of age, DCneu significantly delayed 
tumor onset when immunization conducted in mice at a younger age.  Taken together, 
we demonstrated that a HER-2/neu-gene modified DC vaccine is more potent than a 
plasmid DNA vaccine in inducing neu specific immune responses resulting in greater 
protective and preventative effects in the tumor models examined.   
 In another study, we examined the use of a DC-based cancer vaccine involving 
the phagocytosis of apoptotic tumor cells expressing heat shock protein 70 (HSP70).  
The dual role of HSP70, as an antigenic peptide chaperone and danger signal, makes it 
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especially important in DC-based vaccination.  In this study, we investigated the impacts 
of apoptotic transgenic MCA/HSP tumor cells expressing HSP70 on DC maturation, T 
cell stimulation and overall vaccine efficacy.  We found that DC with phagocytosis of 
MCA/HSP in the early phase of apoptosis expressed more peptide-major 
histocompatibility class (pMHC) I complexes, stimulated stronger cytotoxic T 
lymphocytes (CTL) responses and induced greater immune protection against MCA 
tumor cell challenge, compared to mice immunized with DC that phagocytosed 
MCA/HSP cells in the late phase of apoptosis.  Taken together, our data demonstrated 
that HSP70 expression on apoptotic tumor cells stimulated DC maturation and DC with 
phagocytosis of apoptotic tumor cells expressing HSP70 in early phase of apoptosis 
more efficiently induced tumor-specific CTL responses and immunity than DC with 
phagocytosis of apoptotic tumor cells in late phase of apoptosis. 
 Overall, we have examined variations in designing DC-based cancer vaccines in 
two completely different model systems.  Taken together, our results may have an 
important impact in designing DC-based antitumor vaccines.  
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 1.0 REVIEW OF THE LITERATURE 
 
1.1. Introduction 
Traditional forms of cancer treatments includes the use of surgical resection, 
chemotherapy and radiation therapy, with the latter two focusing directly on the ability 
to inhibit DNA replication and cell division (Atkins and Gershell 2002).  Generally, 
these conventional forms of treatment do not specifically target the tumor itself directly.  
However, with the increasing knowledge in the fields of immunology and molecular 
biology and its applications, the area of tumor immunology, more specifically cancer 
immunotherapy, has emerged and newer forms of cancer treatments are being studied to 
address the issue of tumor specificity (Tuting et al. 1997b; Davis et al. 2003).  The use 
of cancer vaccines allows one to target specific defined antigens expressed on tumor 
cells and to induce antitumor immune response.  These developments in tumor 
immunology have stemmed from our increased understanding of how the immune 
response works and the identification of tumor Ag.   
 
1.2. The antitumor immune response 
The immune system is comprised of various players on a team, divided into both 
the innate and the adaptive arms of immunity.  The innate immune response is non-
specific and is involved in surveying the local milieu or microenvironment to provide 
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“danger” signals to work in collaboration with the adaptive immune response.  The 
generation of effective Ag-specific adaptive immune responses requires presentation of 
the Ag, the selection and activation of T cells that differentiate to provide various 
effector mechanisms to eliminate tumor cells.  It is also important to note that tumors 
have also evolved various active and passive immune escape mechanisms to evade the 
immune system (Ahmad et al. 2004; Campoli et al. 2005).  An overview of the adaptive 
arm of the immune response is described in the following section.   
   
1.2.1. Antigen presenting cells 
There are three types of antigen presenting cells (APC) involved with the uptake 
of Ag and presentation of epitope peptides to naïve T cells for activation.  Each of them 
is involved in generating different types of immune responses.  Dendritic cells (DC) are 
one of the most powerful professional APC in the body.  DC are characterized by their 
efficient uptake of Ag, constitutive expression of major histocompatibility complex 
(MHC) class II molecules and costimulatory molecules, such as B7-1 (CD80), and play 
a vital role in immune responses (Banchereau and Steinman 1998).  B cells also 
constitutively express MHC class II molecules but only express costimulatory molecules 
following activation.  On the other hand, macrophages only express MHC class II and 
costimulatory molecules upon activation.  These three types of APC differentially 
express MHC class II molecules and costimulatory molecules and they are involved in 
different aspects of generating an immune response (Abbas et al. 2000).  
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1.2.2. Antigen presentation 
Two main pathways for Ag presentation have been categorized for the loading of 
Ag peptides on MHC molecules to activate specific subsets of T cells.  These pathways 
are (i) the endogenous pathway and (ii) the exogenous pathway for peptide presentation 
on MHC class I and II molecules, respectively. 
 
1.2.2.1.  Endogenous pathway 
In the endogenous pathway, intracellular Ag and proteins are transported from 
the cytoplasm into the endoplasmic reticulum (ER) by first passing through the 
proteasome for proteolytic cleavage.  Proteins are targeted to the proteasome by 
ubiquitination then unfolded and cleaved into peptides 8-12 amino acids (aa) in length.  
These peptides are transported into the ER with the aid of a membrane protein called 
transporter associated with Ag processing (TAP).  The peptides in the ER are loaded into 
the binding grooves of MHC class I molecules, consisting of the class I α chains and β2 
microglobulin, and the interaction stabilized.  MHC class I-peptide complexes are 
transported from the ER to the cell surface where they interact with the T cell receptor 
(TCR) of CD8+ T cells (Germain 1995; Abbas et al. 2000).  The expression of MHC 
class I molecules is not restricted, as all nucleated cells express it on their cell surfaces.   
 
1.2.2.2.  Exogenous pathway 
The exogenous pathway is involved with the uptake of captured Ag from the 
extracellular environment and internalization through endocytosis or phagocytosis.  The 
proteins are enzymatically degraded in the formed endosomes and lysosomes to generate 
peptides of 10 to 30 aa in length.  These generated peptides then interact with the newly 
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synthesized MHC class II molecules, consisting of α and β chains, to form a stable MHC 
class II-peptide complex.  The stabilized complex is then transported to the cell surface 
for expression and potential interaction with the TCR on CD4+ T cells (Germain 1995; 
Watts 2004).  Expression of MHC class II molecules is limited exclusively to cells with 
Ag presentation capabilities such as DCs.  It is also important to note that the fate of Ag 
presentation of exogenous Ag is not limited to MHC class II molecules but also has the 
ability to be cross-presented onto MHC class I molecules (Heath and Carbone 2001; 
Ackerman and Cresswell 2004).  This is done through a process called cross-priming or 
cross-presentation, first described by Bevan (Bevan 1976), and can stimulate CD8+ T 
cells to mount an immune response.  Some of the mechanisms involved with cross-
priming include the regurgitation of peptides and loading onto MHC class I molecules 
via Ag in the phagolysosomes acquiring access to the cytosol through the use of heat 
shock proteins (HSPs), direct entry through macropinocytosis and high concentrations of 
the Ag (Heath and Carbone 2001; Ackerman and Cresswell 2004). 
 
1.2.3. Generating the immune response 
1.2.3.1.  Cell activation 
The activation of naïve T cells requires the presence of the necessary signals to 
ensure the appropriate immune response is generated, either a cellular or humoral 
response.  The cellular response is characterized by the generation of CD8+ cytotoxic T 
lymphocytes (CTL) that are able to recognize and lyse tumor cells while the humoral 
response involves antibodies (Ab) generated from B cells.  The activation of T cells 
requires a coordinated effort provided by two signals (Bretscher and Cohn 1970).  The 
Ag-specific interaction between the TCR of naïve T cells with the peptide-MHC 
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molecule complex on APC consists of the first signal.  The second signal stems from 
costimulatory molecules expressed on APC, such as B7-1 (CD80), B7-2 (CD86) and 
other costimulatory family members, and interacting with its cognate receptor on T cells, 
such as CD28 for B7-1 and B7-2.  For both T or B cells that only interact with the 
peptide-MHC molecule, but fail to receive a costimulatory signal, the cells are not 
activated and become tolerant or anergic.  Upon receiving the proper signals, the 
activated cells rapidly proliferate and are able to begin their effector functions.  In 
addition, the activation of T helper (Th) cells is central to the development of an immune 
response by activating Ag-specific effector cells and the recruitment of cells in the 
innate immune response (Hung et al. 1998). 
 
1.2.3.2.  Cell mediated immunity  
Cell mediated immunity (CMI), or cellular response, involves the generation of 
CTLs that effectively and specifically lyse their target cells.  CMI is generally regarded 
as the most favorable effective antitumor immune response.  The CTL response can be 
generated through a T helper (Th) cell-dependent and Th cell-independent process.  The 
Th cell-dependent process requires the presence of CD4+ Th1 cells, upon receiving the 
appropriate signals, for the interactions between the APC and both CD4+ T-helper 1 
(Th1) and CD8+ T cells.  This is important because tumor cells generally do not express 
MHC class II; however, this is not absolute as a significant proportion of melanoma cells 
in tumors have been shown to express one or more MHC class II genes (Altomonte et al. 
2003).  Activated Th1 cells also express CD40 ligand (CD40L) that interacts with CD40 
expressed on APCs, including DCs, to further enhance their effector functions by up-
regulating the expression of pro-inflammatory cytokines and important cell surface 
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molecules such as MHC and B7-1 molecules.  Th1 cells are also able to produce 
interleukin-2 (IL-2) and interferon-γ (IFN-γ) to provide support for clonal expansion and 
differentiation of CD8+ T cells, either directly or indirectly (Knutson and Disis 2005).  
Generation of CD8+ T cell response via Th1 cell-independent methods can also be 
induced, as seen in virus-infected cells, whereby the APC directly stimulates the CD8+ T 
cell and bypasses the need for coordinated help from Th1 CD4+ T cells. 
Once the activated T cells have proliferated and differentiated into effector T 
cells, CD8+ CTL cells are able to recognize cells displaying a specific epitope on MHC 
class I molecules and mediate cytolysis through the release of cytotoxic granule proteins, 
mainly perforin and granzymes.  Another mechanism of cytolysis involves the 
interaction of Fas ligand (FasL), expressed on CTL, interacting with the target protein 
Fas to result in apoptosis of the target cell.  Previously, the effector functions for Th1 
cells were once thought to only provide the necessary help required in activating CTLs; 
however, Th1 cells are also able to recognize target cells.  This results in direct cytolysis 
through FasL-Fas pathways, TNF-related apoptosis-inducing ligand (TRAIL) and the 
release of cytokines inducing cytotoxicity (Knutson and Disis 2005).  
 
1.2.3.3.  Humoral immunity 
B cell activation resulting in the production of Ab is characteristic of humoral 
immunity that specifically recognizes the Ag.  B cells have the ability to process Ag and 
present short-length peptides bound to MHC class II molecules.  The CD4+ Th2 cells 
recognize the peptide-MHC class II complex on B cells and the cells become activated 
with costimulation.  Activated Th2 cells express CD40L that is able to interact with 
constitutively expressed CD40 on B cells in germinal centers.  Th2 cells also secrete 
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characteristic cytokines such as IL-4 and IL-10, and determine the immunoglobulin (Ig) 
subclass produced.  The IgG1 subtype is normally associated with the humoral response, 
whereas the presence of IFN-γ induces class switching of the Ab to IgG2a.  The IgG2a 
subtype is commonly associated with CMI response.  B cells proliferate and undergo 
somatic mutation of the Ig genes, to end up with B cells producing Ab with the highest 
affinity for the Ag.  Abs generated would be Ag specific and mediate their effects 
through a variety of effector mechanisms such as complement dependent cytotoxicity 
(CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC).  ADCC involves 
macrophages and natural killer (NK) cells mediating the cell cytotoxicity effects through 
the recognition of a receptor on the constant Fc portion of the Ig.    
 
1.2.4. Tolerance 
T cells play a crucial role in the development of immune responses and initially 
undergo a maturation process in the thymus.  The T cells first go through an intrathymic 
selection method to remove non-self restricted thymocytes and high affinity double-
positive self-reactive thymocytes by deletion then undergo a negative selection method 
to remove high avidity binding self-reactive single-positive T cells prior to leaving the 
thymus (De Visser et al. 2003; Hogquist et al. 2005).  This selection method provides 
the mechanism for central tolerance since high affinity T cells are removed by clonal 
deletion (Hogquist et al. 2005).  However, self-reactive mature T cells may still exist in 
the periphery, as some self-Ags are not expressed in the thymus but the T cells become 
tolerant by peripheral tolerance mechanisms such as clonal elimination, ignorance or 
activation induced cell death.  Remaining T cells may also be rendered unresponsive or 
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anergic due to the failure to provide the T cells with the proper costimulatory activation 
(Goodnow 1996).   
Another component of tolerance arises from immunoregulation of T cells 
through suppression from a specialized subset of CD4+ T cells, known as regulatory T 
cells (Tr).  Tr cells play an important role in autoimmunity and tumor immunity 
(Sakaguchi et al. 1995; Shimizu et al. 1999; Sakaguchi et al. 2001).  Tr represent only 5-
10% of CD4+ T cells in healthy mice and adults.  These cells are identified based upon 
their expression of CD25 (α chain of IL-2 receptor), high expression levels of CTL 
associated protein-4 (CTLA-4), glucocorticoid-induced TNF-related receptor (GITR) 
and the forkhead transcription factor Foxp3 (O'Garra and Vieira 2004; Wei et al. 2004).  
Natural self-Ag-reactive Tr cells develop in the thymus and then enter into peripheral 
tissues, where they function to suppress the activation of other self-reactive T cells in a 
non-Ag-specific manner (Bluestone and Abbas 2003; Cozzo et al. 2003).  The presence 
of CD4+CD25+ Tr cells has been investigated in cancers, with elevated numbers of 
CD4+CD25+ Tr cells detected in cancer patients compared to healthy individuals 
(Liyanage et al. 2002; Curiel et al. 2004).  These CD4+CD25+ Tr cells were tumor Ag-
specific and able to mediate immune suppression of antitumor immunity in both an Ag-
specific and cell-dependent fashion (O'Garra and Vieira 2004; Wang et al. 2004a).  
There are also other suppressor T cells such as IL-10 and transforming growth factor β 
(TGF-β) CD4+ subsets of Tr cell, referred to as T regulatory 1 (Tr1) and Th3 cells, 
respectively.   
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1.3. Tumor Ag 
The ideal tumor Ag would be specifically expressed only on tumor cells while 
completely absent in normal cells and deemed critical for cancer cell survival.  This is 
not the case, as early classification schemes grouped tumor Ags into two categories: (i) 
tumor specific Ags (TSA) and (ii) tumor associated Ags (TAA).  The definition of TSAs 
was used to identify Ags that were uniquely and solely expressed in tumor cells.  On the 
other hand, TAA was defined as being expressed in normal cells but aberrant or 
dysregulated expression observed in tumors.  This suggested that TAAs were of lower 
immunogenicity and patients with tumors were already tolerized to the Ag.  For the 
tumor Ags identified, very few TSA have been identified with a fair majority of the 
tumor Ag being TAA identified.   
With newer methods available for molecularly identifying and characterizing 
tumor Ags, modifications to the classification scheme have been made over time; taking 
into consideration that majority of the tumor Ags were TAAs.  The new classification 
scheme was devised based upon the function or the expression pattern of the Ag and 
classified into five different categories as follows: (Tuting et al. 1997b; Abbas et al. 
2000; Renkvist et al. 2001; Davis et al. 2003; Novellino et al. 2005)   
 
(i) Differentiation Ag, which includes the well-studied melanocyte Ags 
tyrosinase, glycoprotein-100 (gp100), Melan-A/melanoma antigen 
recognized by T cell (MART-1) Ag, prostate specific Ag (PSA), 
prostate-specific membrane Ag. 
(ii) Cancer-testis Ag or oncofetal Ag, where the TAA expression is 
limited in normal tissues to gametes and trophoblasts but becomes 
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aberrantly expressed in a wide variety of cancers.  Some examples 
include melanoma antigen-1 (MAGE-1), MAGE-3, 
carcinoembryonic antigen (CEA) and alpha-fetoprotein (AFP). 
(iii) Overexpressed oncogenes or mutated tumor suppressor genes such as 
HER-2/neu and p21ras, bcr/abl rearrangement, p53  
(iv) Oncogenic viral Ags commonly associated with cancer formation 
such as the E6 and E7 Ags of human papilloma virus serotypes 16 
and 18 (HPV 16/18) in cervical cancers, Epstein-Barr Virus (EBV) in 
Burkitt lymphomas, hepatitis B and C 
(v) Unique Ags that are products of mutations or rearrangements 
expressed from an individual patient such as a clonal idiotype Ab 
from B cell malignancy.   
 
 
1.4. HER-2/neu 
 
1.4.1. Gene identification 
In the early 1980s, the rat neu gene was first identified in N-ethyl-N-nitrourea 
chemically induced neuroblastomas and glioblastomas in rats and seemed to be involved 
with the transforming capabilities into tumorigenic cells (Padhy et al. 1982; Drebin et al. 
1984; Schechter et al. 1984).  The resulting gene expressed a transmembrane protein 
with a relative molecular mass of 185,000 (p185) and subsequently termed neu.  The 
human homologue was identified based upon its sequence similarity with the avian 
erythroblastosis viral gene, v-erb-B, and named as c-erb-B2 (King et al. 1985; Semba et 
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al. 1985).  Meanwhile, epidermal growth factor receptors (EGFR) were being studied 
and a gene that localized to the same region of the chromosome similar to neu, but was 
completely different from EGFR or human EGFR-1 (HER-1), was given the name HER-
2 (Coussens et al. 1985).  The human gene was located on the long arm of chromosome 
17 at q21 (Coussens et al. 1985).  It was later confirmed by sequence analysis that the rat 
neu gene identified was exactly identical to the HER-2 gene (Yamamoto et al. 1986), 
resulting in the name HER-2/neu.   
To provide some clarity throughout this dissertation, neu directly refers to the rat 
gene and its expressed protein whereas HER-2 refers to the human gene/protein.  When 
referring to the gene and its gene product in general terms, HER-2/neu will be used.  
The human HER-2 gene encodes for a 185 kilo-Dalton (kDa) protein that 
consists of 1255 aa.  There are 653 aa that encodes for the extracellular domain (ECD) 
containing 4 subdomains including two cysteine rich domains and the signal sequence, 
22 aa for the transmembrane domain (TM) and the remaining 580 aa encodes for the 
intracellular domain (ICD) containing the conserved tyrosine kinase domain.  In a 
similar fashion, neu consists of a total 1260 aa, of which the first 657 aa from the amino 
end is the ECD, followed by the 22 aa TM and the remainder encoding for the ICD.  
Figure 1.1 shows a protein sequence alignment between the aa sequences of HER-2 and 
neu; notice there is a high degree of homology (~89%) observed between these two 
sequences.   
 
1.5. Other Human Epidermal Growth Factor Receptor family members 
There are currently four members of the human epidermal growth factor receptor 
(HER) family, including HER-2/neu, identified and functions as receptor tyrosine  
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Figure 1.1  Amino acid sequence alignment between human HER-2 (1255 amino acid) 
and rat neu (1260 amino acid) protein.  Identical matching amino acids are indicated 
with an asterisk (*).  A ClustalW alignment algorithm was performed. 
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kinases (RTKs), as described below.   The main general characteristics for each of these 
members include an extracellular ligand-binding domain and two cysteine rich domains 
with a short hydrophobic transmembrane region.  This is followed with an intracellular 
domain containing a highly conserved tyrosine kinase domain and a cytoplasmic tail 
containing specific binding motifs for src-homology domain (SH2) signaling proteins 
(Albanell and Baselga 1999; Slichenmyer and Fry 2001).   
 
1.5.1. EGFR/HER-1 
HER-1, also commonly referred to as epidermal growth factor receptor (EGFR) 
or c-erbB1, was the first RTK to be identified as the cellular homologue of the retroviral 
avian erythroblastosis tumor gene, v-erbB (Cohen and Taylor 1974; Downward et al. 
1984).  The known ligands that binds to this 170 kDa protein include epidermal growth 
factor (EGF), transforming growth factor-α (TGF-α), amphiregulin, heparin-binding 
EGF-like growth factor (HB-EGF), betacellulin and epiregulin (Rubin and Yarden 
2001).  HER-1 is one of the classical receptors studied in cancers and is commonly over-
expressed in a wide variety of human tumors (Kim et al. 2001; Harari 2004). 
 
1.5.2. HER-3 
HER-3, also referred to as c-erbB3, is a unique member of the HER family as it 
is the only HER family member lacking tyrosine kinase activity (Guy et al. 1994).  
Known ligands that binds to the 160 kDa HER-3 receptor includes heregulins and neu-
differentiation factors, which are also known as neuregulins (Rubin and Yarden 2001).  
Since HER-3 is unable to be involved directly in cell signaling, the ligand bound HER-3 
forms heterodimers with its preferred partner, HER-2 (Kim et al. 1998). 
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 1.5.3. HER-4 
HER-4, also referred to as c-erbB4, is a 180 kDa protein (Plowman et al. 1993) 
that has similar ligand binding affinity with HER-3 but posses RTK activity.  
Interestingly, this gene undergoes alternative splicing resulting in four different isoforms 
present (Junttila et al. 2000).   Overexpression of HER-4 has also been observed in 
various tumors. 
 
1.6. Functional properties of HER-2/neu 
 
1.6.1. Normal functions of HER-2/neu 
Cell signaling with the HER family RTK requires the formation of homodimers 
and heterodimers upon ligand binding.  There are ten different dimer combination 
possibilities within the four family members, in which HER-2/neu is associated in three 
heterodimers (HER-1/HER-2, HER-2/HER-3 and HER-2/HER-4) and its homodimer.  
HER-2 is considered an orphan receptor in respect to that there are no known ligands 
that binds to it; however, it has the capability of inducing ligand-dependent and ligand-
independent dimerizations (Brennan et al. 2000).  The formation of heterodimers or even 
the cleavage of the ECD results in cell signaling (Egeblad et al. 2001).  The formation of 
heterodimers results in more potent signal transduction compared to homodimers, in 
particular when HER-2 is a part of the heterodimer (Graus-Porta et al. 1997; Rubin and 
Yarden 2001).  The most common partner for HER-2 is HER-3, which has a high 
binding affinity site for the ligand but lacks kinase activity.  
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After receptor dimerization, certain tyrosine residues located in the kinase 
domain are autophosphorylated.  This allows for recruitment of signal transducers and 
activators of intracellular substrates that contains binding motifs such as the Src 
homology region 2 (Shc2) and phosphotyrosine binding domain (PTB) to interact with 
phosphatidylinositol-3-kinase (PI3K), Src, ras-GAP, phospholipase C-γ (PLCγ), Shc, 
Grb-2, Grb-7, Crk, c-Cbl, c-Abl and Shp-2 (Prenzel et al. 2001; Baxevanis et al. 2004).  
This in turn allows for the activation of the mitogen-activated protein kinases (MAPK) 
and c-Jun N-terminal kinases (JUNK) and Akt pathway (Tzahar and Yarden 1998; 
Yarden and Sliwkowski 2001) for cell proliferation.  Receptor endocytosis occurs at a 
drastically delayed rate for HER-2 hetero/homodimers in comparison to the fast rate of 
endocytosis commonly seen with EGFR (HER-1) endocytosis, resulting in important 
biological consequences as a result of the prolonged signaling (Karunagaran et al. 1996; 
Prenzel et al. 2001; Baxevanis et al. 2004).  The formation of heterodimers also forms a 
hierarchical network to allow for various ligands to bind and cross-talk for intracellular 
signaling to initiate a series of events involved with gene transcription, cell growth, 
differentiation, survival and migration (Yu and Hung 2000).  Under normal conditions, 
with minimal formation of HER-2 heterodimers and subsequent weak signaling 
activation, cells grow normally (Baxevanis et al. 2004).  Figure 1.2 shows the signaling 
network created by the HER hetero/homodimers formed. 
 
1.6.2. HER-2/neu involvement in development 
HER family proteins are expressed throughout development and at low levels in 
adult epithelial tissues.  These proteins play an important role in cell growth and 
differentiation.  HER-2 is the most widely expressed receptor with expression detected  
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Figure 1.2  HER Family members and its signaling network. (a) The input layer is 
comprised of the various ligands and the ten dimeric receptor combinations (b) For 
clarity, the signaling involved with the signal-processing layer is shown only for two 
receptor dimers: ErbB1 homodimer and ErbB2–ErbB3 heterodimer. Only some of the 
pathways and transcription factors are represented in this layer. (c) The effects on cell 
apoptosis, migration, growth, adhesion and differentiation are seen in the output layer. 
(Adapted from Yarden and Sliwkowski 2001). 
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in the gastrointestinal tract, lung, breast, pancreas, ovary, skin, central nervous system 
and genitourinary tracts of fetal and adult tissues (Press et al. 1990; Olayioye et al. 
2000).  The absolute importance of the HER-2/neu gene has been demonstrated in HER-
2/neu knockout mice. The absence of HER-2/neu during development causes embryonic 
lethality by E11 (embryonic day 11) due to trabeculae malformation resulting in severe 
heart malformation and nervous system deficiencies (Lee et al. 1995; Morris et al. 
1999).   
 
1.6.3. HER-2/neu involvement in malignancies 
In a normal cell, there are two copies of the HER-2 gene (one on each 
chromosome) with as many as 20,000-50,000 receptors expressed on the cell surface of 
normal cells.  However, gene amplification/overexpression of HER-2 increases the 
number up to 2 million receptors (Pegram et al. 2000; Lohrisch and Piccart 2001) that 
may contribute to disease initiation and progression of cancer (Yarden 2001).  The 
overexpression of HER-2 results in increased cell proliferation, anchorage-independent 
cell growth, tumorigenicity and metastatic potential compared to cells expressing basal 
levels of HER-2 (Pegram et al. 2000).  
In clinical cases, gene amplification and overexpression of HER-2 is seen in a 
variety of cancers such as carcinomas of the bladder (Sato et al. 1992; Sauter et al. 1993; 
Tetu et al. 1996), pancreas (Yamanaka et al. 1993; Lei et al. 1995), non-small-cell lung 
cancer (Kern et al. 1990; Weiner et al. 1990; Shi et al. 1992), ovary (Slamon et al. 1989; 
Meden and Kuhn 1997), endometrium (Saffari et al. 1995; Rolitsky et al. 1999), colon 
(D'Emilia et al. 1989), renal (Herrera 1991), stomach (Jaehne et al. 1992; Kono et al. 
2002a), prostate (Arai et al. 1997; Mark et al. 1999) and breast cancer (Slamon et al. 
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1987; Slamon et al. 1989; Ross and Fletcher 1999).  The commonly used methods to 
detect gene amplifications and protein overexpressions are fluorescence in situ 
hybridization (FISH) and immunohistochemistry (IHC), respectively.   
 
1.7.   Role of HER-2/neu in breast cancer 
The overexpression of HER-2/neu has been implicated in the transformation of 
breast cells resulting in a malignant phenotype.  Gene amplification or overexpression is 
commonly seen in 30% of invasive breast cancers, 50% of inflammatory breast cancer 
and 60%-70% of ductal carcinoma in situ (DCIS) (Slamon et al. 1987; Slamon et al. 
1989; Ross and Fletcher 1999).  The main mechanism for increased HER-2 expression 
in more than 90% of these cases is gene amplification, whereby a cell may have as many 
as 50 to 100 gene copies found in transformed cells (Pauletti et al. 1996; Pegram et al. 
2000).  Transcriptional and post-transcriptional dysregulation account for the remainder 
of the receptor overexpression (Slamon et al. 1989).     
The transforming capabilities were first suggested when the neu gene was 
transfected into mouse fibroblasts 3T3 cells, resulting in cellular transformation and 
tumorigenesis (Padhy et al. 1982; Drebin et al. 1986; Bargmann et al. 1986a).  Similar 
results were seen when HER-2 was transfected into mouse 3T3 cells (Hudziak et al. 
1987).  As well, the presence of anti-neu Abs resulted in inhibition of cell growth and 
seemed to reverse the transformed phenotype observed (Drebin et al. 1986).   
Further sequence analysis revealed the presence of a mutation in neu whereby 
the valine (Val;V) found at aa residue 664 is replaced with a glutamic acid (Glu;E), 
V664E, (Bargmann et al. 1986b).  This mutation occurred within the transmembrane 
domain and caused constitutive homodimerization in a ligand independent fashion 
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maintaining a permanently active signaling complex (Weiner et al. 1989a; Weiner et al. 
1989b).  Other somatic mutations in neu have been observed including deletions, 
insertions, point mutations and splice variants within the ECD that induces mammary 
tumorigenesis in neu-transgenic (Tg) mice (Siegel and Muller 1996; Siegel et al. 1999).  
In contrast to HER-2, gene amplification/overexpression is not observed as one of the 
main mechanisms of neu leading to a tumorigenic phenotype.   
Meanwhile, no mutations to date have been identified in HER-2 that are identical 
to neu that results in transformation (Lemoine et al. 1990; Zoll et al. 1992).  However, a 
single nucleotide polymorphism at codon 655 involving an adenine-to-guanine 
substitution, converting the codon from isoleucine (Ile; I) to valine (Val; V), within the 
TM region of HER-2, has been identified (Papewalis et al. 1991).  This mutation has 
been linked to an increased risk of breast cancer (Xie et al. 2000; Millikan et al. 2005).  
Younger women with the Ile/Val or Val/Val genotype are associated with an increased 
risk; however, this remains controversial as numerous other studies have found no 
additional risk associated for individuals in developing breast cancers with the same 
polymorphism (Hishida et al. 2002; Nelson et al. 2005).   
The role of HER-2/neu involvement in breast cancer has also been demonstrated 
in transgenic (Tg) mouse animal models.  The expression of both wildtype and 
activating forms of neu, under the control of the mouse mammary tumor virus (MMTV) 
promoter long terminal repeat (LTR), in Tg mice leads to the formation of mammary 
tumors (Muller et al. 1988; Bouchard et al. 1989; Suda et al. 1990; Guy et al. 1992; 
Lucchini et al. 1992; Guy et al. 1996).  Interestingly, Tg mice containing the activated 
forms of neu developed mammary tumors at an accelerated rate while wildtype neu Tg 
mice developed tumors in a stochastic fashion and lung metastasis after a long latency 
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period (Guy et al. 1992; Guy et al. 1996).  One of these mice, FVB/N-
TgN(MMTVneu)202Mul Tg mice, herein referred to as FVBneuN Tg mice, develop 
spontaneous breast tumors after 6 months of age (Guy et al. 1992).  The development of 
mammary tumors in these mice share similar morphological features with human breast 
adenocarcinomas as well as the progression from atypical hyperplasia to in situ 
carcinoma and then to invasive carcinoma (Munn et al. 1995; Cardiff and Wellings 
1999; Nanni et al. 2003).  Another Tg strain developed is the BALB-neuT mice, which 
carry the activated form of neu.  This animal model is a more aggressive model of 
mammary carcinogenesis with neu overexpression beginning at 3 weeks of age, atypical 
hyperplasia by 6 weeks that leads to invasive, metastasizing tumors in all ten mammary 
glands by 25 weeks of age (Boggio et al. 1998; Di Carlo et al. 1999; Cifaldi et al. 2001).   
A variety of other Tg mouse models have been created using the endogenous neu 
promoter (Weinstein et al. 2000; Andrechek et al. 2003) and HER-2 under the control of 
the whey acidic protein (Piechocki et al. 2003). 
 
1.8.   Clinical significance in breast cancer 
 
1.8.1.  Prognostic factor 
Breast cancer is one of the most common cancers affecting women.  An estimated 1 
in 9 women will develop breast cancer and 21,800 female Canadians will be diagnosed 
with the disease this year (Canadian Cancer Society, 2005).  HER-2 overexpression is 
commonly used as both a prognostic and predictive factor in breast cancer.  Prognostic 
factors are associated with the potential growth of the primary tumor and metastases 
while predictive factors are associated with the relative sensitivity to specific therapies 
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(Kaptain et al. 2001).  Slamon’s group initially correlated overexpression of HER-2 in 
patients with shortened relapse-free interval and reduced survival compared to patients 
with normal HER-2 expression (Slamon et al. 1987) and has been extensively examined 
by various groups as reviewed by Ross and Fletcher (Ross and Fletcher 1999).  It is now 
commonly accepted that patients with node-positive and HER-2 overexpressing tumor 
have an overall worse prognosis (Kaptain et al. 2001).  As well, HER-2 expression in 
tumors has been associated with the absence of estrogen receptor and progesterone 
receptor staining, DNA aneuploidy, high proliferation rates, high nuclear grade and 
invasive disease (Ross and Fletcher 1999; Ross et al. 2003). 
 
1.8.2.   Predictive factor 
The use of HER-2 as a predictive factor would be beneficial in predicting the 
potential therapeutic response in treating breast cancers.  A common association is the 
resistance of HER-2 overexpressing tumor to anti-hormone therapy treatment with 
tumors undergoing ER-independent tumor growth and resisting tamoxifen therapy (Ross 
and Fletcher 1999; Lohrisch and Piccart 2001).  The predictive response rates for 
chemotherapy treatment have been contradictory as the majority of reports are based 
upon retrospective studies and involve small sample sizes (Lohrisch and Piccart 2001; 
Ross et al. 2004). 
 
1.9.   HER-2/neu as an immunotherapy target 
HER-2/neu serves as an attractive tumor marker, because of its 
amplified/overexpressed pattern seen in a wide variety of human malignancies.  It is also 
an ideal therapeutic target in the case of breast cancer because (i) its functional 
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important in breast cancer growth, (ii) its high levels expression in breast tumors but low 
levels of expression in normal tissue, (iii) HER-2/neu is a transmembrane protein and 
amenable to both humoral and cellular immune effector mechanisms responses (Ross et 
al. 2003).  Immunological intervention using monoclonal Ab (mAb) inhibits neoplastic 
changes and shows tumor selectivity with human breast tumor cells expressing the 
highest levels of HER-2 obtaining the highest levels of cell growth inhibition (Hudziak 
et al. 1989).   
As well, the presence of pre-existing T and B-cell immune responses (both 
cellular and Ab) against HER-2 has been observed in breast cancer patients as reported 
by Disis’ group (Disis et al. 1994; Disis et al. 1997; Disis et al. 2000).  Despite the 
generation of an immune response against a self-protein, patients expressing natural Ab 
and T-cell immunity towards HER-2 do not seem to develop classical signs or 
indications of autoimmunity.  However, these generated immune responses are often not 
strong enough to counteract the tumors as the tumors continue to grow.    Despite this, 
the existence of pre-existing immune responses suggested tolerance towards HER-2/neu 
is circumventable.   Also, HER-2 specific T-cells have been identified in patients with 
HER-2 overexpressing tumors, which indicated a portion of the T cell repertoire is able 
to recognize a self Ag (Fisk et al. 1995; Peoples et al. 1995).  All of these factors 
combined make HER-2/neu suitable for immunotherapeutic targeting with passive or 
active methods of immune vaccination.  
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 1.10.  Passive immunotherapeutic strategies targeting HER-2/neu 
 
1.10.1.   Monoclonal antibodies 
1.10.1.1.   Herceptin  
Herceptin (trastuzumab) is a recombinant humanized mAb developed by 
Genentech Inc. (San Francisco, CA) that was approved by the Federal Drug 
Administration (FDA) of the United States in 1998 as a single agent or in combination 
with chemotherapy for the treatment of metastatic breast cancers.  The Ab directly 
targets the ECD between aa 529 and 627 in a cysteine rich domain of HER-2/neu 
(Frankel 2002).  The Ab was humanized through a series of modifications by taking the 
complimentary determining regions (CDR) of the mouse mAb, 4D5 (Hudziak et al. 
1989) and placing it into the framework of the human IgG1 and various aa substitutions 
resulting in a chimeric antibody that contains 95% human sequences with only 5% 
murine sequences remaining (Carter et al. 1992).  The resulting Ab also has a higher 
binding affinity to HER-2 (Kd=0.1 nM) compared to the original mouse mAb, 4D5 
(Kd=0.3 nM).  It also maintains similar in vitro properties to the parent antibody such as 
HER-2 specific suppression of HER-2 positive tumor cell growth and prevents the 
growth of human breast tumor xenografts in vivo (Harries and Smith 2002). 
The exact mechanisms by which Herceptin acts upon HER-2 positive cells are 
unknown, but various mechanisms have been proposed supported by in vitro studies.   
Herceptin may induce HER-2 receptor downregulation whereby the internalized receptor 
inhibits signal transduction due to decreased formation of homo- and hetero-dimers and 
antagonizes cell division and growth.  Other mechanisms of actions may include reduced 
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production of vascular endothelial growth factor (VEGF), which is required in 
angiogenesis, preventing the cleavage of HER-2 ECD and involving the host immune 
response via induction of ADCC and CDC (Sliwkowski et al. 1999; Baselga and 
Albanell 2001; Adams and Weiner 2005).  As well, improved cell lysis from HER-2 
specific CTL clones were observed when target cells were treated with Herceptin (zum 
Buschenfelde et al. 2002).  Preclinical studies using combinations of Herceptin with 
chemotherapy drugs such as paclitaxel, doxorubicin and cisplatin, which are common 
chemotherapeutic drugs used for breast cancer treatment, has shown synergistic effects 
compared to modest effects when the chemotherapeutic agents were used alone 
(Colomer et al. 2001; Harries and Smith 2002).   
Herceptin has a favorable pharmacological profile with minimal toxicity; 
however, cardiotoxicity has been observed when combined with anthracycline 
chemotherapy (Harries and Smith 2002).  One of the pivotal studies showing the 
effectiveness of Herceptin in a monotherapy treatment regimen was in a phase II clinical 
trial involving 222 women previously treated with chemotherapy.  The overall response 
rate (including both complete responses rate and partial response rates) was 15% with a 
median response duration of 9.1 months (Cobleigh et al. 1999).  In another Phase II 
study by Vogel and colleagues, patients were given Herceptin at an earlier stage and the 
response rate (including complete and partial response rates) was 26% with a median 
duration of 18.8 months (Vogel et al. 2002).  Phase II clinical trials from Slamon’s 
research group incorporated the use of chemotherapy with Herceptin showed dramatic 
increase in response rate, prolonged duration of responses and lengthened survival in 
metastatic breast cancer patients (Slamon et al. 2001).  Similar clinical trials involving 
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patients given Herceptin with various chemotherapy drugs has also shown improved 
response rates and survival (Horton 2002).   
The use of Herceptin as a form of adjuvant therapy has recently been evaluated 
in various international clinical trials, based upon the impressive results seen when 
Herceptin was used in treating metastatic breast cancers.  In 2005, the phase III 
HERceptin Adjuvant (HERA) study reported women with HER2 positive early-stage 
invasive breast cancer given one year Herceptin treatment after adjuvant chemotherapy 
had a significantly improved disease survival (Piccart-Gebhart et al. 2005).  Similar 
results were also reported by the National Surgical Adjuvant Breast and Bowel Project 
and the North Central Cancer Group Trial N9831, that differed only slightly in trial 
design compared to the HERA trial (Romond et al. 2005).         
Although there is much interest and success in the use of Herceptin in the 
treatment of breast cancers, there are a few drawbacks.  One of them is that it does not 
completely resolve the cancer as Herceptin acts in a cytostatic fashion, which requires 
constant infusion of the Ab.  This passive mechanism of immunity is also short-lived 
and the Ab is eventually cleared from the body.  As well, a large number of patients still 
fail to respond to treatment or even if they do respond, patients often will relapse (Foy et 
al. 2002).    
 
1.10.1.2. Omnitarg (Pertuzumab)  
Omnitarg (Pertuzumab) is another humanized mAb recently developed by 
Genentech Inc. that is HER-2 specific and derived from the mouse mAb, 2C4.  This 
novel mAb, Omnitarg, functions differently from its counterpart, Herceptin, in that its 
epitope is located in the ECD region that is completely different from that of Herceptin 
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and functions by inhibiting the formation of heterodimers between HER-2 and its other 
family members (Spicer 2004; Adams et al. 2005).  Omnitarg is the first member of a 
newer class of agents referred to as HER dimerization inhibitors (HDIs).  HDI gets its 
name based upon the mechanism of action mediated through inhibition of 
heterodimerization of HER-2/EGFR and HER-2/HER-3 in both normal and 
overexpressing cells, which downregulate receptor phosphorylation and intracellular 
signaling pathways (Agus et al. 2002); however immune mediated responses may also 
occur.  In preclinical animal models, administration of Omnitarg alone resulted in 
growth inhibition of tumor xenografts while the combination of Omnitarg with 
chemotherapy showed either additive or synergistic effects (Spicer 2004).  The 
combination of Herceptin with Omnitarg has also shown synergistic inhibition in tumor 
cell growth in vitro (Nahta et al. 2004).  Currently, Omnitarg, is being examined for its 
effectiveness in several phase II clinical trials in a wide variety of cancers but results 
from phase I trials indicate it is well tolerated, has a favorable pharmacologic profile and 
clinical activity (Agus et al. 2005).     
 
1.11.  Active immunotherapeutic strategies targeting HER-2/neu  
 
1.11.1.  Protein based vaccines 
An advantage of using a protein-based vaccine is the ability to display the entire 
array of peptide epitopes that would be able to stimulate an immune response.  However, 
one important drawback is the inefficient generation of CTL responses, since the 
proteins taken up by APCs are generally presented through the exogenous pathway onto 
MHC class II molecules and not onto MHC class I molecules. 
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Disis and several other groups have shown that immunization with the whole 
HER-2 protein or the ECD induces tolerance (Bernards et al. 1987; Disis et al. 1996b).  
However, other groups demonstrated an anti-HER-2 immune response after 
immunization with recombinant ECD, though it was too weak to protect mice against 
s.c. tumor challenge (Taylor et al. 1996; Dela Cruz et al. 2003).  Interestingly, 
immunization of with the HER-2 ICD protein induced an immune response that 
circumvents the tolerance observed in rats (Disis et al. 1998) or in combination with heat 
shock protein (HSP) complexes (Manjili et al. 2002) and partially protected mice from 
tumor challenge (Foy et al. 2001).  In most of these reports, the proteins were mixed 
with adjuvants, such as complete Freund’s adjuvant and Montanide 720, to induce 
stronger immune responses against the protein.  In one report, Disis’ group immunized 
patients with the HER-2 ICD protein with granulocyte/macrophage-colony stimulating 
factor (GM-CSF) intradermally (i.d.) and found both HER-2 specific-T and B cells were 
elicited (Disis et al. 2004b), suggesting that the ICD is more immunogenic then the 
ECD.  Several surprising results were also obtained in studies using Tg mice showing 
induction of anti-neu humoral and cellular immunity, prevention of tumor development 
in 50% of mice immunized with ECD protein and delayed the formation of spontaneous 
tumors (Esserman et al. 1999).  
 
1.11.2.  Peptide based vaccines 
The use of synthetic peptides offers an alternative vaccine strategy to the use of 
proteins and has several advantages.  Peptides are simple, economical to produce, lack 
infectious and oncogenic potential and can induce a very epitope specific response.  
However, one major drawback to the use of peptides is the requirement for identification 
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of epitopes that would be able to bind to MHC class I and class II molecules.  Another 
drawback is haplotype restriction based upon the individual.  This process is both 
tedious and time-consuming, resulting in the lack of epitopes identified for all TAA.   
Often times, tumors also down-regulate their expression of MHC class molecules as a 
mechanism to evade the host immune system.  As well, direct injections of peptides 
themselves are considered to be weakly immunogenic (Disis et al. 1996a).  There is also 
the potential that targeting a single epitope would become ineffective when Ag-negative 
tumors develop. 
 In the case of HER-2/neu, a variety of different approaches have been utilized to 
identify class I human leukocyte Ag-A2 (HLA-A2) restricted peptide epitopes (Fisk et 
al. 1995; Peoples et al. 1995; Kawashima et al. 1998; Kono et al. 1998; Rongcun et al. 
1999; Baxevanis et al. 2006), HLA-A24 (Nagata et al. 1997), HLA-A3 (Kawashima et 
al. 1999), murine H-2Kd (Nagata et al. 1997) and H-2Kq (Ercolini et al. 2003).  Both 
human and murine MHC class II HER-2/neu epitopes have also been identified that 
would be able to provide T helper responses (Disis et al. 1999; Kobayashi et al. 2000; 
Perez et al. 2002; Baxevanis et al. 2006).  The identification of these epitopes have 
allowed groups to employ them for use in various methods such as direct peptide 
vaccination with GM-CSF as an adjuvant injected intradermally (i.d.) (Disis et al. 1996a; 
Knutson et al. 2001; Murray et al. 2002) and polysaccharide-peptide conjugates (Gu et 
al. 1998).  Disis et al have also previously shown that although the whole HER-2 protein 
is not immunogenic itself, immunization of both rats and humans with multiple peptides 
derived from HER-2/neu elicited strong humoral and T cell responses (Disis et al. 
1996b; Disis et al. 1999; Salazar et al. 2003).  Although clinical studies using HER-2 
peptide vaccine induced HER-2/neu-specific CD4+ and CD8+ T cells and humoral 
response in breast cancer patients, it has not resulted in tumor rejection (Zaks and 
Rosenberg 1998; Disis et al. 1999; Baxevanis et al. 2006).  One possibility for this may 
be due to the short-lived peptide specific immunity derived from HER-2/neu peptide 
immunization (Knutson et al. 2002).  One interesting feature that has been observed in 
some peptide vaccination regimens is epitope spreading (Lehmann et al. 1992), whereby 
an immune response, both cellular and humoral, is generated to other regions of the Ag 
not originally included in the vaccine (Disis et al. 1999; Anderson et al. 2000a; Disis et 
al. 2002; Disis et al. 2004a). 
 
1.11.3. Cell based vaccines 
Tumor cell based vaccines offer the potential for multiple tumor Ag presentation; 
however, they tend to be less immunogenic as they do not express MHC class II 
molecules or costimulatory molecules.  Another disadvantage of this type of vaccine is 
the lack of specific tumor Ag targeting and the limited availability of patient samples for 
an autologous cancer vaccine.  The immunogenicity of tumor cells may be further 
improved by engineering them to express various cytokines or even the use of allogeneic 
tumor cells (Nawrocki et al. 2001).   
HER-2/neu-positive tumor cells have been used as vaccines to induce preventive 
antitumor immune responses (Cefai et al. 1999; Reilly et al. 2000; Nanni et al. 2001; 
Reilly et al. 2001).  Recently, it has been reported that combinatorial vaccination of mice 
with tumor cells engineered to secrete GM-CSF combined with the use of 
cyclophosphamide (Cy) or with an antitumor antibody reduced the development of 
spontaneous tumors in Tg mice (Machiels et al. 2001; Wolpoe et al. 2003).  More 
recently, it has also been shown that IL-12 engineered allogeneic tumor cell vaccines 
 29
greatly enhanced antitumor immune responses (De Giovanni et al. 2004; Nanni et al. 
2004).   
 
1.11.4. DNA based vaccines 
In the early 1980’s, reports emerged detailing the induction of immune responses 
against transgene products expressed from DNA plasmids.  The first published report 
using direct intramuscular (i.m.) inoculation of naked plasmid DNA for gene expression 
in mice appeared in 1990 (Wolff et al. 1990) followed by the first reported application of 
a DNA vaccine demonstrating cellular immunity and protective efficacy against the 
influenza nucleoprotein (Ulmer et al. 1993).  This sparked a tremendous amount of 
interest resulting in the use of DNA vaccination in a wide variety of model systems for 
protective immunity and potential use in cancer immunotherapy.  
 
1.11.4.1. Advantages and disadvantages of using DNA vaccines 
DNA vaccines offer several advantages for its use such as DNA is economically 
feasible to produce and relatively easy to purify in large quantities with high purity.  
DNA also does not require specialized handling or storage conditions.  It has the 
capability of expressing the Ag in its natural form with the appropriate post-translational 
modifications in the host while not inducing neutralizing Abs, commonly associated 
with the use of viral vectors, to allow for repeated boosters.  There is also a constant and 
persistent source of the Ag from the prolonged expression of the Ag from the plasmid 
vector.  DNA vaccines are capable of inducing both CD4+ Th and CD8+ CTL and 
humoral immune responses specific for the target Ag.  This method allows for 
unrestricted MHC presentation of a broad range of epitopes on MHC class I and II 
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molecules.  More importantly, DNA sequences can easily be modified to remove or 
insert special sequences to enhance Ag immunogenicity (Gurunathan et al. 2000; Reyes-
Sandoval and Ertl 2001; Haupt et al. 2002; Donnelly et al. 2005). 
 A disadvantage of using DNA vaccines is the potential risk of the plasmid DNA 
integrating into the host genome, which may disrupt the functions of proto-oncogenes 
and tumor suppressor genes.  There may also be the ability for the host to develop 
autoreactive Abs and T cells against DNA that may lead to autoimmunity.  Another 
disadvantage is the potential for the host to become tolerant to the Ag with the persistent 
source of Ag expression.  In addition, the possibility of mutagenic integration and 
subsequent tumor development with the use of plasmid DNA has not been fully 
evaluated (Mahon et al. 1998). 
 
1.11.4.2. Design of plasmid vectors 
DNA vaccines require the use of a plasmid vector that contains several key 
elements along with the gene encoding the Ag.  Key elements of a plasmid vector 
include a replication of origin (ori) to allow the plasmid to replicate within cells, a 
selective marker such as an antibiotic resistance gene, and eukaryotic transcription 
regulatory elements such as promoters/enhancers located upstream from the gene.  Some 
common promoters utilized in plasmids are the strong cytomegalovirus (CMV) 
immediate early region and the simian virus 40 (SV40) promoter.  Another key element 
is a method to stabilize the mRNA transcript, which is accomplished with the addition of 
bovine growth hormone or SV40 polyadenylation sequences (Gurunathan et al. 2000). 
Another feature inherent with DNA plasmids isolated from bacteria is the 
presence of CpG motifs, composed of cytosine guanine dinucleotide pairs (CpG) flanked 
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by two 5’ purines and two 3’ pyrimidines.  CpG motifs are generally methylated in 
eukaryotes but remain unmethylated in bacteria.  These unmethylated CpG motifs act in 
an immunostimulatory fashion and considered a member of the pathogen-associated 
molecular pattern molecules (PAMPs) to act as a danger signal (Pardoll 2002).  PAMPs 
interact with the Toll-like receptors (TLRs) expressed on APCs and activates the APCs 
to produce proinflammatory cytokines such as tumor necrosis factor-α (TNF-α), 
interferons, IL-6, IL-12 and IL-18 (Yamamoto et al. 1992; Krieg 1996).   Figure 1.3 
shows a schematic representation of a basic plasmid vector. 
 
1.11.4.3. Formulation and delivery route  
DNA vaccines are versatile in the fact that different formulations and routes of 
immunization are available.  The plasmid DNA may be resuspended in an aqueous 
solution, such as saline, and commonly used for injectable delivery via intramuscular 
(i.m.) or i.d. or even coated with gold particles for gene gun-mediated delivery (Fynan et 
al. 1993).  For i.m. injections, doses of 10 to 100 µg of DNA is injected into skeletal 
muscle cells (myocytes) whereas gene gun-mediated uses a smaller fraction (<1 µg) to 
delivery the DNA with a helium-driven biolistic bombardment device.  Gene gun-
mediated delivery results in higher levels of transgene expression compared to i.m. 
injection using comparable doses (Yoshida et al. 2000). An alternative approach to 
improve gene expression with i.m. injection has been through the use of electroporation 
to induce small pores in cells and effectively increasing the transfer of plasmid DNA 
into the cell (Banga and Prausnitz 1998; Widera et al. 2000). 
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Figure 1.3  Schematic view of a simple DNA plasmid vector.  There are a few basic 
elements found in all plasmid vectors used in DNA vaccines.  There is a promoter such 
as the CMV promoter followed by a multiple cloning site (MCS) to insert your gene of 
interest for expression, and a poly A signal.  There is also a resistance gene, such as 
ampicillin, used for culturing and selecting the plasmid in bacteria and an origin of 
replication (ori), to increase number of plasmid vector copies.  Unmethylated CpG 
motifs are located at various all throughout the plasmid.  Figure created using Discovery 
Studio Gene program (Accelrys San Diego, CA). 
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1.11.4.4. Development of immune responses using DNA vaccines 
The DNA injected i.m. is taken up by myocytes from the extracellular spaces 
either through phagocytosis or pinocytosis; meanwhile, gene gun-mediated methods 
propels the DNA-coated gold particles directly into the cell cytoplasm.  The uptake of 
DNA into myocytes is inefficient as deoxyribonucleases (DNases) will degrade 90% of 
the DNA, and less than 1% of the remaining 10% enters into the nucleus for gene 
expression (Babiuk et al. 2003).  These targeted cells act as a source for Ag expression, 
which in myocytes can last between one month to beyond 1.5 years (Wolff et al. 1992; 
Robinson 1999).  However, myocytes are not directly involved with Ag presentation and 
stimulating an immune response.  It is known that myocytes express low levels of MHC 
class I molecules and lack the expression of costimulatory molecules, which would 
induce immune tolerance or ignorance.  Myocytes also lack MHC class II expression.  
Further proof that myocytes are not directly involved is shown with surgical excision of 
muscle tissues immediately after injection did not abrogate the immune response (Torres 
et al. 1997) and suggests another key player is involved.  This finding was also 
supported in experiments using mouse bone marrow chimeras that upon immunization, 
revealed Ag-specific T cells that were restricted to the donor’s bone marrow and not to 
the host myocytes (Corr et al. 1996; Iwasaki et al. 1997).  This suggested the 
involvement of bone marrow derived APC, such as DC, play a key role in DNA 
vaccination. 
The actual mechanisms involved with DNA vaccine have not been truly defined; 
however, there is experimental evidence to support that DC can be directly transfected at 
the inoculation site, the draining lymph nodes or through indirect methods.  It has been 
shown that a small proportion of DC (~0.4%) in the draining lymph node and 
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Langerhans’ cell in the skin carries the plasmid DNA for Ag presentation to T cells 
(Casares et al. 1997).  This was reconfirmed using green fluorescent protein (GFP) 
reporter plasmid (Condon et al. 1996; Chattergoon et al. 1998) or fluorescein 
isothiocyanate (FITC) labeled DNA (Dupuis et al. 2000).  Direct transfer of plasmid 
DNA allows for endogenous synthesis of the encoded Ag in DC with peptides directly 
loaded onto MHC class I molecules.  There is also evidence that cross-priming occurs, 
whereby DC can present peptide epitopes on MHC class I molecules with out de novo 
synthesis.  This is accomplished by DC acquiring secreted proteins/peptides from 
transfected cells or even phagocytosis of apoptotic or necrotic bodies and presenting 
peptides on both MHC class I and class II molecules (Albert et al. 1998b; Reyes-
Sandoval and Ertl 2001).  The combination of the two proposed methods may aid in 
explaining the mechanisms involved in generating immune responses using DNA 
vaccines (Srivastava and Liu 2003; Donnelly et al. 2005), as outlined in Figure 1.4. 
  Immune responses generated from DNA vaccines generally results in a balanced 
Th1/Th2 response but varies depending upon type, dose and form of the encoded Ag, the 
genetic background of experimental animals, the presence of immunostimulatory 
cytokines and adjuvants as well as the route of delivery.  Studies have also shown that 
i.m. injections tend to preferentially favor induction of a Th1 biased immune response 
with expansion of IFN-γ-producing CD4+ T cells and production of IgG2a isotype 
antibodies.  Gene gun targeting, on the other hand, induced a Th2 biased immune 
response with increased IgG1 Ab production and IL-4 release.  (Pertmer et al. 1996; 
Feltquate et al. 1997; Gurunathan et al. 2000). 
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Figure 1.4  Mechanisms involved with DNA vaccination.  (A) A previous mechanism, 
but no longer believed, involved DNA transfection of myocytes which in turn would 
interact directly with T cell.  (B) Current mechanisms include direct transfection of 
APCs.  This allows for transgene expression and direct Ag presentation to mediate T cell 
interaction.  (C) Another possible mechanism involves the injected DNA plasmid 
entering into the myocyte.  The expressed transgene from the DNA plasmid is then 
secreted from the myocyte and subsequently taken up by APCs for presentation and T 
cell stimulation.  (Adapted from Srivastava and Liu 2003). 
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1.11.4.5. HER-2/neu targeted DNA vaccines 
DNA vaccines have previously been used in several preclinical models involving 
mice.  Genetic DNA vaccines using plasmid DNA expressing various forms of the ECD 
and complete HER-2/neu have been reported to induce both HER-2/neu-specific 
humoral and T-cell immune responses (Amici et al. 1998; Chen et al. 1998; Esserman et 
al. 1999; Piechocki et al. 2001; Pilon et al. 2001).  DNA vaccine expressing the ICD 
induced stronger anti-neu immunity than the ECD (Foy et al. 2001); whereas, the full-
length HER-2 DNA vaccine induced stronger antitumor immune responses (Wei et al. 
1999).  In general, however, these antitumor immune responses could only partially 
protect mice from rechallenge of HER-2/neu positive tumor cells and only partially 
reduced tumor development in various rat neu gene Tg mice (Amici et al. 1998; 
Esserman et al. 1999; Foy et al. 2001; Renard et al. 2003).  Recent reports using  
electroporated DNA and xenogeneic DNA vaccines have shown enhanced induction of 
antitumor immunity (Quaglino et al. 2004a; Gallo et al. 2005; Pupa et al. 2005).  In 
addition, the inclusion of weekly cytokine injections such as IL-12 along with DNA 
immunization elicited stronger antitumor immune responses that protected 63% of 
BALB-neuT mice after two DNA electroporations or complete protection after four 
electroporations (Spadaro et al. 2005).  However, most of these DNA vaccines were not 
able to induce any beneficial therapeutic effects (Amici et al. 1998; Esserman et al. 
1999; Foy et al. 2001; Quaglino et al. 2004a).  Although promising, the effectiveness of 
DNA-based vaccine might not be able to efficiently break CTL tolerance (Rovero et al. 
2000).   
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1.11.5. Dendritic cells 
DC represent the most powerful professional APC of the immune system and 
quintessential for not only the initiation but also the regulation of immune responses 
(Banchereau and Steinman 1998).  DCs comprises only less than 1% of circulating cells 
and are a heterogeneous population that serve as sentinel cells found in tissues such as 
the skin, spleen and liver.  The first DC described were Langerhans cells, discovered by 
Paul Langerhans in the late 1800s.  DCs were later “rediscovered” by Steinman and 
Cohn in 1973 as an adherent cell type in mouse splenocytes with stellate morphology 
(Steinman and Cohn 1973).  This cell was later termed DC based upon morphological 
features such as the numerous cytoplasmic extensions or membrane processes that form 
dendrites, pseudopods or veils.  DCs characteristically express high levels of MHC class 
I and II molecules, accessory/costimulatory molecules B7-1 (CD80), B7-2 (CD86), 
CD40, adhesion molecules CD11b, CD11c and intracellular adhesion molecules 
(ICAMs)–ICAM-1 (CD54).  They also express receptors for efficient Ag capture and 
secrete chemokines, as outlined in Figure 1.5.  DC are characterized by the lack of 
lineage specific expression markers such as CD3 (T cells), CD19 (B cells), CD14 
(monocytes/macrophages), CD56 (NK cells) and CD66b (granulocytes) (Timmerman 
and Levy 1999; Brossart et al. 2001; Steinman and Dhodapkar 2001).  DC have often 
been termed as “nature’s adjuvant” for their ability to activate naïve T cells and to 
generate an effective immune response (Steinman and Dhodapkar 2001; Steinman and 
Pope 2002).  In the last few decades, the functions of DC have been extensively studied 
and their immunotherapeutic potential sought. 
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Figure 1.5  The characteristics of dendritic cells (DC).  Illustrated are the various cell 
surface receptors and cytokines/chemokines that dendritic cells express and their general 
phenotypic functions.    
 
 
1.11.5.1. Sources of DC 
Circulating DC comprise only a small amount of circulating cells in the blood 
and require tremendous leukapheresis efforts to obtain sufficient numbers.  The 
administration of cytokines such as GM-CSF and fms-like tyrosine ligand 3 (Flt-3L) 
allows for expansion of DC in vivo.  Examining the ability to generate vast quantities of 
DC using ex vivo methods have allowed for a better understanding of DC biology and its 
use in immunotherapy.  DC, in both mice and humans, is derived from a bone marrow 
common progenitor cell (Ardavin 2003).  In mice, bone marrow cells are cultured in the 
presence of GM-CSF to stimulate the proliferation of myeloid cells, which includes 
granulocytes, macrophages and monocytes (Inaba et al. 1992; Inaba et al. 1993a).  Large 
quantities of BM-derived DC can be obtained by culturing BM cells in the presence of 
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GM-CSF and IL-4 for 5-7 days (Lutz et al. 1999).  In humans, CD34+ hematopoietic 
stem cells, found either in the bone marrow or in the blood, differentiate to become DC.  
CD34+ stem cells are cultured in vitro with cytokine cocktails containing GM-CSF with 
TNF-α, stem cell factor (SCF), IL-4, IL-13 and Flt-3L (Santiago-Schwarz et al. 1992; 
Romani et al. 1994; Caux et al. 1996; Cella et al. 1997b).  Another common source of 
DC in humans is CD14+ blood monocytes.  CD14+ monocyte cells are isolated directly 
from the blood, either through phlebotomy or apheresis, and differentiated simply using 
GM-CSF and IL-4 culture media (Sallusto and Lanzavecchia 1994; Berger and Schultz 
2003).  There are also numerous subsets of DCs identified to date and involved in the 
generation of immune responses and immune tolerance (Reid et al. 2000; Shortman and 
Liu 2002).  
 
1.11.5.2. Immunobiology of DC 
The biological cycle of DC involves maximal capture of Ag from the 
microenvironment and efficient presentation to lymphocytes.  This cycle is divided into 
two distinct phases, based upon maturational status:  immature and mature DCs.  
Characteristics of immature DC include highly efficient capture of Ag with low T cell 
stimulatory activity and commonly found in peripheral tissues.  On the other hand, 
characteristics of mature DC include low Ag capture capability, high T cell stimulatory 
activity and migratory activity to secondary lymphoid tissues or regional lymph nodes 
(Bancherau, 1998).  Figure 1.6 illustrates the overall life cycle of DC between the two 
phases. 
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Figure 1.6  The life cycle of dendritic cells (DC).  Precursor DC circulating in the blood 
enter into tissues as immature DCs.  Upon encountering pathogens (e.g. viruses), various 
cytokines such as IFN are secreted, which in turn activated eosinophils, macrophages 
(MF) and natural killer (NK) cells.  After antigen capture, immature DCs undergo a 
maturational process and migrate to lymphoid organs.  This maturational process 
induces the DC to display peptide-MHC, which allow for the selection of rare 
circulating antigen-specific lymphocytes and act in a concerted fashion to induce 
terminal maturation of DC and allow for lymphocyte expansion and differentiation.  The 
activated T lymphocytes migrate to the injured tissue site to cross the epithelial border.  
Helper T cells function by secreting cytokines, which permit the activation of 
macrophages, NK cells and eosinophils.  Generation of cytotoxic T cells (CTL) 
eventually lyse infected cells and B cells, activated by both T cells and DCs, mature to 
become plasma cells and produce antibodies.  (Adapted from Banchereau et al. 2000).  
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1.11.5.2.1. Immature DC 
Immature DC, derived from the bone marrow, enter into the blood and reside in a 
steady state in tissues as resident cells.  At these sites, immature DCs efficiently capture 
Ags through various mechanisms.  This includes extracellular fluid macropinocytosis 
(Sallusto et al. 1995; Steinman and Swanson 1995), phagocytosis (Inaba et al. 1993b), 
receptor mediated endocytosis using C-type lectins such as the mannose receptor 
(Sallusto et al. 1995), Fcγ receptor I (CD64) and II (CD32) mediated endocytosis 
[uptake of immune complexes or opsonized particles] (Sallusto and Lanzavecchia 1994) 
and DEC-205 (Jiang et al. 1995; Guermonprez et al. 2002).  The integrins αvβ3 and 
αvβ5 and CD36 may also be involved in the uptake of dying and apoptotic cells (Albert 
et al. 1998a).   Immature DC also internalize peptides complexed with chaperone 
proteins such as heat shock protein (HSP) gp96 and HSP70 as well as bacteria, viruses 
and intracellular parasites (Banchereau et al. 2000).  Captured Ags are processed 
intracellularly through the exogenous pathway and the DC undergoes a maturation 
process, which eventually loads the peptide onto MHC class II molecules.  Meanwhile, 
cross-priming does occur whereby captured Ag accesses the cytoplasm and peptide 
epitopes are presented in complex with MHC class I molecules.  The processing 
capabilities and environmental stimuli will determine if immature DCs undergo the 
maturational process to become a mature DC or remain as immature DC to induce T- 
cell hyporesponsiveness leading to inhibition of immunoreactivity (Banchereau and 
Steinman 1998; Lutz et al. 2000).  In this case, immature DC lacking expression of 
costimulatory molecules travel to the regional LN where it attempts to present the Ag to 
T cells but fails to activate the T cell.  This induces T cell anergy and possibly deletion. 
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Immature DC also express CD40, CD54, CD58, CD80, CD86 and CCR7, a 
chemokine receptor, at relatively low levels.  On the other hand, immature DC secrete 
proinflammatory chemokines including macrophage inflammatory protein (MIP)-1α 
(CCL3), MIP-1β (CCL4), monocyte chemoattractant protein (MCP)-1 (CCL2), MCP-2 
(CCL8), MCP-4 (CCL13), Regulated upon Activation, Normal T cell Expressed and 
Secreted (RANTES; CCL5), thymus-expressed chemokine (TECK; CCL25) and stromal 
derived factor (SDF-1; CXCL12) (Brossart et al. 2001; Whiteside and Odoux 2004). 
Proinflammatory chemokines produced upon DC activation signal the migration of the 
DC and recruitment of naïve T cells to the regional LN.  There is also abundant 
expression of the chemokine receptors CCR1, CCR2, CCR5, CCR6, CXCR1 and 
CXCR4 to allow for DC recruitment to sites of inflammation for Ag uptake (Caux et al. 
2000; Chen et al. 2001b; Berger and Schultz 2003).    
 
1.11.5.2.2. Mature DCs 
After immature DC capture the Ag and the encountered local inflammatory 
mediators or “danger signals” induces a programmed coordinated maturational process 
to enhance DC capabilities of peptide presentation to T cells to generate an immune 
response.  Some of the mediators of DC maturation include (i) PAMPs such as 
lipopolysaccharide (LPS), bacterial DNA and double stranded RNA (Pardoll 2002), (ii) 
proinflammatory cytokines including TNF-α, IL-1β, prostaglandin E2, IL-6, (iii) T cell 
derived signals such as CD40L, (iv) apoptotic body uptake, which in turn can stimulate a 
variety of other cells to produce potent mediators.  On the other hand, presence of IL-10 
in the microenvironment impedes DC maturation.   
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Maturation mediators are controlled by a series of cell surface receptors such as 
TLR, cytokine receptors, TNF-receptor (TNF-R), Fc receptors and sensors of cell death 
(Guermonprez et al. 2002; Steinman and Pope 2002).  Upon receiving the maturation 
stimuli, a coordinated series of events results in down-regulation of Ag uptake 
machinery, loss of endocytic activity, upregulated expression of adhesion molecules, 
costimulatory molecules and stable peptide-MHC molecules on the cell surface of DC.  
This up-regulation can achieve 10-100 fold greater density of molecules compared to 
monocytes or B cells (Timmerman, 1999).  The costimulatory molecules, CD80, CD86 
and CD40 are expressed at high levels along with adhesion molecules, CD54, CD11b 
and CD11c.  MHC class II expression is upregulated with majority of the peptide-MHC 
complexes expressed on the cell surface instead of remaining intracellularly localized in 
the lysosomes.  Also, the MHC class II complexes remains stable for longer periods of 
time in comparison to the short half-life of MHC class II molecules seen in immature 
DC (Cella et al. 1997a; Pierre et al. 1997; Banchereau et al. 2000).  This increased 
expression and stability allows for enhanced interaction with CD4+ Th cells.   
There are also distinctive changes in the morphology with the loss of cell 
adhesiveness, cytoskeleton reorganization allowing the numerous veils to be longer, and 
high cell motility.  Mature DCs, in humans, have easily been identified with the 
expression of CD83; however, mouse DC do not have a true maturation marker 
identified.  During the maturational process, the expression of proinflammatory 
chemokines previously expressed by immature DC and chemokine receptors are 
decreased or down-regulated, while the DC becomes responsive to MIP-3β (ELC; 
CCL19) and secondary lymphoid tissue chemokine (SLC; 6Ckine; CCL21).  Mature DC 
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are also able to express cytokines such as IL-1, IL-6, IL-12 and IL-18 (Liu 2001).  In 
conjunction, expression of the CCR7 chemokine receptor is upregulated in mature DC, 
to respond to MIP-3β and SLC chemokines, while down-regulating the CCR1, CCR2, 
CXCR-4 and CCR5 receptors (Caux et al. 2000; Chen et al. 2001b). 
 
1.11.6. DC vaccines  
The unique immunostimulatory activities of DCs and their inherent involvement 
in previous vaccine strategies have made them an attractive tool for immunotherapeutic 
use in the treatment of malignant diseases.  Previous cancer vaccine strategies (protein, 
peptide, cell and DNA-based vaccines) required the host APC for priming T cell 
responses.  However, APC from patients and tumor bearing mice are often functionally 
impaired (Chaux et al. 1997; Gabrilovich et al. 1997; Troy et al. 1998).  An approach to 
correct this problem was to use DC-based vaccines, which would directly allow for 
interaction with T cells instead of going through various non-efficient intermediate 
steps.  The first clinical study involving a DC vaccine was reported in 1996 resulting in 
one patient with complete tumor regression and further sparked the utility of DC cancer 
vaccines (Hsu et al. 1996).  DC are able to deliver tumor Ag derived from various 
sources that would allow efficient presentation to engage an antitumor immune 
response.  DC-based vaccines have been reported to be superior compared to peptide 
and DNA-based vaccines by stimulating a more efficient antitumor immunity (Toes et 
al. 1998; Yang et al. 1999; Bellone et al. 2000).  Certain aspects of DC-based vaccine 
require a brief examination such as maturation, methods of administration and Ag 
loading, as discussed in the following sections below. 
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 1.11.6.1. The importance of the maturation status  
Various studies have shown the importance of DC maturational status on the 
induction of antitumor immune responses.  In comparing DC cultured under various 
conditions, ranging from GM-CSF alone to GM-CSF and IL-4, and the addition of 
various maturation stimuli, Labeur et al analyzed both the phenotypic and functional 
characteristics of the generated DC (Labeur et al. 1999).  They showed DC cultures 
supplemented with IL-4 induced relative maturation compared to culture with GM-CSF 
alone.  Moreover, the addition of CD40L increased the maturation of DC and resulted in 
greater antitumor immunity and immunotherapy in mice with established tumors in a 
squamous cell carcinoma model (Labeur et al. 1999).  Similar results have also been 
confirmed by other groups in preclinical and clinical studies (Chen et al. 2001b; de Vries 
et al. 2003).  In a systematic analysis on the relative impact of maturation on the surface 
phenotype, cytokine and cytokine/chemokine receptors and antitumor immunity was 
performed.  DC cultured in GM-CSF and IL-4 with the addition of LPS exhibited 
significantly greater expression of MHC class II, CD40, CD54, CD80 and CD86 on the 
cell surface.  Increased expression of cytokines, such as Flt-3L, granuloctye-colony 
stimulating factor (G-CSF), IL-1α, IL-1β, IL-6, IL-12, MCP-1 (CCL-2), MIP-1α (CCL-
3), MIP-1β (CCL-4), RANTES (CCL-5), TARC (CCL-17), macrophage derived 
chemokine (MDC; CCL-22), MIP-2 (CXCL2) and the chemokine receptor CCR7 was 
detected in comparison to intermediate mature and immature DC (Chen et al. 2001b).  
On the other hand, immature DCs are useful in inducing Ag-specific tolerance or 
immune silencing for potential applications in managing transplantation, allergy, 
autoimmune and chronic inflammatory diseases (Jonuleit et al. 2000; Dhodapkar et al. 
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2001).  Therefore, the maturation status of DC is an important factor to consider in the 
utilization of DC vaccines. 
 
1.11.6.2. Route of DC vaccination 
The route of administration plays an influential role in the migration of DC to 
lymphoid tissues and its overall efficacy in a DC-based vaccine.  The various methods of 
administration include subcutaneous (s.c.), i.d., intravenous (i.v.), intranodal, 
intralymphatic (i.l.), intraperitoneal (i.p.) and intratumoral (i.t.) injections (Nencioni and 
Brossart 2004).  Studies in mice have shown direct evidence that DC injected s.c. 
preferentially migrated to the draining LN compared to i.v. injected (Eggert et al. 1999; 
Okada et al. 2001a).   DC injected i.v. accumulated largely in the spleen, liver and lungs, 
whereas s.c. injected DC were able to home to the T cell areas of the draining LN via the 
afferent system.  DC injected s.c. were found in the popliteal LN 24 hours after injection 
and peaked at 48 hours but remained detectable for five days (Lappin et al. 1999).  In 
another animal study, a single vaccination given either i.d. and s.c. resulted in greater 
protective immunity from tumor challenge compared to i.p. and i.v. injection (Okada et 
al. 2001a).  A clinical study involving three cohorts of prostate cancer patients 
immunized with Ag-loaded DC via i.v., i.d. and i.l. routes resulted in the development of 
specific T cell responses irregardless of the route of immunization; however, greater 
levels of IFN-γ were observed with i.d. and i.l. routes of immunization (Fong et al. 
2001b).  This suggested that the route of immunization affects the quality of the T cell 
response generated.  Alternatively, intranodal injection, which substantially increases the 
number of DC in the LN to interact with T cells, produced more potent responses but 
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destroyed the LN architecture (Barratt-Boyes and Figdor 2004).   However, more studies 
are required to determine the optimal route for DC immunization.    
 
1.11.6.3. Methods for Ag loading 
A wide variety of methods are available for ex vivo loading of tumor Ag into DC 
that have been developed and used in both preclinical and clinical studies (Markiewicz 
and Kast 2004).  Table 1.1 describes the multitude of ex vivo methods available for 
loading tumor Ag and only some of the common methods are discussed further in 
Sections 1.11.6.3.1 to 1.11.6.3.6. 
 
 
 
Table 1.1:  Methods for ex vivo loading of tumor Ag onto DC1
 
 
• Synthetic or eluted peptides 
• Soluble protein 
• Transfection with cDNA or RNA encoding tumor Ag 
• Recombinant viral vectors 
• DC-tumor cell fusions (Hybrid cells) 
• DC derived exosomes 
• Heat shock proteins 
• Tumor lysates 
• Apoptotic bodies, necrotic cells 
• Tumor RNA 
o Defined Ag 
o Tumor-derived 
o Transfection via electroporation, liposomes 
• DNA 
o Immunomodulatory molecules/tumor Ag 
o Transfection  
 Electroporation, Naked, liposomes 
o Viral Transduction 
 
 
1.  Adapted from Brossart et al. 2001; Markiewicz and Kast 2004 
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1.11.6.3.1. Tumor lysates 
Vaccination strategies targeting a single peptide epitope may be defined too 
narrowly with the immune system devoting enormous effector resources into a single 
response.  This increases the chances of failing upon antigenic changes within the tumor.  
As tumors are heterogeneous in nature, tumors may express a wide variety of TAAs.  
The use of tumor lysates as a source of Ag offers the potential advantage of inducing a 
response against multiple known and unknown TAA expressed in tumors.  Tumor 
lysates are obtained by repeated freezing/thawing or by sonicating tumor cells.  This 
method decreases the time consuming and substantial efforts of identifying and 
synthesizing individual immunodominant peptide epitopes by allowing the DC to 
naturally process the tumor-derived Ags (Zhou et al. 2002).  The drawback to this 
method is the limited availability of tumor cells obtained from patients.  However, tumor 
Ag laden DC have been shown to induce tumor Ag specific CTL responses and provide 
some beneficial responses for patients (Zhang et al. 2002). 
 
1.11.6.3.2. Exosomes 
Exosomes are late-endosome derived small membrane vesicles ranging from 60-
90 nm in diameter and secreted by both DC and tumor cells.  Exosomes contain 
numerous MHC class I and II molecules, costimulatory molecules such as CD86 and 
various cell derived products such as HSP (Steinman and Dhodapkar 2001; Zhou et al. 
2002).   Mice immunized using DC loaded with tumor-derived exosomes or even DC 
derived exosomes resulted in tumor protection and therapeutic effects leading to 
regression of established tumors (Zitvogel et al. 1998; Wolfers et al. 2001).  This method 
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can be further used for pulsing in vitro generated DC or for cell-free based vaccines 
(Andre et al. 2004). 
 
1.11.6.3.3. Proteins 
Immature DC allows for increased Ag loading by allowing the protein to be 
captured, processed then presented by DC as immunogenic peptides in complex with 
MHC molecules.  By directly co-culturing the protein with DC, it bypasses the 
MHC/HLA haplotype restriction issue, circumventing the need to identify epitopes.  
Both Ag-specific CTL responses in vitro and antitumor immunity in vivo have been 
detected in both animal models and humans.  This method has been successfully used in 
clinical studies for follicular lymphoma and multiple myeloma using idiotype 
immunoglobulins (Markiewicz and Kast 2004).  However, it should also be noted that 
the incorporation of exogenous soluble Ags into DC results in inefficient processing and 
loading onto MHC class I molecules.   
In addition to using native proteins, modifications to incorporate specific 
sequences, thus creating fusion proteins, can facilitate the processing more effectively or 
even enhance the immunogenicity of the protein.  Fusion proteins containing the human 
immunodeficiency virus (HIV) trans-activating (TAT) protein transduction domain 
allow for proficient protein entry into cells.  In preclinical models, ovalbumin (OVA)-
TAT fusion protein were efficiently taken up by murine DC and processed the Ag to 
stimulate both CD8+ and CD4+ T cells that prevented tumor engraftment of OVA-
expressing tumor cells (Shibagaki and Udey 2002).  TAT-based fusion proteins have 
also been applied to HER-2/neu in both preclinical in vitro and in vivo animal studies 
with encouraging results (Tanaka et al. 2003; Viehl et al. 2005).  Moreover, proteins 
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complexed with hydrophobized polysaccharide nanoparticles such as cholesteryl group 
bearing mannan or pullulan, induced both cellular and humoral immune responses 
effectively preventing tumor growth upon tumor challenge (Gu et al. 1998; Wang et al. 
1999).   
 
1.11.6.3.4. Peptides 
Peptides are easily adaptable for use in DC based cancer vaccines simply by 
pulsing the peptides to DC.  This route allows for direct peptide loading onto MHC class 
I and II molecules, depending upon the peptide epitope, to induce epitope-specific T 
cells responses.  Sources of peptides include chemically derived synthesis, acid elution 
of peptides from tumor cells or affinity purification of MHC-peptide complexes (Zhou et 
al. 2002).  Peptide pulsed DC have been shown to induce both peptide specific CD8+ 
and CD4+ T cell responses in preclinical animal models, healthy volunteers and patients 
in a wide assortment of cancers (Mayordomo et al. 1995; Zitvogel et al. 1996; 
Meidenbauer et al. 2001; Zhang et al. 2002; Allan et al. 2004).  Peptide pulsed DC 
remains one of the most widely used methods to load Ag onto DC to date. 
In the case of HER-2/neu, peptide pulsed DC have been examined as potential 
candidates in both preclinical animal and human clinical trials.  Using the HER-2 
peptides p63-71 and p780-788, BALB/c (H-2Kd) mice immunized weekly with peptide 
pulsed DC suppressed the growth of a previously transplanted HER-2 expressing 
syngeneic tumor and efficiently stimulated both CD4+ and CD8+ T cell responses (Shiku 
et al. 2000).  These results were encouraging as the peptide motif for murine H-2Kd 
shares a similar binding motif with the human HLA-A24 and in vitro stimulated CTL 
were detected in both healthy individuals and ovarian cancer patients using peripheral 
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blood lymphocytes (PBL) (Ikuta et al. 2000; Okugawa et al. 2000; Ikuta et al. 2002).  
Similar studies with human PBL have examined in vitro generated HLA-A2 restricted 
CTLs in both cancer patients and healthy individuals using the HER-2 peptides p369-
377 [E75], p435-443 and p689-697 (Rongcun et al. 1999; Anderson et al. 2000b; Seliger 
et al. 2000; Baxevanis et al. 2002; Kono et al. 2002b; Morse et al. 2003; Sotiropoulou et 
al. 2003a; Sotiropoulou et al. 2003b; Baxevanis et al. 2006).  In one study, Muller et al. 
reported the generation of HER-2 specific CTL with cytolytic activity in vitro using the 
PBL from acute lymphoblastic leukemia patients, which indicated the wide scale 
applicability of peptide-pulsed DC vaccines for a variety of cancers (Muller et al. 2003).   
Besides using peptide pulsed DC to generate CTL in vitro, they have also been 
used to mount a specific immune response in vivo.  A clinical study by Brossart et al. 
utilized monocyte-derived DC with two different HLA-A2-restricted HER-2 peptides or 
MUC-1 peptides to generate CTLs in patients with advanced breast cancer or ovarian 
cancers.  Ag specific CTL were detected in 50% of the patients examined, as assessed by 
IFN-γ and cytotoxicity assays (Brossart et al. 2000a).  More recently, a phase I/II trial 
utilized CD34+ expanded DC pulsed with the HLA-A2 restricted HER-2 peptide, p654-
662 or a modified, more stable form of the peptide.  This resulted in two patients with 
partial response to therapy while an additional two patients developed IFN-γ producing 
CD8+ T cells (Dees et al. 2004).   
In a mouse animal model, DC pulsed with a recently identified H-2Dq restricted-
neu peptide induced specific lysis activity and completely protected wild-type FVB/N 
mice from challenge with NT2 neu expressing tumor cells; however, even after two 
immunizations with the vaccine, no protective response was observed in FVBneuN Tg 
mice, which are already tolerized to neu (Ercolini et al. 2003).  In addition, recent work 
 52
has shown that multiple vaccinations were required with a HLA-A2-restricted peptide-
pulsed DC in A2 x neu crossed Tg mice (A2/Kb Tg mice crossed with FVBneuN mice).  
The addition of IL-12 and anti-OX40 mAb also induced a more robust immune 
response.  This resulted in a greater degree of tumor growth inhibition compared to 
unmodified peptide-pulsed DC (45% inhibition versus 12-25% inhibition) (Lustgarten et 
al. 2004).  The T cells within these crossed Tg mice were of low avidity and clinically 
represented the tolerance situation observed in patients involving the deletion of high 
avidity T cells.    Overall, these studies have shown that HER-2/neu peptide pulsed DC 
can generate CTL but still does not provide adequate protection or therapeutic response 
in a clinical setting. 
  
1.11.6.3.5.  Necrotic and apoptotic Cells  
DC can easily phagocytose dying (both apoptotic and necrotic) tumor cells to 
induce protective immunity (Albert et al. 1998b; Fonteneau et al. 2001).  Advantages of 
using dying tumor cells for ex vivo loading of DCs include the ability for DC to present 
and to cross present the entire spectrum of Ag from the tumor cell on both MHC class I 
and II molecules.  This would be independent of the MHC/HLA haplotype restriction 
allowing for applicability in all patients, unlike the restriction imposed for peptide-
pulsed DC.  There should also be a reduction in the probability of the tumor escaping 
from the generation of Ag-negative variants (Zhang et al. 2002; Berger and Schultz 
2003).  On the other hand, several disadvantages have arisen with the use of this method.  
One of them is the potential risk of inducing autoimmunity (Ludewig et al. 2000) even 
though immature DC can induce tolerance to self-Ag from apoptotic cells (Steinman et 
al. 2000).  Another pitfall is the lack of sufficient quantities of patient tumor samples but 
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this too may be addressed using allogeneic tumor cell lines as an alternative.  Some 
other disadvantages include the lack of monitoring since no defined tumor Ag is 
identified and an inherent limitation of DC to present a subset of epitopes from tumor 
cells instead of the complete set of epitopes (Berger and Schultz 2003)  
Apoptotic cell death is a common way for a cell to die and characterized by cell 
shrinkage, chromatin condensation, DNA cleavage and laddering and membrane 
blebbing.  This process is also important in self and non-self discrimination, as failure 
would result with dying cells triggering an immune response against themselves 
(Matzinger 1994).  Cells that undergo apoptosis are readily engulfed by DC (Albert et al. 
1998b) via αVβ5, CD36 (Albert et al. 1998a) and phosphatidylserine (PS) receptor 
(Fadok et al. 2000).  Subsequently, DC efficiently present the Ags of apoptotic cells to 
class I-restricted CTLs (Albert et al. 1998b).  Apoptosis occurs at two different stages 
with the first stage considered as early apoptosis, phenotypically characterized by the 
expression of Annexin V and lack of propidium iodide staining (PI) staining.  The 
second stage of apoptosis, called late apoptosis or secondary necrosis, is a result when 
the plasma membrane and intracellular organelles breakdown.  Characteristics of late 
phase apoptosis are cells staining for both Annexin V and PI.  On the other hand, cells 
dying of necrosis are phagocytosed through the interaction of CD91 (Basu et al. 2001) 
and c-type lectin LOX1 (Delneste et al. 2002) receptors with HSP expressed on necrotic 
tumor cells.  The uptake of dying tumor cells has been shown to impact both DC 
maturation and DC immunogenicity. 
Controversy still exists with respect to the optimal form of killed tumor cells for 
stimulating effective immune priming and antitumor activity in DC-based vaccine 
strategies.  The contradictory and discordant findings stem from earlier reports showing 
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DC that phagocytosed apoptotic cells could exclusively cross-present Ags to CTLs 
(Albert et al. 1998b).  DC pulsed with apoptotic tumor cells induced a strong Ag-
specific T cell response in vitro, and when injected into mice, such pulsed DC induced 
tumor-specific CTL responses and long-term protection from parental tumor challenge 
(Henry et al. 1999).  It was later shown that necrotic, but not apoptotic cells could induce 
DC maturation to elicit immunity (Basu et al. 2000; Sauter et al. 2000).  In another 
report, however, both apoptotic and necrotic tumor cells could equivalently induce DC-
mediated immune priming and antitumor therapeutic efficacy (Kotera et al. 2001).  More 
recently, it has further been shown that DC charged with apoptotic tumor cells induced 
long-lived protective CD4+ and CD8+ T cell immunity (Scheffer et al. 2003) and 
apoptotic but not necrotic tumor cells are efficient vaccines in vivo (Goldszmid et al. 
2003).  Apparently contradicting these results, it has also been reported that the presence 
of apoptotic cells during macrophage activation increases their secretion of anti-
inflammatory mediators (Fadok et al. 1998) and decreases their secretion of 
proinflammatory cytokines (Voll et al. 1997), resulting in inflammatory response 
suppression and immune tolerance (Steinman et al. 2000; Liu et al. 2002).  In line with 
this notion, there is also evidence for the lack of immunogenicity (Ochsenbein et al. 
1999) or reduced immunogenicity of apoptotic tumor cells as compared with their viable 
counterparts (Ponner et al. 1998).  Given the predominance of apoptotic cell death in 
most common cancer treatment regimens (Thompson 1995), it is important to know 
whether the enhanced tumor Ag presentation associated with DC presenting these Ags 
will enhance the development of immunity, or of immune tolerance to the tumor. 
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1.11.6.3.5.1. Role of HSP70 
HSPs are intracellular molecular chaperones located in the cytoplasm, ER or the 
mitochondria.  HSPs are present at low levels and function at a steady state under 
normal conditions but easily induced to high levels upon encountering cellular stress to 
prevent protein aggregation and to protect cells from apoptosis (Todryk et al. 2003; 
Beere 2005; Calderwood et al. 2005).  HSP70 is expressed in the cytoplasm and is one 
of the prototypes in the HSP family.  The release of HSP70 from cells undergoing a 
necrotic cell death rather than apoptosis provides an enhanced immunogenic effort.  
Studies have shown that HSP70 has immunomodulatory effects in Ag processing and 
presentation in DC through a variety of mechanisms (Li et al. 2002; Noessner et al. 
2002; Millar et al. 2003; Calderwood et al. 2005).  Cleaved peptides derived from 
protein degradation can interact with HSP70 to form HSP-peptide complexes within the 
stressed cell, in turn allowing for presentation on MHC class I molecules.  The HSP-
peptide complexes exposed on the cell surface or released from stressed cells can also be 
taken up by APC, which in turn processes and presents the Ag peptides on MHC 
molecules.  It has also been demonstrated that receptor-mediated internalization of 
HSP70 induced DC maturation (Kuppner et al. 2001; Noessner et al. 2002; Castelli et al. 
2004).  This suggested the discordant results observed may be a function of HSP70 
expression.  For example, recent reports showed early phase apoptotic cells inhibited DC 
maturation while late phase apoptotic cells increased the expression of HSP70 
expression and induced DC maturation (Melcher et al. 1999; Pietra et al. 2001; 
Buttiglieri et al. 2003; Galetto et al. 2003; Masse et al. 2004).  
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1.11.6.3.6. Engineered DC 
Modifying DC with DNA to express an array of cytokines, chemokines and 
tumor Ag (i.e. TAA) have provided a powerful advantage to manipulate the properties of 
DC for use in cancer therapies.  Gene engineered DC offers several attractive advantages 
compared to ex vivo Ag pulsing with peptides and whole tumor cell preparations (Arthur 
et al. 1997; Humrich and Jenne 2003; Nakamura et al. 2005).  One advantage of using 
tumor Ag expression within DC is the constant source of Ag available for presentation 
and the prolonged duration of Ag presentation.  This contrasts the use of lysate or 
peptide pulsed DC, where the duration of expression is restricted not only by the 
peptide’s affinity to bind to the MHC molecule but by the half-life of the peptide-MHC 
complex formed and the MHC turn over rate (Kaplan et al. 1999; Kirk and Mule 2000).  
Whole tumor cell preparations face the issues involved with standardization of the TAA 
and availability of tumor cells.  As well, gene-engineered DC with the tumor Ag 
guarantees that the Ag is processed endogenously for presentation onto MHC class I 
molecules, which leads to effective generation of a CTL-mediated immune response.  
Another important advantage with engineered DC is the reduced requirement to identify 
specific epitopes as the Ag presents both naturally processed CTL and helper epitopes.  
It has also been found that DC expressing tumor Ag transgene are more potent primers 
of antitumor immune responses than their soluble Ag-pulsed counterparts in both in 
vitro and in vivo animal studies (Tuting et al. 1997a; Zhang et al. 2002).  Several 
different methods, both non-viral and viral methods have been developed for ex vivo 
loading of DC.  It should also be noted that the aim of this form of DC-based 
immunotherapy is not necessarily the long-term expression of genes but rather the 
development of strong TAA-specific cellular and humoral immune responses. 
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 1.11.6.3.6.1. Non-viral methods 
A common method for tumor Ag transgene expression is the use of a plasmid 
encoding the cDNA for the Ag, similar to the expression vectors used in DNA 
vaccination.  The direct uptake of plasmid DNA by DC is one of the mechanisms for 
how DNA vaccines function; however, only a small fraction of DC is directly 
transfected by the plasmid.  Traditional methods for gene transfection such as 
liposomes-mediated transfection, calcium phosphate precipitation and electroporation 
have been used for transgene expression in DC (Alijagic et al. 1995; Arthur et al. 1997; 
Van Tendeloo et al. 1998; Lohmann et al. 2000; Rughetti et al. 2000; Lundqvist et al. 
2002).  In these studies, variable levels of gene expression have been observed with 
relatively low efficiency between 5-20%.  Often times, expression levels were not 
repeatable or consistent, suggesting the vehicle used in gene transfer is important for 
transfection efficiency (Kirk and Mule 2000).  Transfections using non-viral methods 
are generally inefficient, possibly due to the limited ability of the DNA to reach the 
nucleus for transcription to occur (Luo and Saltzman 2000).  In addition, the physical 
methods perturbed and altered both the function and phenotype of DC or became highly 
toxic (Arthur et al. 1997; Rughetti et al. 2000; Lundqvist et al. 2002).  On the other 
hand, electroporation of RNA has shown increased transfection efficiency and cell 
viability (Lundqvist et al. 2002; Grunebach et al. 2005). 
There have also been some recent improvements made in the use of non-viral 
delivery systems.  One recent development is the usage of a novel 35 aa cationic peptide 
CL22 complexed with plasmid DNA (Irvine et al. 2000).  This stimulated stronger 
autologous T cell responses and CTL activation against the influenza A nucleoprotein 
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using human DC and generated stronger specific T cell responses that resulted in tumor 
rejection in a mouse animal model.  Immunolipoplexes incorporating Ab targeting DC 
surface molecules such as anti-CD11c, anti-CD71 (transferrin receptor) and anti-CD205 
(mouse DEC205 homologue), increased the transfection efficiency and induced strong 
antitumor immune responses with antitumor effects (Altin et al. 2004; Tan et al. 2005a).  
Furthermore, gene gun based methods for transfection has also shown dramatic increase 
in the transfection efficiency compared to electroporation and naked DNA delivery 
alone (Larregina et al. 2004). 
 
1.11.6.3.6.2. Viral vectors 
Viral vectors posseses the capabilities to dramatically increase the efficacy of 
transgene expression to levels as high as 90-100% compared to the 5-20% seen with 
traditional transfection methods (Arthur et al. 1997; Dietz and Vuk-Pavlovic 1998; 
Zhong et al. 1999).  Recombinant viral vectors containing a transgene insert used for DC 
transduction have included retroviruses, lentiviruses, adenoviruses (AdV), pox virus, 
herpes virus, influenza virus, and adeno-associated viruses (Humrich and Jenne 2003).  
The use of viral vectors to transduce DC allow for (i) controlling the maturation status of 
transduced DC, (ii) the expression levels of the TAA and (iii) the site of injection to 
induce the optimal antitumor immune response.  Two viral vectors most commonly used 
for genetic modification of DC are retrovirus and AdV vectors, as discussed below. 
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a) Retroviruses 
Retroviruses are RNA viruses and a member of the Retroviridae family.  
Retroviruses replicate through a double stranded DNA intermediate, eventually reaching 
the nucleus and integrating into the host genome.  An advantage of using retroviral 
vectors is the ability for the TAA to be presented on both MHC class I and II molecules 
to activate TAA-specific CD8+ and CD4+ T cells.  Retroviruses are also autologous 
units, which do not lead to the development of neutralizing antibodies that would limit 
their ability to infect cells (Reeves et al. 1996; Specht et al. 1997).  Reports have also 
indicated the requirement for cognate help from CD4+ Th cells in eliciting protective and 
therapeutic antitumor immunity (De Veerman et al. 1999; Schnell et al. 2000).  As well, 
retroviral vectors limits the alteration in DC viability, phenotype, maturation or 
functions while the transgene remains stably expressed.  Retrovirus vectors, which are 
replication deficient and based upon the Moloney murine leukemia virus (MMLV) 
genome, have been used to express a wide variety of TAA ranging from mucin-1 (MUC-
1) (Henderson et al. 1996), melanoma MART-1 (Reeves et al. 1996), gp100 (Lapointe et 
al. 2001) and HER-2/neu (Meyer zum Buschenfelde et al. 2000; zum Buschenfelde et al. 
2001).  Retrovirally transduced human CD34+ derived DC expressing HER-2 from 
healthy normal individuals and patients with breast cancer induced HER2-specific CD8+ 
CTL and CD4+ Th1 cells that recognize different epitopes of HER-2 (Meyer zum 
Buschenfelde et al. 2000; zum Buschenfelde et al. 2001). 
Despite the immune responses observed, there are some drawbacks associated 
with the use of retroviruses as a viral vector.  One of them is the requirement of actively 
dividing cells, such as the CD34+ hematopoietic stem cells and bone marrow cells, for 
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efficient transduction and integration into the cell.  Transduction efficiency with both 
differentiated immature and mature DC resulted in reduced efficiency.  To bypass this, 
progenitor cells are used for viral transduction and differentiated into mature DC 
afterwards (Aicher et al. 1997; Meyer zum Buschenfelde et al. 2000; Markiewicz and 
Kast 2004).  
Lentiviruses, a member of the Retroviridae virus family, which includes the 
Human Immunodeficiency Virus (HIV) and simian immunodeficiency virus have also 
been used to transduce DC.  Lentiviruses, in contrast to retroviral vectors, easily 
transduces both actively dividing and non-dividing cells, such as the differentiated 
immature and mature DC (Robbins and Ghivizzani 1998; Humrich and Jenne 2003).  
Lentiviral vectors or lentivectors have also shown the ability to induce strong long 
lasting T cell responses that translate into effective protective and therapeutic responses 
in various model systems (Cui et al. 2003; Breckpot et al. 2004; He et al. 2005; Kim et 
al. 2005b).  One of the main drawbacks that remain in the use of these vectors is the 
safety issues such as DNA integration, which needs to be continually addressed. 
 
b) Adenovirus  
The other most commonly utilized viral vector is AdV.  More specifically, first 
generation AdV vectors, used traditionally in gene therapy applications but extended for 
immunotherapy application, allows for efficient transgene expression in DC.  An 
overview of AdV and its vectors are discussed below and in the following section.  AdV 
is a favorite vehicle for gene delivery to DC for several reasons such as its safety.  AdV 
vectors transiently express the transgene and does not involve viral DNA integration into 
the host genome; therefore, avoiding the possibility of disrupting vital cellular genes or 
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inducing cancer as seen for retroviral vectors (Dave et al. 2004).  AdV vectors also have 
a large gene carrying capacity allowing insertion up to 37 kb in size, limited 
pathogenicity with the deletion of E1 and E3 viral genes and are relatively easy to 
construct and to propagate with large quantities produced (Zhang 1999; Basak et al. 
2004).  Ex vivo transduced DC provide an advantage to overcoming pre-existing anti-
AdV immunity and does not involve injection of “free” AdV viral particles, thus 
allowing for induction of effective anti-tumor immune responses (Brossart et al. 1997; 
Kaplan et al. 1999; Wan et al. 1999; Basak et al. 2004). 
A vast improvement in the transduction efficiency using AdV is seen compared 
to other physical methods.  Rates greater than 90% are seen in transduced immature DC 
and the efficiency is reduced (~50%) in transduced mature DC (Dietz and Vuk-Pavlovic 
1998; Zhong et al. 1999).  Reports have shown varying transduction efficiencies ranging 
between 20%-83% in murine and human DC when using multiplicities of infection 
(MOI) between 50-1000 are used (Song et al. 1997; Dietz and Vuk-Pavlovic 1998; 
Miller et al. 2002; Nakamura et al. 2002; Tuettenberg et al. 2003).  Discrepancies may 
be attributed to the culture conditions used as well as the number of viral particles 
present in prepared AdV stocks (Hirschowitz et al. 2000).  Interestingly, high MOI 
levels are often required to obtain these transduction rates, and are dose-dependent.  The 
requirement of high MOI is based upon DC lacking expression of the coxsackie-
adenovirus receptor (CAR), one of the surface receptors needed for AdV attachment to 
the cell (Rea et al. 1999; Zhong et al. 1999; Okada et al. 2001b).  It is important to note 
that the high MOI required for transduction also creates cytotoxic effects to DC in a dose 
dependent manner.  This has recently spurred interests in determining methods to 
improve the transduction efficiency while decreasing the amount of AdV required for 
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transduction.  One approach has been complexing the AdV with liposomes, resulting in 
a five-fold increase in transduction efficiency in human DC (Dietz and Vuk-Pavlovic 
1998). Other methods include altering the viral tropism by adding adapter molecules 
such a bispecific antibodies targeting CD40 (Tillman et al. 1999) or creating genetic 
fusions between the fiber and receptor-specific ligand (Kashentseva et al. 2002; 
Belousova et al. 2003).  Another method includes the incorporation of an arginine-
glycine-aspartic acid (Arg-Gly-Asp, RGD) motif into the HI loop of the fiber protein 
thereby allowing for CAR-independent attachment and entry into the cell via the αvβ3 
and αvβ5 integrins (Okada et al. 2001b; Okada et al. 2003b; Worgall et al. 2004).  The 
RGD-fiber modified AdV allowed for a 10-fold increase in transduction efficiency and 
5-10 fold increase in transgene expression compared to unmodified AdV, leading to 
enhanced antitumor activities.   
One issue that has shown conflicting results is whether AdV induces maturation 
of DC.  Zhong et al. reported that AdV transduction does not perturb the DC 
maturational status (Zhong et al. 1999).  However, additional studies by other groups 
have shown that AdV vectors can indeed modulate DC maturation by increasing the 
expression of MHC, costimulatory molecules and adhesion molecules such as CD40, 
CD54, CD80 and CD86 (Rea et al. 1999; Hirschowitz et al. 2000; Morelli et al. 2000; 
Miller et al. 2002; Molinier-Frenkel et al. 2003).  Maturation of DC may be mediated by 
the viral fiber protein independent of viral gene or transgene expression (Hirschowitz et 
al. 2000; Miller et al. 2003; Molinier-Frenkel et al. 2003; Okada et al. 2003a).  This in 
turn allows for signaling through PI3K and induces production of TNF-α and type I-
IFNs (both α and β) for maturation (Philpott et al. 2004; Hensley et al. 2005).  Increased 
expression of IL-1β, IL-6, IL-12 p40/IL-12 p70, IL-15 and IFN-γ has also been observed 
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in AdV transduced DC, in a dose-dependent manner (Hirschowitz et al. 2000; Morelli et 
al. 2000; Tan et al. 2005b).  Decreased expression of CCR6 with increasing expression 
of CCR7 is also observed (Okada et al. 2003a). 
AdV-mediated expression of TAA in DC results in endogenous synthesis of the 
Ag for processing through MHC class I and II presentation pathways.  This in turn 
allows for interaction and activation of CD4+ and CD8+ T cells, along with B cells to 
induce an antibody response, as illustrated in Figure 1.7.  Numerous studies have 
previously shown AdV-mediated expression of TAA elicited strong CTL and CD4+ Th 
cellular antitumor responses (Song et al. 1997; Tuting et al. 1999; Song et al. 2000; 
Nakamura et al. 2002; Nakamura et al. 2005). 
 
1.11.6.4. HER-2/neu targeted DC vaccines 
Previous studies using HER-2/neu engineered DC vaccines have shown the 
ability to induce an antitumor immune response.  DC derived from CD34+ hematopoietic 
progenitor cells were transduced with a retrovirus vector containing the full length HER-
2 gene resulting in a low efficiency transduction rate but led to the generation of both 
CTL and Th1 T cell clones in vitro in both normal and breast cancer patients (Meyer 
zum Buschenfelde et al. 2000; zum Buschenfelde et al. 2001).   Chen et al utilized an 
AdV expressing the full length neu (AdNeuTK) to transduce DC that elicited protective 
immunity in 60% of mice against a lethal challenge against neu expressing NDL tumor 
cells (Chen et al. 2001a).   CD4+ T cells were required during the initiation phase while 
the main effector cells were CD8+ T cells for rejection of tumors.  In a different study by 
Chen et al, DC transduced with AdVHER expressing only the ECD and TM of HER-2 
induced HER-2 specific CTL responses but only resulted in 25% of mice protected from  
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Figure 1.7  Adenovirus-mediated gene transfer to dendritic cells.  An adenoviral vector 
carrying a gene expression cassette encoding for a tumor associated antigen such as 
HER-2/neu into DC.  The expressed antigen can be processed and presented with MHC 
class I to induce a CTL response or with MHC class II to induce a CD4+ Th response, 
which, in turn, can further stimulate the CTL or the Ab response. 
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a challenge of 3x105 MCA26/HER-2 tumor cells (Chen et al. 2002c).  To enhance the 
efficacy of the DCHER-2 vaccine, DC were cotransduced with both AdVHER-2 and 
AdVTNF-α, forming DCHER-2/TNF-α, that further increased the expression of CD40, CD86 
and ICAM-1 (CD54) and mounted a 36% stronger HER-2 specific T cell response.  
More importantly, DCHER-2/TNF-α, immunized mice were completely protected upon 
lethal challenge of HER-2 expressing tumor cells in this animal model.  In a more recent 
report, transduction of DC with an AdV expressing truncated neu (Ad.neu) stimulated 
the production of both neu-specific antibodies and T cells in Tg mice (Sakai et al. 2004).  
Moreover, immunization of BALB-neuT mice, which generally develops mammary 
tumors in all ten glands by 25 weeks of age, resulted in 65% of the mice remaining 
tumor free at 28 weeks of age using the engineered DC vaccine compared to the control 
groups that all developed tumors by this same period.   These studies indicated that DC-
based vaccines targeting HER-2/neu is an attractive strategy.  
   
1.12.Overview of AdV vectors 
 
1.12.1. AdV family 
Human adenoviruses (HAd, and referred to as AdV) are non-enveloped, double 
stranded DNA viruses.  AdV were first isolated in the early 1950s from human tonsils 
and adenoid tissue as well as respiratory secretions by two different groups (Rowe et al. 
1953; Hilleman and Werner 1954).  The viruses isolated by both groups were related and 
given a variety of names until a mutually agreed upon name, adenoviruses, was given.  
The name was based upon the original tissue (adenoid) the virus isolates were detected 
in (Enders et al. 1956).  HAd represents one group amongst the Adenoviridae family, 
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which also includes avian, bovine and simian adenoviruses.  Currently, there are 51 
different HAd serotypes, grouped from A to F based upon genome size, composition, 
homology, organization and the ability to agglutinate red blood cells.  To date, the most 
well studied AdV is type 2 and type 5 of subgroup C. 
 
1.12.2. Virus structure 
AdV are non-enveloped, double stranded DNA viruses of ~36 kilobases (kb) in 
size.  The capsid is an icosahedral protein shell consisting of 20 triangular surfaces and 
12 vertices that surrounds the linear, double-stranded DNA.  The capsid structure of 
AdV is composed of the hexon, which is the major protein component of the capsid 
surface, the twelve-penton bases at each of the vertices and the twelve fiber 
homotrimers, differing in length between the serotypes.  Several minor proteins (VI, 
VIII, IX and IVa2) also comprise the remainder of the viral capsid.   
The AdV genome contains two identical short, inverted terminal repeats (ITR) 
located at both the left and right ends of the genome.  The ITR allows DNA replication 
to occur at both ends.  A cis-acting packaging sequence is located within several 
hundred base pairs (bp) of the left end of the viral genome to allow for encapsidation of 
viral DNA within the virus capsid. 
 
1.12.3. AdV replication 
The replication cycle of AdV has been well studied and first requires attachment 
of the virus to the cell.  This occurs via a high affinity interaction between the fiber knob 
of AdV and CAR, the primary cellular receptor (Bergelson et al. 1997).  Other primary 
cellular receptors for attachment include MHC-class Iα2 subunit and sialic acid.  
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Following this, a secondary interaction with the RGD motif of the penton base with the 
secondary host cell receptors αvβ3 and αvβ5 integrins occurs to mediate virus 
internalization (Wickham et al. 1993).  The binding to αvβ3 and αvβ5 integrins promotes 
receptor-mediated endocytosis mediated by clathrin-coated pits.  The rate-limiting step 
for AdV replication is the ability of the virus to interact with CAR. CAR is expressed on 
a variety of cells such as epithelial cells and muscle cells but not on hematopoietic cells, 
including DC.  CAR expression is also highly variable within tumors (Douglas et al. 
2001; Kim et al. 2002; Okada et al. 2003a).  Once the virus is inside the cell, a 
coordinated, sequential disassembly of the capsid proteins allows the virus to escape 
from the endosome and enter into the cytoplasm.  Subsequently, the virion is transported 
to the nuclear pore complex and the viral DNA is released into the nucleus to initiate 
viral gene expressions (Greber et al. 1993).  Transcription from both the left and right 
ITR produces at least 30 different mRNA species.  Based upon the onset of viral DNA 
replication, the mRNA transcripts are divided into three classes: early transcripts (E1A, 
E1B, E2, E3 and E4), delayed early transcripts (IX and IVa2) and late transcripts (L1 to 
L5) (Shenk 1996).  An overview of the AdV life cycle is illustrated in Figure 1.8. 
Of the early transcripts, the E1A and E1B proteins are first to be synthesized and 
deemed necessary for virus replication.  These proteins engage in a multitude of 
regulatory functions including i) induction of DNA synthesis in quiescent cells, ii) 
immortalization of primary cells, iii) activation of other early and late genes, and iv) 
induction of apoptosis.  Early proteins encoded by E3 transcripts are not necessarily 
required for virus replication; however, the E3 proteins are involved with evading the 
host immune system and related to AdV mediated pathogenesis.  The E3 proteins 
(10.4K, 14.5K and 14.7K) inhibits TNF activity and ultimately prevents viral replication  
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Figure 1.8  The replicative life-cycle of an adenovirus.  The replication cycle of AdV 
begins with the attachment of the viral fiber protein to the CAR receptor.  Subsequently, 
the interaction between the penton base and the integrins on the cell surface mediates 
internalization of the adenoviral particle through endocytosis.  The virion (viron) is then 
transported to the nuclear pore complex and releases its DNA into the nucleus for 
initiation of a viral gene expression cascade, producing the early and late proteins.  The 
newly synthesized viral DNA becomes encapsidated into the viral capsid in the nucleus 
and progeny viruses are released through cell lysis. 
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(Wold 1993).  The E3-11.6K Ad “death protein” facilitates the release of viral particles 
and gp19K reduces MHC class I expression thus preventing the host immune response 
from eliminating the virus (Ginsberg et al. 1989). E2 transcripts encode for terminal 
protein, DNA polymerase and DNA-binding protein, all of which are involved in viral 
DNA replication.  After the onset of viral DNA replication, the late genes are expressed 
by alternative splicing and polyadenylation of a large pre-mRNA generated at the single 
major late promoter.  All late mRNA transcripts have a tripartite leader at the 5’ termini 
to enhance translation of viral structural proteins.  The accumulation of viral structural 
proteins and newly synthesized viral DNA in the nucleus triggers virus assembly and 
virions are released from infected cells 2 to 3 days after infection.   
 
1.12.4. AdV vectors 
AdV vectors have provided an immense tool in gene transfer technology.  Some 
of the advantages of using AdV include its high gene transfer efficiency, the ability to 
infect both dividing and non-dividing cells, transient expression with no concerns over 
viral DNA integration.  AdV can package an additional 2 kb of their original size to a 
maximum of 38 kb without deleterious effects; however, issues arise in regards to gene 
insert fragment size and safety concerns with increasing gene insert sizes (Bett et al. 
1993; Zhang 1999).  Thus in order to increase the insert size, genes from within the Ad 
genome is deleted to necessitate the accommodation of large gene inserts.  Different 
generations of vectors have been designed to allow for increased gene insert sizes, while 
at the same time reducing AdV antigenicity.  One of the problems associated with Adv 
is the high prevalence of AdV within the normal population with majority of individuals 
already possessing neutralizing Abs and cellular responses.  Figure 1.9 illustrates the 
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transcripts of the early and late proteins of AdV as well as depicting the differences 
between the AdV vector generations produced to date. 
 
1.12.4.1. First generation vectors 
First generation AdV have been the most widely studied and remains the most 
commonly used viral vector to date.  These vectors are constructed by deleting E1 and/or 
E3 regions (Graham and Prevec 1992, 1995).  This allows for an insert of 7.5 kb of 
foreign DNA up to a maximum of 8.2 kb size, based upon the capability of AdV to 
package 105% of its genome size (Bett et al. 1993; Bett et al. 1994).  The deletion of E1 
gene also abolishes the oncogenic potential and inhibits viral replication, resulting in a 
replication-deficient virus.  In order for the replication deficient virus to replicate, 
complementing cell lines are required to provide the E1 proteins in trans.  Some of the 
complementing cell lines developed include human embryonic kidney (HEK) 293 
(Graham et al. 1977), 911 (Fallaux et al. 1996) and PER.C6 (Fallaux et al. 1998) cell 
lines.  The latter two cell lines have shown the distinct advantage of reducing the 
probability of creating replication-competent Ad (RCA).  RCA are generated when 
recombination occurs between the endogenous E1 gene from the complementing cell 
line and the E1 deficient vector (Zhang 1999).   
AdV vectors are produced through three different methods: (i) the Stow method 
involving in vitro ligation to join AdV genome fragments; (ii) intracellular homologous 
recombination between partial viral genomes (Zhang 1999) and (iii) intracellular 
homologous recombination using plasmids.  The cloning systems used include 
cotransfecting into 293 cells (Miyake et al. 1996; Shenk 1996), yeast artificial cloning 
systems (Ketner et al. 1994) and Escherichia coli (E. coli) bacterial cloning systems  
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Figure 1.9  The transcripts from AdV and the different types of AdV vector.  The 
arrowhead depicts the promoter region for the transcript while the arrows depict the 
transcripts produced.  Early transcripts (E1-E4) are shown using thinner arrows and the 
late transcripts (L1-L5) are shown with thick arrowheads.  The ITR are located at both 
the left and right ends of the genome (not shown). 
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(Chartier et al. 1996; Shenk 1996; Crouzet et al. 1997).  Both the first and second 
methods mentioned are not commonly used due to the scarcity of unique restriction sites 
in the AdV genome, low efficiency of homologous recombination, cumbersome process 
of generating an Ad and increased contamination by RCA.  The latter method is the 
most preferred method commonly used and involves the use of highly efficient 
homologous recombination systems such as Cre-lox recombination based methods 
and/or bacterial cloning systems (Danthinne and Imperiale 2000).   
In general, recombination system utilizes two vectors to produce the AdV vector.  
The first vector contains a fair majority of the right side of the AdV genome and the 
right ITR, but lacks the E1 and E3 genes.  This cosmid or “backbone” vector contains its 
own ori and selection marker but lacks the viral packaging signal rendering the 
expressed gene products unable to package itself.  The second vector, referred to as the 
shuttle vector, contains the gene of interest flanked by two homology arms and a small 
portion of the left side of the AdV genome that contains the packaging signal and the left 
ITR.  When the homologous recombination event occurs between the backbone vector 
and the shuttle vector, the resulting vector will contain the transgene as well as both ends 
of the ITR.  The resulting vector is then transfected into the packaging cell line that 
eventually produce the replication deficient/defective AdV. 
Resulting E1 and/or E3 deleted AdV vectors provide transient transgene 
expression in vivo, reaching expression peak levels at 3-4 days and lasting up to 2 
weeks.  These first generation AdV vectors have been utilized in various applications for 
cancer gene therapy encoding genes for cytokines, thymidine kinase (HSV-TK) and p53.   
It was initially believed that the replication-deficient nature of the E1/E3 deleted 
virus would not allow transcription of any of the viral gene products; however, low 
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levels of viral transcripts are still produced and viral gene products can further stimulate 
an immune response (Imperiale and Kochanek 2004).  Therefore, one of the major 
drawbacks or possibly an advantage to the use of first generation AdV vectors is its 
immunogenicity factor.  These Ad have the tendency to elicit strong immune responses 
against viral proteins, by inducing neutralizing Ab against the vector capsid proteins and 
CTL against the transgene products and viral Ag (Yang et al. 1994; Yang et al. 1995b; 
Worgall et al. 1997).  In addition, during the inflammatory phase, cytokines such as 
TNF-α are secreted that further limit the transgene expression from AdV.  Development 
of these AdV responses potentially limits the number of applications the AdV could be 
given since the presence of both neutralizing Ab and CTL would limit entry of the AdV 
into cells and ultimately its expression in targeted cells.     
 
1.12.4.2. Second generation vectors 
Second generation AdV vectors were created by further deleting additional early 
genes such as E2 and E4 genes and further preventing viral replication.  The deletion of 
these genes provides a further increase to the insert gene size and improvement in the 
transgene persistence.  This will result in reduced inflammation (Armentano et al. 1995; 
Gao et al. 1996; Amalfitano et al. 1998).  However, in some studies, second generation 
AdV still remained immunogenic as evidenced by detection of T cell responses (O'Neal 
et al. 1998; Xu et al. 2005) and reduced transgene expression (Andrews et al. 2001).  As 
well, the immunogenicity of AdV have been question following the death of an 18 year 
old patient in 1999 given gene therapy treatment with an E1/E4 deleted Ad to correct a 
partial ornithine transcarbamoylase (OTC) deficiency (Marshall 1999; Raper et al. 2002; 
Raper et al. 2003).   The patient’s death was a result of direct infusion of an extremely 
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high dose of 3.8x1013 Ad particles into the hepatic artery that led to disseminated 
intravascular coagulation and multi-organ failure. 
 
1.12.4.3. Third generation (gutted) vectors 
A third generation of AdV vector, dubbed the gutted, gutless or helper dependent 
AdV, was developed allowing for further increase in the size of transgene insert and a 
further reduction in the AdV immunogenicity.  Gutted AdV vectors were created by the 
removal of all AdV genes except for cis-regulatory elements necessary for replication 
and packaging (i.e. the ITR and the packaging signal).  Inserts up to 36-37 kb in size are 
achievable and this vector allows for a variety of constructs to be created by including 
tissue-specific promoters and numerous expression cassettes, with the remainder filled in 
with non coding stuffer DNA to achieve the appropriate packaging size (Kochanek 
1999).  For viral replication of the gutted vector, an E1-deleted helper virus is coinfected 
into 293 cells to provide the necessary viral genes in trans to allow for viral replication 
and packaging (Volpers and Kochanek 2004).  Studies have shown the use of gutted 
vectors generated greatly reduced toxicity thus immunogenicity and improved transgene 
expression in comparison to the first generation Ad, while allowing for stable transgene 
expression, detected beyond one year (Muruve et al. 2004).  
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2.0 HYPOTHESIS AND SPECIFIC AIMS 
This thesis presents research data from two projects, broken into Parts A and B, 
both of which involve the use of DC and the development of a cancer vaccine for their 
respective tumor animal models. 
 
2.1. Part A:  Adenovirus mediated transfer of the rat neu gene into DC as a breast 
cancer vaccine 
 
RATIONALE:  Breast cancer affects one in nine women and HER-2/neu is commonly 
overexpressed in 30% of breast cancer cases.  Overexpression of HER-2/neu is 
correlated with a rather poor prognosis and overall an aggressive disease for patients.  
Developing a therapy to prevent/protect individuals from breast cancer would benefit a 
large section of the human population, given that one in nine women will develop breast 
cancer.  HER-2/neu is a suitable target for immunotherapy especially since the FDA 
approved in 1998 the clinical use of Herceptin, a human mAb targeting HER-2/neu, for 
metastatic breast cancer patients.  Despite the positive clinical signs observed with 
Herceptin, there are limitations to this passive form of immunotherapy used and more 
active forms are being sought. Active forms of immunotherapy attempt to use the body’s 
own immune system to mount an effective antitumor immune response against HER-
2/neu expressing tumors (Emens et al. 2005).  DC represent powerful professional APC 
involved in initiation of an immune response.  DC are easily loaded with tumor Ag by 
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various methods.  Taken into consideration that most cancer vaccines to date involve the 
use of DC, either indirectly or directly, DC-based vaccines make complete sense.  DC 
vaccines are very popular and are a common entity in the various types of cancer 
vaccines utilized within our lab.  Harnessing the powerful capabilities of DC and 
specific TAA targeting allows efficient generation of antitumor immune responses and 
effective protection and prevention of tumors from forming.  Taken together, the main 
focus in Part A of this thesis dissertation seeks to determine if DC transduced with a 
replication defective AdV encoding the full length rat neu gene (DCneu) would induce an 
immune response that provides protective and preventive effects from tumors forming in 
mouse animal models of breast cancer.  We also sought to compare, in a side-by-side 
study, the efficacies between our DCneu vaccine and plasmid DNA vaccine encoding the 
full-length rat neu gene. 
 
HYPOTHESIS:  By transducing DC with a replication deficient AdV, the rat neu gene 
would be expressed within DCneu and be privileged for efficient Ag processing.  This 
would result in the neu Ag peptide loaded onto both MHC class I and class II molecules 
to stimulate both CD8+ and CD4+ T cells, respectively.  This, in turn, would stimulate 
strong immune responses, mainly T cell responses and provide protective immunity in 
mice challenged with a neu expressing tumor cell line.  It would also provide sufficient 
levels of immunity to prevent spontaneous tumor development in a Tg mouse model.   
 
Specific Aim One:  We wanted to examine the ability of DCneu to stimulate an 
immune response that provides effective protection against challenge with neu 
expressing tumor cells in various mouse animal models and to compare in a side by side 
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study the mechanisms involved with the antitumor immune mechanisms and overall 
effectiveness of our DCneu vaccine with plasmid DNA-based vaccine. (Section 4.1) 
 
Specific Aim Two:  We wanted to utilize a xenogeneic approach with a DC-based 
vaccine to improve the immunogenicity and assist in overcoming the tolerance of neu in 
FVBneuN Tg mice. (Section 4.2) 
 
2.2. Part B:  Enhancement of T cell immunity induced by DC phagocytosis of 
HSP70-transfected tumor cells on antitumor immunity 
 
RATIONALE:  DC are powerful APC that function in initiation of antitumor immune 
responses by presenting TAA and stimulating tumor specific T cell responses.  DC can 
acquire soluble Ag from living cells and even take up cells that are dying through 
apoptotic or necrotic pathways.  Currently, controversy exists in the literature as to the 
effects apoptotic cells have on the maturation status of DC, with some reports indicating 
that apoptotic cells are better than necrotic cells, vice versa or no difference observed. 
 In Dr. Xiang’s lab, we have previously demonstrated that apoptotic tumor cells 
with secondary necrosis induced DC maturation.  Furthermore, vaccination of DC that 
phagocytosed apoptotic tumor cells in the late phase of apoptosis efficiently stimulated 
antitumor immunity (Chen et al. 2001c).  However, the potential critical role of HSP70 
expression in this model was not investigated at that time.  There are some reports 
indicating necrotic tumor cells expressing HSP70 can promote DC maturation where as 
apoptotic cells are not able to (Basu et al. 2000; Sauter et al. 2000).  On the other hand, it 
is possible that the effects of dying tumor cells on the maturation and function of DC 
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may depend not only on the type of cell death (apoptosis versus necrosis), but also on 
the phase of tumor cell apoptosis (early apoptosis versus late apoptosis) in relation to the 
expression of HSP70.   
 
HYPOTHESIS:  We hypothesized that the expression of HSP70 in apoptotic tumor 
cells and subsequently used for phagocytosis by DC in vitro would affect DC maturation 
and efficiently induce tumor-specific CTL responses.  This will reveal that the phase of 
apoptosis relative to the expression of HSP70 would have an important effect.  This in 
turn would induce stronger antitumor immunity by protecting immunized mice from 
tumor challenge.   
 
Specific Aim One:  We wanted to investigate the impact of apoptotic tumor cells 
at different phases of apoptosis, in respect to the presence of cellular HSP70 expression 
or lack thereof, on functional stimulation of DC maturation, T cell stimulatory activity 
and vaccine efficiency in a mouse tumor model of cancer.  (Section 4.3) 
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3.0 MATERIALS AND METHODS 
 
3.1. Reagents and suppliers 
The reagents used in the experiments presented in this thesis are listed in Table 
3.1.  All of the reagents used were molecular biology or research grade.  Commercially 
available kits directly used in this study are listed in Table 3.2.  The addresses of the 
companies where the reagents were obtained are shown in Table 3.3. 
 
 
Table 3.1:  List of reagents and suppliers 
 
Reagent Supplier Name 
[α-33P]-UTP Amersham Biosciences 
[3H]-methyl-thymidine Amersham Biosciences 
[51Cr]-sodium chromate Amersham Biosciences 
Acrylamide:bisacrylamide  Bio-Rad 
Agar Invitrogen 
Agarose Invitrogen 
Alkaline phosphatase New England Biolab 
Ammonium chloride EM Sciences 
Ammonium persulfate Gibco 
Ampicillin Sigma 
Bacto-tryptone BD 
Bovine insulin Sigma 
BSA Sigma 
Calcium chloride Sigma 
Cesium chloride Sigma 
CFSE Molecular Probes 
Chloroform EM Sciences 
Coomassie Blue Bio-Rad 
DMEM Gibco 
DMSO Sigma 
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Reagent Supplier Name 
dNTP mix (dATP, dCTP, dGTP, dTTP) Invitrogen 
Electroporation cuvette (0.2cm, 0.4 cm gap) Bio-Rad 
EMEM Gibco 
Ethanol EM Sciences 
Ethidium bromide Sigma 
FBS Cyclone 
Ficoll-Paque Amersham Biosciences 
Formalin EM Sciences 
Gentamicin Reagent Solution Gibco 
Glutaraldehyde Sigma 
Glycerol BDH Inc 
Glycine EM Sciences 
GM-CSF R&D Systems 
Hydrochloric acid EM Sciences 
IL-2 Peprotech 
IL-4 R&D Systems 
IPTG Gibco 
Isopropanol EM Sciences 
Kanamycin Sigma 
Klenow Fragment Invitrogen 
Lysozyme Sigma 
magnesium chloride Sigma 
Methanol EM Sciences 
Mouse CD4 (L3T4) Paramagnetic beads Dynal 
Non-fat dry milk Carnation 
Nylon wool Interscience 
PEG-8000 Sigma 
PfuTurbo DNA polymerase Stratagene 
Pfx DNA polymerase Invitrogen 
Phenol EM Sciences 
Prestained molecular weight protein marker Bio-Rad 
Proteinase K Invitrogen 
RNAse Amersham Biosciences 
RPMI 1640  Gibco 
SDS Sigma/Bio-Rad 
Sodium acetate BDH Inc 
Sodium azide Sigma 
Sodium hydroxide EM Science 
Streptomycin Sigma 
Sucrose BDH Inc 
Sulfuric Acid (H2SO4) BDH Inc 
T4 DNA ligase USB 
Taq DNA polymerase Invitrogen 
TEMED Gibco 
TRIS EM Science 
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Reagent Supplier Name 
Triton X-100 Sigma 
Trypan Blue Stain  Gibco 
Trypsin/EDTA Gibco 
Tween 20 Bio-Rad 
X-gal Gibco 
Yeast Extract Difco 
Β-mercaptoethanol Bio-Rad 
λDNA/HindIII marker Invitrogen 
φX174/HaeIII fragment marker Invitrogen 
 
 
 
Table 3.2:  Commercially available kits used in this study 
 
 
Commercial Kits Supplier Name 
Annexin V FITC Apoptosis Detection kit BD Biosciences 
CellTiter 96 Nonradioactive cell 
proliferation assay 
Promega 
Elutip-D columns Scheicher & Schuell 
Endo-free Giga Kit Qiagen 
Endo-free Mega Kit Qiagen 
GenElute Agarose Spin column Sigma 
OptEIA Mouse IFNγ ELISA kit Pharmingen/BD Biosciences 
OptEIA Mouse IL-4 ELISA kit Pharmingen/BD Biosciences 
OptEIA Mouse IL-6 ELISA Kit Pharmingen/BD Biosciences 
OptEIA Mouse TNF-α Kit Pharmingen/BD Biosciences 
PE-labeled H-2Kb/OVA257-264 tetramer Beckman-Coulter 
Plasmid Mini Kit Qiagen 
Qiaprep Spin Kit Qiagen 
Quikchange site directed mutagenesis kit Stratagene 
Superscript first strand synthesis for RT-
PCR kit 
Invitrogen Life Technologies 
TMB Substrate Kit Pharmingen 
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Table 3.3:  Addresses of suppliers 
 
 
Companies Addresses 
Amersham Biotech Amersham Biotech, Inc., Baie d’Urfe, Canada 
ATCC American Type Culture Collection, Rockville, MD 
USA 
BD Biosciences BD Biosciences, Mississauga, ON Canada 
BDH BDH Inc., Toronto, ON Canada 
Beckman-Coulter Beckman-Coulter, Miami, FL, USA 
Beckman-Coulter Beckman-Coulter, Fullerton CA  USA 
Bio-Rad Bio-Rad Laboratories, Ltd., Mississauga, ON Canada 
Caltag Caltag Laboratories, Burlingame, CA, USA 
Charles River Laboratories Charles River Laboratories, St. Laurent, Quebec 
Canada 
Difco Difco Laboratories, Detroit, MI, USA 
Dynal Dynal, Inc, Lake Success, NY 
EM Science EM Science, Gibbstown, NJ, USA 
EMD Chemicals EMD Biosciences, La Jolla, CA, USA 
Gibco Gibco (Invitrogen), Gaithersburg, MD  USA 
HyClone HyClone Laboratories, Logan, UT, USA 
Interscience  Interscience Inc., Markham ON, Canada 
Invitrogen Life Technologies Invitrogen Life Technologies, Carlsbad, CA USA 
Jackson ImmunoResearch Jackson ImmunoResearch Laboratories Inc, West 
Grove, PA  USA 
Microbix Microbix Biosystems Inc, Toronto, ON Canada 
Molecular Probes Molecular Probes, Inc., Eugene, OR, USA 
NEB New England BioLabs Inc, Ipswich, MA  USA 
NEN Research Products DuPont NEN Research Products, Boston, MA, USA 
Nunc Nalgene Nunc International, Rochester NY, USA 
Oncogene Research Products Oncogene Research, San Diego, CA, USA 
Peprotech Peprotech, Inc., Rocky Hill NJ, USA 
PerkinElmer PerkinElmer Life Sciences, Inc.  Boston, MA, USA 
Pharmingen BD Biosciences, Mississauga, ON, Canada 
Pierce BioLynx, Brockville, Canada 
Promega Promega Corporation, Madison, WI, USA 
Qiagen Qiagen, Mississauga, Canada 
R&D Systems R&D Systems Inc., Minneapolis, MN, USA 
Schleicher & Schuell Schleicher & Schuell BioScience, Keene, NH, USA 
Sigma Sigma-Aldrich, St. Louis, MO, USA 
Stratagene Stratagene, La Jolla, CA  USA 
USB USB Corporation, Cleveland, OH, USA 
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3.2. Antibodies 
A list of the various antibodies used throughout the study and their respective 
suppliers are listed in Table 3.4.  Abs were either FITC, phycoerythrin (PE), horse radish 
peroxidase (HRP) or biotin labeled. 
 
 
 
Table 3.4:  List of antibodies and respective suppliers 
 
Antibody Supplier 
Anti-CD3 Pharmingen 
Anti-FcγII/III/CD16/32 Pharmingen 
Anti-H-2Kb/OVAI (pMHC I)  Dr. Germain (NIH, Bethesda, MD) 
Anti-HSP70  Pharmingen 
Anti-human HER-2 Dr. Sami (Saskatoon Cancer Centre) 
Anti-IL-6 Pharmingen 
Anti-mouse CD11b Pharmingen 
Anti-mouse CD11c Pharmingen 
Anti-mouse CD25 Pharmingen 
Anti-mouse CD40 Pharmingen 
Anti-mouse CD54 Pharmingen 
Anti-mouse CD8 – FITC labeled Beckman-Coulter 
Anti-mouse CD80 Pharmingen 
Anti-mouse CD86 Pharmingen 
Anti-mouse H-2Kb Pharmingen 
Anti-mouse H-2Kd Pharmingen 
Anti-mouse H-2Kq Pharmingen 
Anti-mouse Iab Pharmingen 
Anti-mouse Iad Pharmingen 
Anti-mouse Iaq Pharmingen 
Anti-neu antibody (Ab-3) Oncogene Research Products 
Anti-neu antibody (Ab-4) Oncogene Research Products 
Goat anti-human IgG-FITC Jackson ImmunoResearch 
Goat anti-mouse IgG1 Caltag 
Goat anti-mouse IgG2a Caltag 
Goat anti-mouse IgG-FITC Jackson ImmunoResearch 
Streptavidin-conjugated phecoerythrin-Texas 
Red-X (ECD) 
Beckman-Coulter 
Streptavidin–FITC conjugated Pharmingen 
Streptavidin-HRP conjugated Jackson ImmunoResearch 
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3.3. Cell lines 
HEK 293 cells, containing the adenoviral E1 genes transformed into the cells, 
were purchased from Microbix (Toronto, ON) and grown in Minimum Essential 
Medium containing Earle’s Salts (EMEM; Gibco) supplemented with 10% (v/v) fetal 
bovine serum (FBS; Hyclone).  All of the media used also included 30 µg/ml gentamicin 
solution (Gibco).  The Tg1-1 mouse breast cancer cell line (H-2Kq) (Chen et al. 1998), 
derived from a spontaneous breast tumor from FVBneuN Tg mouse was obtained from 
Dr. T. Kipps, University of California, San Diego, CA.  Another mouse mammary tumor 
cell line, CaD1, was obtained from Frederick Cancer Research and Development Center 
(Frederick, MD).  MCA-26, a mouse colon cancer cell line, was obtained from 
American Type Culture Collection (ATCC).  These cell lines were maintained in 
Dulbecco’s Modified Eagle’s Medium (DMEM; Gibco) supplemented with 10% FBS 
and gentamicin solution.  The cell lines, EL4, a T cell lymphoma, and its ovalbumin 
(OVA) gene-transfected cell line, EG7, are from a C57BL/6 (H-2Kb) origin and obtained 
from ATCC.  The B cell lymphoma cell line, A20, originating from BALB/c mice (H-
2Kd), was also obtained from ATCC.  These cells were maintained in DMEM, while 
EG7 was maintained in DMEM containing 0.5 mg/ml G418 (Gibco).  The human breast 
cancer cell line, T47-D, was obtained from ATCC and grown in DMEM with 10% FBS 
and containing 8 µg/ml bovine insulin (Sigma).   
In most cases, the cell lines were passaged using Trypsin/ethylenediamine 
tetracetic acid (EDTA; Gibco) whereas 293 cells were passaged using a 1X citric saline 
solution [10% (w/v) KCl and 4.4% (w/v) sodium citrate].  All cell lines were cultured in 
a humidified CO2 incubator with a 5 % CO2 atmosphere and at 37ºC.  Cell counting was 
performed using Trypan-Blue stain (Gibco) and counted on a haemocytometer. 
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 3.4. Animals 
Wild-type female FVB/N (H-2Kq) and Tg FVBneuN (H-2Kq) [FVB/N-
TgN(MMTVneu)202Mul mice] were obtained from Jackson Laboratories (Bar Harbor, 
ME).  Female BALB/c (H-2Kd) and C57BL/6 (H-2Kb) mice were obtained from the 
University of Saskatchewan Animal Resource Centre and Charles River Laboratories 
(St. Laurent, Quebec, Canada), respectively.  Ovalbumin (OVA)-specific T cell receptor 
(TCR)-Tg OT I mice developed on a C57BL/6 background were obtained from Jackson 
Laboratories.  All mice were approximately 4-6 weeks old and housed in the animal 
facility at the Saskatoon Cancer Centre.  All animal experiments were approved by the 
University Committee on Animal Care and Supply committee in accordance with the 
Canadian Council for Animal Care guidelines.  
 
3.5. Bacterial cells 
DH5α Escherichia coli (E. coli) cells were routinely used as the bacterial host for 
vector propagation.  E. coli BJ5183 cells were obtained from Stratagene and used only 
for homologous recombination in the construction of AdV vectors.  Both of these cells 
were grown at 37ºC in a shaking incubator in a flask containing Lauria-Bertani (LB) 
broth consisting of 1.0% (w/v) tryptone (Difco), 0.5% (w/v) yeast extract (Difco) and 
1.0% (w/v) NaCl supplemented with the appropriate antibiotic such as ampicillin 
(100µg/ml) or kanamycin (50µg/ml), depending on the vector.  For isolation of 
transformed bacterial cells, the cells were plated onto selective LB-agar plates, 
containing LB broth with 1.5% (w/v) agar supplemented with the appropriate antibiotic, 
and incubated inverted at 37ºC overnight.  
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 3.6. General molecular biology techniques 
The routine molecular biology protocols used in this study were based upon the 
methods described in Molecular Cloning: A Laboratory Manual by Sambrook et al and 
Sambrook and Russel (Sambrook et al. 1989; Sambrook and Russell 2001). 
 
3.6.1. Restriction enzyme digest 
Restriction enzymes used in this study were obtained from either Amersham 
Biosciences or New England Biolabs.  The restriction enzyme digests were performed 
on at least 1µg DNA in 1X the final recommended buffer suggested by the manufacturer 
and using at least 1 unit of the specified enzymes.  For complete restriction enzyme 
digestion, the reactions were incubated at 37ºC for 1 hour. 
 
3.6.2. Generating blunt ends from recessed or protruding 3’ overhangs 
Recessed 3’ overhangs produced by restriction enzyme digest were extended to 
produce blunt ends.  Recessed ends were extended by adding 1µl of 10 mM dNTP mix 
and 8 units of DNA polymerase I Klenow fragment (Invitrogen) in 1X Nick Translation 
buffer [50 mM Tris-HCl (pH 8.0), 5 mM MgCl2, 1 mM dithiothreitol (DTT)].  The 
sample was incubated at room temperature for 30 min.  The reaction was terminated by 
the addition of 3 µl 0.5 M EDTA and precipitated. 
 
3.6.3. Removal of 5’ terminal phosphate group 
Dephosphorylation of the 5’ phosphate group was accomplished using calf 
intestinal alkaline phosphatase (New England Biolabs) added to digested DNA 
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resuspended in 10 mM NaCl, 5 mM Tris-HCl, 1 mM MgCl2 0.1 mM DTT and incubated 
at 37ºC for 1 hour.  DNA was further purified with either gel purification kits or using 
phenol:chloroform:isoamyl alcohol extraction.  
 
3.6.4. Agarose gel electrophoresis 
Agarose gels were cast using a GelHorizon 58 Apparatus of varying agarose 
concentrations ranging from 0.7% to 2% in TAE buffer [40 mM Tris-acetate, 1 mM 
EDTA containing 1 µg/ml ethidium bromide (EtBR; Sigma)].  DNA samples were 
loaded onto the gels with gel loading buffer [0.042% (w/v) bromophenol blue, 6.67% 
(w/v) sucrose] along with the DNA markers, λDNA/Hind III and φX174/Hae III 
fragment markers (Invitrogen).  Gel electrophoresis was performed between 90 to 110 V 
in TAE buffer for varying times to obtain optimal resolution.  Gels were visualized by 
UV illumination on a gel documentation system (Bio-Rad). 
 
3.6.5. Purifying linear DNA fragments 
Linear DNA fragments for further downstream applications were isolated from 
DNA agarose gels and purified using the GenElute Agarose spin columns (Sigma).  On 
certain occasions, based upon the fragment size or the amount of sample, electroelution 
was performed to elute the DNA from the gel.  The electroeluted DNA sample was 
further purified and concentrated using Elutip-D columns (Schleicher & Schuell) 
according to manufacturer’s protocol, using 200 mM NaCl, 20 mM Tris-HCl and 1.0 
mM EDTA, pH 7.4. 
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3.6.6. Site directed mutagenesis 
Site directed mutagenesis was done accordingly to the protocol set out in the 
Quikchange Site Directed Mutagenesis kit (Stratagene) using complimentary primers 
that span the mutation region of interest and the thermostable, proof-reading enzyme, 
PfuTurbo polymerase (Stratagene).   
 
3.6.7. Ligation 
DNA ligation was performed using 50 ng of vector DNA and at least 200 ng of 
purified, insert DNA in a 10 µl volume containing 10 mM Tris-acetate (pH 7.5), 10 mM 
magnesium acetate, 50 mM potassium acetate, 1 mM ATP and 1-5 unit T4 DNA ligase 
(USB).  Ligations were performed overnight in a 14ºC water bath. 
 
3.6.8. Sequencing 
Automated dideoxy sequencing was performed by Annette Kerviche at the 
Saskatchewan Cancer Agency or at the sequencing facilities at the Plant Biotechnology 
Institute of the National Research Council of Canada in Saskatoon, Canada. 
 
3.6.9. Competent cells and transformation 
3.6.9.1.  Standard competent cells and transformation 
Competent cells was prepared based upon a modified version of the original 
method described by Cohen et al 1972 (Cohen et al. 1972; Sambrook et al. 1989).  
Briefly, an overnight culture of bacterial cells were grown in LB medium until mid log-
phase growth with an OD600 reading between 0.4-0.6 then spun down.  The cell pellet 
was washed twice, using 50 mM CaCl2 10 mM Tris-HCl (pH 8.0) then finally 
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resuspended in the same solution.  Transformations were performed using 100 µl of 
competent cells with the DNA mixture and incubated on ice for 30 min.  The sample 
was heat shocked by quickly placing the sample at 42ºC for 50 sec then returned to ice 
for several minutes.  SOC media [2% (w/v) bacto-tryptone, 0.5% (w/v) yeast-extract, 
0.05% (w/v) NaCl, 20 mM glucose] was added to the sample then incubated at 37ºC to 
allow the bacteria to recover before plating the cells on selective LB-agar plates.  When 
blue-white colony screening was required, selective LB-agar plates containing 50 µg/ml 
X-gal (Gibco) and 0.1 mM isopropylthio-β-D-galactoside (IPTG; Gibco) were used. 
 
3.6.9.2.  Electrocompetent and electrotransformation 
Electrocompetent cells were prepared using the method described previously by 
Dower et al (Dower et al. 1988; Sambrook and Russell 2001).  The bacterial cells were 
grown overnight in selective LB broth then subcultured into fresh media the following 
morning.  The fresh culture was grown until mid-log phase was reached, as evidenced 
when the culture reached the specified OD600 previously determined.  Bacterial cells 
were chilled then centrifuged at 1,000 x g in a J10 rotor (Beckman).  The sample was  
washed twice and resuspended in a 10% (v/v) glycerol in water solution then stored at -
80°C until required.  Bacterial cells were then placed into chilled electroporation 
cuvettes (0.2 cm gap; Bio-Rad) with the DNA and electroporated using the following 
conditions: 200 Ω (ohms), 2.5 kV and 25 µFD using a Gene Pulser with Pulse Controller 
(Bio-Rad).  LB media was added to the sample and incubated at 37ºC for one hour to 
allow bacteria to recover prior to plating the culture onto selective LB-agar plates with 
the appropriate antibiotic. 
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 3.6.10. Isolation of plasmid DNA from host bacterial cells 
3.6.10.1. Small scale (mini-preps) 
To screen colonies after transformation for positive recombinants, small scale 
preparations using an alkali lysis method was performed.  Briefly, single isolated 
colonies were selected and cultured overnight in LB containing the appropriate 
antibiotic.  The overnight cultured cells were resuspended in 50 mM glucose, 10 mM 
EDTA, 25 mM Tris-HCl (pH 8.0), 2 mg/ml lysozyme (Sigma) then lysed with a 200 
mM NaOH, 1% sodium dodecyl sulfate (SDS) solution followed by the addition of 3M 
sodium acetate, pH 5.2.  This precipitated out the bacteria chromosomal DNA, cellular 
protein and debris.  The supernatant was then extracted twice with 
phenol:chloroform:isoamyl alcohol followed by ethanol precipitation.  The precipitated 
DNA was resuspended in TE (pH 8.0) containing 40µg/ml RNAse A.  DNA 
concentration was measured by standard A260/A280 spectrophotometric readings and 
visualizing on agarose gels. 
 
3.6.10.2. Large scale (large-prep) 
Bacterial cells were grown overnight in Terrific broth (TB) [1.2% (w/v) bacto-
tryptone, 2.4% (w/v) yeast-extract, 0.4% (v/v) glycerol, 17 mM KH2PO4 and 72 mM 
K2HPO4] in a shaking incubator at 37ºC.  The sample was treated using the same 
solutions used for small preps but also included a polyethylene glycol (PEG) purification 
step.  The purified DNA was resuspended in TE (pH 8.0) or in sterile PBS for use in 
transfections and the concentration determined using methods mentioned above. 
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3.6.10.3. Endotoxin free preparation 
Endotoxin free preparations of vector DNA, for use in plasmid DNA 
immunizations, were done using Endofree plasmid Mega and Giga kits (Qiagen).  The 
manufacturer’s protocol was followed with the bacterial cells grown in LB broth, 
alkaline lysed, removal of endotoxin (LPS) and isopropanol precipitation of plasmid 
DNA.  The concentration of isolated plasmid DNA was determined with standard 
A260/A280 spectrophotometric readings.  Plasmid DNA was resuspended in sterile PBS at 
a final concentration of 1 mg/ml and stored at –20ºC until use.  
 
3.6.11. RNA isolation  
RNA was isolated from freshly isolated tissue culture samples using the RNeasy 
mini kit (Qiagen), according to the manufacturer’s suggested protocol.  Isolated RNA 
was resuspended in RNase free distilled water with the concentration and purity 
determined by standard A260/A280 spectrophotometric readings.  Samples were stored at -
80ºC until needed. 
 
3.6.12. Reverse transcriptase PCR (RT-PCR) and cDNA synthesis 
Isolated RNA was used as a template for cDNA synthesis using the SuperScript 
First-strand Synthesis System for RT-PCR (Invitrogen), according to the instructions 
provided by the manufacturer.  Briefly, 5µg of RNA was incubated in 20 mM Tris-HCl 
(pH 8.4), 50 mM KCl, 5 mM MgCl2, 10 mM DTT, 0.5 mM of each dNTP, 0.5 µg 
Oligo(dT)12-18, 40 units of RNase inhibitor and 50 units SuperScript II reverse 
transcriptase enzyme, for a final volume of 20 µl.  The sample was incubated at 42ºC for 
50 min followed by 70ºC for 15 min to terminate the reaction.  The remaining RNA was 
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removed by further treating the sample with 1 unit of RNase H.  Samples were used 
either immediately for PCR reaction or stored at -20ºC until needed. 
 
3.6.13. PCR reactions 
Typical PCR reactions were performed using a predetermined amount of 
template DNA/cDNA in a final volume of 100 µl containing 20 mM Tris-HCl (pH 8.0), 
20 mM KCl, 1.5 mM MgCl2, 1 mM dNTP mix, 10 ng of each primer and 2.5 units of 
Taq polymerase (Invitrogen).  The typical cycles used in PCR reactions include the 
initial DNA denaturing step at 94ºC for 5 min followed by 25-30 amplification cycles at 
94ºC for 1 min, 56-58ºC for 1 min and 72ºC for 1 min followed with a final termination 
step for 10 min at 72ºC.  After PCR amplification, one-tenth of the reaction volume was 
resolved by standard agarose gel electrophoresis.  Water was used as the template to 
serve as the negative controls.  For RT-PCR samples, a control reaction detecting the 
levels of the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
was performed using the forward primer, 5’-CAGGTTGTCTCCTGCGACTT-3’, and 
the reverse primer, 5’-CTTGCTCAGTGTCCTTGCTG-3’.   
 
3.7. Expression vector construction 
3.7.1. Expression vectors 
The psV2-neu vector, containing the full-length rat neu gene, was obtained from 
Dr. R. Weinberg (Whitehead Institute for Biomedical Research, Cambridge, MA).  
Vectors pUC18 and pcDNA3.1 (both + and -) were readily available in Dr. Xiang’s lab.  
The vectors, pCR2.1 and pCR-Blunt, from the TA cloning kit (Invitrogen) and Zero 
Blunt PCR cloning kit (Invitrogen), were also present in the lab. 
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 3.7.1.1.Construction of the rat neu expression vector 
The pSV2-neu vector was digested with Hind III and Sal I, liberating the 4.6 kb 
full length rat neu gene fragment and gel-purified.  This fragment was ligated into the 
Hind III/Sal I cut pUC18 vector forming the vector, pUC18/neu.  Next, pUC18/neu was 
digested with Hind III and Kpn I and the resulting 4.7 kb fragment was gel purified.  
This fragment was then ligated into the Hind III/Kpn I digested pCDNA3.1(+) vector, 
resulting in pcDNA-neu (Figure 3.1A).  The vector construct was verified by restriction 
digest analysis.   
 
3.7.1.2.Construction of the HER-2 expression vector 
The cDNA for the full-length human HER-2 gene was cloned by RT-PCR using 
a cDNA library obtained from the human breast cancer cell line, T47-D, known to 
express HER-2.  The primers used for this were the forward primer 5’-
CAGTGAGCAACCATGGAGCTGG-3’ and the reverse primer 5’-
TCCACAAAGACTCCCCAGTC-3’.  To minimize the number of mutations 
incorporated based upon the polymerase used, the PCR amplification step was 
performed using a high fidelity polymerase, Platinum Pfx DNA Polymerase 
(Invitrogen), according to the manufacturer’s protocol.  The resulting PCR product was 
resolved on an agarose gel and the 4 kb fragment was gel purified for ligation into the 
blunt ended pCR-Blunt vector.  This ligation created the vector pCR-Blunt-HER2.  
Automated dideoxy nucleotide sequencing, using the M13 Reverse primer, T7 promoter 
primer and various primers spanning the full length HER-2 gene, was performed to 
ensure the product contained no mutations induced by the polymerase and to determine  
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Figure 3.1  Physical maps of expression vectors used.  The expression vectors used 
include pcDNAneu (A), pcDNA-HER2mut (B) and pCDNA-HSP70 (C). 
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the gene orientation within the vector.   
To address safety concerns with using HER-2, we mutated codon 753 from AAA 
to GCA, which changed the residue from a lysine to an alanine.  This mutation occurred 
in the cytoplasmic domain in a critical area that prevents ATP from binding (Ben-Levy 
et al. 1994; Xu et al. 2001).  The QuikChange Site Directed Mutagenesis kit (Stratagene) 
was used to perform site-directed mutagenesis, according to the manufacturer’s protocol 
using pCR-Blunt-HER2 as the template DNA.  Complimentary primers 5’-
CCAGTGGCCATCGCAGTGTTGAGGGAAAACACATCC-3’ and 5’-
GGATGTGTTTTCCCTCAACACTGCGATGGCCACTGG-3’, where the bolded 
underlined sequence represents the incorporation of the mutation, were used.  Sequence 
analysis was done to verify the presence of the directed mutation within the gene.  The 
resulting vector containing the mutation was renamed as pCR-Blunt-HER2mut.  Next, 
pCR-Blunt-HER2mut was digested with the restriction enzymes Hind III and Xba I, 
resulting in the release of a 4.1 kb fragment that was gel purified and used in a 
subsequent ligation into Hind III/Xba I digested pcDNA3.1(-) vector creating pCDNA-
HER2mut (Figure 3.1B). 
 
3.7.1.3.Construction of the HSP70 expression vector. 
Total RNA was extracted from EG7 tumor cells using RNeasy Mini Kit (Qiagen). 
A 2.0–kb cDNA fragment coding for the open reading frame of HSP70 molecule was 
cloned by RT-PCR from a cDNA library of EG7 cells using PFU polymerase and both 
the sense primer 5'- AGCCTTCCAGAAGCAGAGCG-3' and the antisense primer 5'-
GCAGCTATCAAGTGCAAAGAGTCTG-3’).  The cloned cDNA fragment of HSP70 
was ligated into the pCR2.1 vector, to form pCR2.1/HSP70. The HSP70 gene sequence 
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was verified by dideoxy nucleotide sequencing method. The HSP70 gene fragment 
(EcoR V/Bam H1) was digested and cloned into the plasmid pcDNA3.1, forming the 
expression vector pcDNA-HSP70 (Figure 3.1C).  
 
3.8. Adenovirus vectors construction 
AdVpLpA, containing no transgene, was previously created and readily available 
in Dr. Xiang’s lab (Wright et al. 1999).  Both AdVneu and AdVHER2mut were created using 
the AdEasy system, incorporating the use of efficient homologous recombination events 
in bacterial cells (He et al. 1998).  The vectors pShuttleCMV and pAdEasy-1 were 
obtained from Dr. Lixin Zhang (John Hopkins/Sidney Kimmel) and Stratagene, 
respectively. 
 
3.8.1. AdVneu 
The vector, pcDNA-neu, was digested with Hind III and EcoR V releasing a 4.7 
kb fragment containing the rat neu gene.  This fragment was directionally cloned into 
Hind III/EcoR V digested pShuttleCMV, creating pShuttleCMV-neu (Figure 3.2).  The 
DNA vectors was purified using Qiagen columns then subsequently used for digest with 
Pme I to linearize the vector.  The linearized vector was treated with alkaline 
phosphatase and gel purified followed by ethanol precipitation.  The DNA was spun 
down, dried and resuspended in distilled water.  A total of 1 µg of the Pme I-linearized 
pShuttleCMV-neu and 100 ng of pAdEasy-1 (Figure 3.2) were used in the 
cotransformation of BJ5183 E. coli competent cells via electrotransformation (as 
outlined in Section 3.6.9.2).  The transformed cells were plated on selective LB-agar 
plates containing 100 µg/ml kanamycin overnight inverted.  Several small colonies were  
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selected and grown in LB broth with 100 µg/ml kanamycin overnight.  Mini-preps were 
performed to isolate the vector DNA from bacteria and the DNA was screened using 
restriction enzyme analysis then analyzed on a 0.7% agarose gel.  This allowed for 
positive selection of the recombinant vector.  The recombinant vector, pAdEasy-neu, 
was further transformed into DH5α host bacterial cells using standard transformation 
methods.  This step allowed for further plasmid amplification and purification of the 
viral vector of approximately 40 kb in size.   
After purifying the plasmid DNA using plasmid mini kits (Qiagen), pAdEasy-
neu was digested with Pac I, releasing a small fragment consisting of the kanamycin 
resistance gene and the ori.  The complete Pac I digest was confirmed by 
electrophoreses on a 0.7% agarose gel electrophoresis and the reaction cleaned up using 
a phenol:chloroform:isoamyl alcohol (25:24:1) extraction followed by ethanol 
precipitation.  A total of 5 µg of Pac I-digested pAdEasy-neu DNA was resuspended in 
sterile water for use in 293 cells transfection using Lipofectamine, according to 
manufacturer’s protocol, to produce AdVneu.  An outline of the steps involved in creating 
the adenovirus using the AdEasy system is illustrated in Figure 3.3.  After transfection, 
the flasks were monitored for 7-10 days for the formation of plaques.  Cells were 
harvested when cytopathic effects (CPE) were apparent and extensive in the flask.  After 
the cells were harvested, the remaining cell pellet was resuspended in serum free EMEM 
with five rounds of freeze/thaws performed at -80˚C and 37˚C, respectively, to prepare a 
crude viral lysate.  
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3.8.2. AdVHER2mut 
A similar method used in the creation of AdVneu was used for the creation of 
AdVHER2mut.  The gel purified Not I/Hind III full length, mutated HER-2 gene fragment 
was obtained from the digest of pCR-Blunt-HER2mut and ligated into the Not I/Hind 
III-digested pShuttleCMV vector, forming pShuttleCMV-HER2mut (Figure 3-2).   This 
vector was then linearized with Pme I and gel purified.  A modification was made to the 
bacterial cotransformation step, whereby the Pme I-linearized pShuttleCMV-HER2mut 
was used to transform electrocompetent BAD cells instead of BJ5183 E. coli cells.  The 
only difference between BAD and BJ5183 cells was that BAD cells were simply BJ5183 
cells already containing the pAdEasy-1 vector (Zeng et al. 2001).  This method 
increased the recombinant efficiency between the backbone vector (pAdEasy-1) and the 
shuttle vector.  Isolated recombinants were renamed as pAdEasy-HER2mut then 
transformed into DH5α cells for further plasmid amplification and purification.  After 
plasmid purification, pAdEasy-HER2mut was subsequently digested with Pac I, purified 
and transfected into 293 cells, as described previously, to produce the adenovirus, 
AdVHER2mut. 
 
3.9. Adenovirus amplification and purification 
 
3.9.1. Amplification 
Infected cell culture pellets were harvested when extensive CPE was observed.  
Cell pellets were resuspended in serum-free EMEM and subjected to five rounds of 
freeze-thaw cycles at -80°C and 37°C, respectively.  The sample was spun down and the 
supernatant was used as the virus seed to further infect additional flasks of 293 cells.  
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During each amplification step, additional flasks of 293 cells were used, with the final 
amplification step using a total of 36 T175cm2 flasks.  
 
3.9.2. Purification 
After harvesting the infected cells from the last amplification step, cells were 
subjected to five rounds of freeze-thaw cycles.  The sample was then spun down at 9,500 
x g in a JA-17 rotor for 10 min then the supernatant was gently layered on top of a 
cesium chloride (CsCl) discontinuous gradient using Quick-Seal Centrifuge tubes for 
ultracentrifugation.  The discontinuous gradient consisted of a layer of 1.25 gm/ml CsCl 
layered gently over the 1.40 gm/ml CsCl layer.  All of the CsCl solutions were prepared 
using 1X TD buffer consisting of 140 mM NaCl, 5 mM KCl, 25 mM Tris and 0.7 mM 
Na2HPO4.  Samples were then spun in a Beckman ultracentrifuge for 2 hours at 142,000 
x g (45,000 rpm) using a Type 80 Ti rotor at 20°C.  The opalescent band was collected 
then placed onto a 1.34 gm/ml CsCl continuous gradient and spun at 142,000 x g for 18 
hours at 20°C.  After which, the viral band was carefully aspirated and placed into a 
Slide-A-lyzer dialyzing cassette (Pierce) and dialyzed in 10 mM Tris-HCL pH 7.4, 1mM 
MgCl2, buffer solution for several hours at 4ºC involving several buffer changes to 
remove the cesium chloride.  Afterwards, glycerol was added for a final concentration of 
10% (v/v) glycerol to the sample.  The viral concentration was determined 
spectrophotometrically at A260, with an optical density (O.D.) unit of 1 equivalent to 1010 
plaque forming units (PFU)/ml (Xiang and Wu 2003).  Purified AdVs were stored at -
80°C until required. 
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3.10.  Adenovirus PCR 
To determine the presence of the gene insert within the purified AdV product, 
viral samples were first treated with Proteinase K (Invitrogen) for 1 hour at 56°C 
followed by heat inactivation at 95°C for 5 min.  Sources of the DNA template included 
infected cell pellet, culture media or the purified AdV.  The PCR reaction was 
performed using 4µl of the DNA template, 1X PCR buffer [20 mM Tris-HCl (pH 8.0), 
50 mM KCl], 1.5 mM MgCl2, 1 mM dNTP (0.25 mM each of dATP, dCTP, dGTP, 
dTTP), 1 µg/µl each primer and 2.5 units Taq DNA polymerase in a final volume of 100 
µl.  Water was used as a negative control and the respective pShuttleCMV vectors or 
pAdEasy-recombinants were used as positive controls.   
The neu specific primers used include the forward primer 5’-
AGATTGCCAAGGGGATGAGC-3’ and the reverse primer 
5’CTGGATGACCACAAAACGCTG-3’, resulting in a 488 bp product.  The HER-2 
specific primers were the forward primer 5’CTCAGTGACCTGTTTTGGACCG-3’ and 
reverse primer 5’-TCCACAAAGACTCCCCAGTGC-3’, resulting in a 2.3 kb (2277 bp) 
product.  The cycling conditions for PCR reactions included the initial denaturing step at 
94ºC for 5 min followed by two amplification cycles at 94ºC for 1 min, 65ºC for 1 min 
and 72ºC for 1 min.  Another two additional amplification cycles at 94ºC for 1 min, 60º 
for 1 min and 72ºC for 1 min followed by the remaining 30 cycles at 94ºC for 1 min, 
58ºC for 1 min and 72ºC for 1 min then a final incubation at 72ºC for 10 min.  In the 
case of HER-2, the extension times at 72°C were performed for 2.5 min to obtain the 
expected fragment size, estimating Taq polymerase activity at 1 kb/min.  Following the 
PCR amplification, 10µl of the PCR products were resolved by standard agarose gel 
electrophoresis. 
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 3.11.  Transfections 
 
3.11.1. Electroporation 
MCA-26 cell were transfected with the expression vector pcDNAneu, as 
previously described (Chen et al. 2002c).  Briefly, twenty million MCA-26 cells were 
resuspended in 0.7 ml PBS and mixed with 0.3 ml PBS containing 10 µg pcDNA-neu or 
pcDNA-HSP70 DNA.  Tumor cells were transfected via electroporation using a Gene 
Pulser (BioRad, Richmond, CA) with parameters of 300 V and 125 µFD capacitance in 
an electroporation cuvette with a 0.4 cm gap (BioRad).  Transfected cells were selected 
for growth in medium containing 4 mg/ml G418.  Selected clones, MCA-26neu and 
MCA-26-HSP70 (MCA-HSP70), were maintained in growth medium containing 0.5 
mg/ml G418 and expression analyzed by flow cytometry and Western blotting. 
 
3.11.2.  Liposomes 
The liposome-based method was used for transfection of recombinant adenoviral 
plasmid vectors created using the AdEasy system into 293 cells to produce the resulting 
AdV.  The day before transfection, 293 cells were re-plated at a cell density at 2x106 
cells per T25cm2 flask.  For transfections, 5 µg of the adenoviral vector plasmid 
(pAdEasy-neu and pAdEasy-HER2mut) was mixed with 20 µl of Lipofectamine 
(Invitrogen) in serum-free EMEM media and incubated at room temperature for 30 min.  
The DNA:liposomes complexes were added to the flasks and incubated for an additional 
4 hours, prior to completely changing the media with EMEM with 10% FCS.  These 
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flasks were continually monitored by microscopy for any signs of CPE.  The growth 
medium was refreshed as required.  Generally, the cells were harvested 7-10 days after 
transfection and used to prepare the initial primary viral stocks. 
 
3.12.  RNase protection assays 
DC were subjected to RNase protection assays (RPA) (Liu et al. 2003) using the 
Riboquant Multi-Probe kit (Pharmingen), in accordance with manufacturer’s 
instructions.  The RNA was extracted from the cells using RNeasy mini kits (Qiagen) 
and spectrophotometrically measured using standard A260/A280 readings.  The 
cytokine/chemokine-related multi-probe template sets (Pharmingen) were radiolabeled 
using [α-33P]-uridine 5’ triphosphate (UTP; Amersham), generated through an in vitro 
transcription reaction using T7 RNA polymerase.  Labeled probes were first purified by 
phenol-chloroform extraction and ethanol precipitated with their counts adjusted to 
3x105 cpm/µl followed by hybridization to RNA samples (5 µg each).  Reaction samples 
were subsequently digested with RNase, followed by Proteinase K treatment and 
phenol-chloroform extraction.  Following ethanol precipitation, the protected samples 
were resuspended in 1x loading buffer and separated on 5.7% acrylamide-bisacrylamide 
TBE-urea gels (Invitrogen) with TBE (100 mM Tris, 90 mM boric acid, 1 mM EDTA) 
buffer.  Gels were dried and exposed to a phosphorimager screen and by routine 
autoradiography.  Results were visualized and the relative expressions of cytokine and 
chemokine encoding mRNA were quantified with Quantity One software (Bio-Rad, 
Hercules, CA).   
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3.13.  Western blotting 
Neu expression in Tg1-1, MCA-26neu and DCneu cells was assessed using 
Western blots. Briefly, cell protein extracts were prepared from these cells using 
extraction buffer containing 125 mM Tris, 0.05% SDS and 10% β–ME and harvested 
from the supernatant after centrifugation at 1000 x g for 5 min.  The supernatants 
containing the protein samples were boiled and electrophoresed through 7.5% 
polyacrylamide gels.  The gel was transferred onto nitrocellulose papers (Schleicher & 
Schull) using 1X transfer buffer [25 mM Tris, 190 mM glycine, 0.05% SDS, 20% (v/v) 
methanol].  The blots were blocked using PBS containing 5% non-fat milk and 
incubated with the anti-neu Ab (Ab-3; Oncogene, 5 µg/ml) followed by horseradish 
peroxidase-conjugated goat anti-mouse IgG Ab (Jackson ImmunoRes), as previously 
described (Chen et al. 2002c).  Detection of HER-2/neu was accomplished by using 
enhanced chemiluminescence reagent (New England Nuclear Life Science Products, 
Boston, Mass.) and exposed to Hyper-ECL film (Amersham). 
 
3.14.  Bone marrow-derived DC 
Bone marrow (BM)-derived DC were prepared as described previously (Chen et 
al. 2002c), based upon a modified protocol described by Inaba et al. (Inaba et al. 1992; 
Lutz et al. 1999).  Briefly, BM cells prepared from the femora and tibiae of mice were 
depleted of red blood cells with 0.84% Tris-ammonium chloride and plated in DC 
culture medium [DMEM plus 10% FCS, GM-CSF (20 ng/ml; R&D System) and IL-4 
(20 ng/ml; R&D System)].  Nonadherent granulocytes, T and B cells were gently 
removed and fresh media were added on the third day. Two days later, loosely adherent 
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proliferating DC aggregates were dislodged and replated.  Nonadherent cells were 
harvested on the sixth day.  DCs generated in this manner displayed the typical 
morphologic features of DC (i.e., numerous dendritic processes) and used for phenotypic 
analysis, AdV transductions or co-cultivation with apoptotic cells.  
 
3.15.  DC transduction with AdV 
DCs were transduced with the AdV, AdVpLpA, AdVneu or AdVHER2mut, at an 
optimal multiplicity of infection (MOI) of 100, as previously described (Chen et al. 
2002c).  Transduced DCs were termed DCpLpA, DCneu, and DCHER2mut, respectively.  To 
enact this, day 6 cultured DC were harvested and following viral adsorption for 1 h at 
37oC in DMEM in 6-well culture plates, DC culture medium was replaced with DMEM 
containing 20% FCS.  The transduced cells were incubated for an additional 24-36 h at 
37oC then harvested for phenotypic analysis by flow cytometry, Western blot or used for 
immunizing mice. 
 
3.16.  Peptides 
Peptides were synthesized, purified by high-performance liquid chromatography, 
resulting in >95% purity and validated by mass spectrometry.  These peptides include 
the neu peptide PDSLRDLSVF, that spans aa 420-429, and an irrelevant peptide, 
RPQASGVYM from LCM N protein (Ercolini et al. 2003).  The OVA I peptide is 
SIINFEKL spanning aa 257-264 of OVA (Li et al. 2001).  These peptides were 
synthesized and purified by Multiple Peptide Systems (San Diego, CA) or at the Peptide 
Core Synthesis Facility at the University of Calgary (Calgary, AB, Canada). 
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3.17.  General immunology techniques 
 
3.17.1. Enzyme linked absorbance assay (ELISA) 
3.17.1.1. Cytokine ELISA 
The cytokine ELISA were performed using mouse-cytokine specific ELISA kits 
(BD OptEIA-IL-4, IL-6, TNF-α and INF-γ) from Pharmingen, according to 
manufacturer’s instructions.  Briefly, the capture antibody was diluted in coating buffer 
[0.1 M sodium carbonate] and added into Maxisorp wells (Nunc) for overnight 
incubation.  The wells were washed using PBS with 0.05% (v/v) Tween-20 and plates 
were blocked using 3% BSA in PBS at room temperature for one hour followed by 
several washes.   A volume of 100 µl of the serially diluted standards, prepared 
according to manufacturer’s protocol, and cell culture supernatants, from either DC or 
LN T cells, were added to the plate and incubated at room temperature for 2 hours.  
Next, the plate was washed several times then incubated with both the detection 
antibody and streptavidin-horseradish peroxidase (HRP) conjugate.  After incubating for 
an hour, the plate was washed a total of 7 times then 3,3’,5,5’ tetramethylbenzidine 
(TMB) substrate (TMB substrate reagent set; Pharmingen) was added to each well.  The 
reaction was stopped after a 30 min incubation period by the addition of 2N H2SO4.  The 
plates were then read on a Bio-Rad microplate reader at a wavelength of 450 nm. 
 
3.17.1.2. Indirect Cell-based ELISA 
An indirect cell-based ELISA was performed to identify the presence and 
subtypes of tumor-specific antibodies, as described previously (Xiang et al. 1996).  
 108
Briefly, 1x105 Tg1-1 cells were plated into 96 well plates and incubated overnight to 
allow for cell attachment to the plate then fixed by adding 0.2% (v/v) glutaraldehyde 
solution (Sigma) to the wells and incubating the plate at 4°C for 15 min.  Following this, 
the wells were washed three times with PBS with 0.05% Tween-20 then blocked with 
3% BSA (w/v) in PBS.  Serum samples from immunized mice diluted 1:20 and four-fold 
afterwards in PBS were added and incubated for 1 hour at 37°C.  Following this, the 
plate was washed with PBS with 0.05% (v/v) Tween-20 and incubated with either biotin 
conjugated goat anti-mouse IgG1 and IgG2a antibody for another hour followed by 
additional washes and the addition of horseradish peroxidase (HRP) conjugated-
streptavidin to the plate.  TMB substrate was added to each well and incubated for 30 
min before the addition of 2N H2SO4.  Developed plates were read on a microplate 
reader at a wavelength of 450 nm. 
 
3.17.2. Lymphocyte purification 
3.17.2.1. Nylon wool columns 
The spleen from naïve and immunized mice were harvested aseptically and a 
single cell suspension was prepared.  The red blood cells were lysed using 0.84% Tris-
ammonium chloride and resuspended in DMEM plus 10% FCS.  The cell suspension 
was loaded onto pre-incubated nylon wool columns (Interscience) and further incubated 
for 1 hour at 37ºC to allow the B cells to adhere to the nylon wool.  Next, DMEM media 
was added to flush out the T cells from the column, resulting in an enriched population 
of T lymphocytes.  
 
 109
3.17.2.2. Magnetic bead separation 
To further isolate a specific population of T lymphocytes, magnetic bead 
separation (Dynal) was employed, in accordance to the manufacturer’s protocol.  
Briefly, the isolated T cells were resuspended in 0.1% BSA in PBS and mixed with 
Dynabeads Mouse CD4 (L3T4) paramagnetic beads for negative selection or a positive 
selection of CD25+ T cells using anti-CD25 microbeads.  The sample was incubated at 
4ºC for 30 min with gentle tilting and rotation on a nutator then placed in the magnet 
apparatus to separate the magnetically bound cells from unbound cells.  In negative 
selection, the supernatant was removed containing the cell of interest whereas positive 
selection required further washing of the bound beads to release the cells. 
 
3.17.3.   Cytotoxicity assay 
3.17.3.1. In vitro cytotoxicity assay 
CTL assay were performed as previously described (Chen et al. 2002c).  The 
spleens were removed from immunized mice for preparation of single cell suspensions 
by pressing the spleens against fine nylon mesh and lysing red blood cells with 0.84% 
Tris-ammonium chloride solution.  The red blood cell-depleted splenic lymphocytes 
from vaccinated mice were co-cultured in 24 well plates with specific target cells.  In 
DCneu and DNA immunized mice, 5x106 lymphocytes were co-cultured with 2x105 
irradiated Tg1-1 cells (20,000 rad) per well containing 2 ml of DMEM plus 10% FCS 
with 20 U/ml IL-2 (Peprotech). For mice vaccinated with DC with phagocytosis of 
apoptotic MCA, MCA/HSP or EG7 tumor cells, the lymphocytes were co-cultured with 
irradiated MCA or EG7 tumor cells (4,000 rad) at a 25:1 ratio (i.e. 5x106 lymphocytes 
and 2X105 irradiated MCA or EG7 cells) in 2 ml of DMEM plus 10% FCS with IL-2 in 
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each well of a 24-well plate, respectively.  After four days, activated T cells were 
harvested and purified by Ficoll-Paque density gradient centrifugation, using Ficoll-
Paque Plus (Amersham).  These activated T cells were used as effector cells in the assay 
and diluted two-fold. 
The target cells were radiolabeled using 50 µl of [51-Cr]-sodium chromate (36 
mCi/ml; Amersham) for 1 hour at 37ºC and washed extensively.  A total of 104 
radiolabeled target cells/well were added to varying concentrations of effector cells 
plated in triplicates to 96 well plates and incubated for 8 hours at 37ºC.  The target cells 
used in the CTL assay with the effector cells from DCneu and DNA immunized mice 
were Tg1-1 and the target control CaD1 cells.   Radiolabeled target cells for effectors 
cells derived from mice immunized with DC with phagocytosis of apoptotic MCA, 
MCA/HSP or EG7 tumor cells are MCA and EG7 cells, whereas A20 and EL4 tumor 
cells served as target controls.   
The amount of 51-Cr released into the culture supernatant upon cell killing was 
determined by transferring a 100µl of the supernatant to a biovial and the radioactivity 
measured using a Gamma 5500 B counter (Beckman).  The percent specific lysis was 
calculated using the formula:  
[(experimental CPM - spontaneous CPM)/(maximal CPM - spontaneous CPM)] x 100 
The spontaneous count per minute (CPM) release in the absence of effector cells was 
less than 10% of specific lysis; maximal CPM release was obtained by adding 1% (v/v) 
Triton X-100 to the wells with target cells.  
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3.17.3.2. In vivo cytotoxicity assay 
In vivo cytotoxicity assay was also performed as previously described (Xiang et 
al. 2005).  Briefly, FVB/N mice were immunized with DNA, DCneu or PBS twice two 
weeks apart.  To generate differentially labeled target cells, splenocytes from naïve mice 
were incubated with varying concentrations of carboxyfluoroscein succinimidyl ester 
(CFSE; Molecular Probes) ranging from high (3.0 µM, CFSEhigh) to low (0.6 µM, 
CFSElow) concentrations.  The CFSEhigh cells were pulsed with the neu peptide, 
PDSLRDLSVF, and the CFSElow cells were pulsed with the irrelevant peptide, 
RPQASGVYM, (Ercolini et al. 2003) and washed extensively.  Both CFSEhigh and 
CFSElow were coinjected i.v. at a ratio of 1:1 in immunized mice, six days following the 
last immunization.  Sixteen hours after injection, spleens were removed to analyze 
residual CFSEhigh and CFSElow target cells remaining in recipients’ spleens by flow 
cytometry.   
 
3.17.4. Proliferation assays 
3.17.4.1. Mixed lymphocyte reaction (MLR) 
a) HSP70 Study 
Spleens were removed from C57BL/6 mice for preparation of a splenocyte 
suspension with red blood cells lysed using 0.84% ammonium chloride. T cells were 
obtained from the splenic lymphocytes by nylon wool non-adherence to deplete residual 
APC.  The primary MLRs were performed as previously described (Chen et al. 2001c). 
Briefly, irradiated BALB/c or C57BL/6 mouse BM-derived DC with phagocytosis of 
apoptotic MCA or EG7 tumor cells (4,000 rad, 0.4x105 cells/well) were incubated in 
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graded doses with a constant amount (1x105 cells/well) of allogeneic T cells from a 
C57BL/6 or BALB/c mouse in each well of 96-well culture plates, respectively.  After 3 
days, T cell proliferation was measured by adding 1 µCi/well of [3H]-thymidine (1 
mCi/ml, Amersham) to cultures followed by subsequent liquid scintillation counting 
after an overnight incubation period.  
 
3.17.4.2. T cell proliferation 
a)  DCneu study 
Naive T cells were prepared from FVB/N mouse splenocytes using nylon wool 
columns (Xiang and Moyana 2000).  CD4+25+ Tr cells were further purified from these 
naive T cells by using anti-CD25 microbeads (Pasare and Medzhitov 2003).  In all 
experiments, 90 to 95% of these isolated T cells were positive for both CD4 and CD25 
markers.  In the T cell proliferation assay, naive T cells (1x105 cells per well) were 
incubated with DCs (0.2x105 cells per well) and its dilutions plus the anti-CD3 Ab (1 
µg/ml) in the absence or presence of CD4+25+ Tr cells or anti-IL-6 Ab (10 µg/ml) in the 
round bottom 96-well plates for 2 days.  T cell proliferation was measured using an 
overnight 3[H]-thymidine (1 mCi/ml) uptake assay (1 µCi/well).  The levels of 3[H]-
thymidine incorporation into the cellular DNA were determined by liquid scintillation 
counting after harvesting the cells onto glass fiber filters (Nunc) (Xiang and Moyana 
2000). 
 
b) HSP70 Study 
Naïve OVA-specific CD8+ T cells were isolated from OT I mouse spleens, and 
enriched by passage through nylon wool columns.  CD8+ cells were then purified by 
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negative selection using anti-mouse CD4 (L3T4) paramagnetic beads (Dynal, Inc) to 
yield populations that were >95% CD8+/Vα2Vβ5+.  A constant number of naïve OT I 
CD8+ T cells (1x105 cells/well) were cultured with irradiated (4,000 rad) DC with 
phagocytosis of apoptotic EG7 tumor cells (0.4x105 cells/well), and their two-fold 
dilutions.  After 3 days, all wells were pulsed for 12-16 hrs with 1 µCi of [3H]-thymidine 
and then harvested onto glass fiber filters, respectively. Harvesting cells in each well 
onto glass fiber filters followed by liquid scintillation counting determined thymidine 
incorporation.  In addition, C57BL/6 mice were i.v. immunized with irradiated (4,000 
rad) DC with phagocytosis of irradiated EG7 tumor cells (5x105 cells).  
To evaluate OVA-specific CD8+ T cell proliferation in vivo, we performed 
tetramer staining six days subsequent to immunizations.  In the tetramer staining assay, 
tail blood samples collected were incubated with PE-H-2Kb/OVA I (SIINFEKL) 
tetramer (Beckman Coulter) and FITC-anti-CD8 Ab.  Erythrocytes were then lysed 
using the Lyse/Fixative Buffer Reagent (Beckman Coulter) and samples were analyzed 
by flow cytometry according to the company's protocol.  
 
 
3.17.4.3.   MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide] assay 
Tumor cell proliferation assays were determined using nonradioactive MTT 
assays.  This was accomplished by using 2x104 Tg1-1 or CaD1 tumor cells mixed with 
sera from immunized mice (1:50) and plated in a 96-well tissue culture plate incubated 
at 37oC (Yang et al. 1995a) in a total volume of 100 µl.  Normal mouse sera and anti-neu 
Ab (Ab-4; clone 7.16.4) were used as negative and positive controls, respectively.  After 
 114
the fifth day of culturing, cell proliferation was measured by MTT assays using CellTiter 
96 Non-radioactive Cell Proliferation Assay kit (Promega, Madison, WI) by adding 15 
µl of the Dye Solution to each sample well.  After incubating for 4 hours at 37ºC, the 
formazen crystals were solubilized using 100 µl of the Solubilization/Stop buffer and 
further incubated overnight before reading spectrophotometrically.  Plates were read at 
595 nm with background subtraction at 655 nm using a microplate reader.  Cell growth 
inhibition was calculated by [(blank absorbance - experimental absorbance)/(blank 
absorbance - background absorbance)] x 100, where blank values refer to wells with no 
serum added and background values refer to wells with no cells added.  
 
3.17.5. Flow cytometry 
Cells were spun down using a Clay Adams SEROFUGE II centrifuge and 
incubated with 5 µg/ml of the respective primary antibody in 100 µl for at least 30 min 
on ice.  Following three washes with PBS, cells were incubated with 50 µl of the 
appropriate secondary antibody, such as FITC-conjugated goat anti-rat IgG antibody 
(1:60), FITC-conjugated goat anti-mouse IgG antibody and FITC-conjugated 
streptavidin, on ice for an additional 30 min.  After washing with PBS, cells were then 
analyzed by flow cytometry using an Epics XL flow cytometer (Beckman-Coulter).  
Isotype-matched monoclonal antibodies were used as controls. 
   
3.17.6. Mouse serum collection 
Mice were tail bled at specified time points and the blood collected into 1.5 ml 
tubes.  The collected blood was then incubated at 37ºC for 1 hour to allow the blood to 
clot followed by incubating the sample at 4ºC overnight.  The next day, the samples 
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were spun twice in a refrigerated centrifuge for 10 min at 10,000 x g.  The sera were 
transferred into new tubes and stored at -20ºC until further use. 
 
3.17.7. Cell irradiation 
Cells were irradiated using a gamma cell counter containing a 60-Cobalt (Co) 
source (MDS Nordion; Ottawa, Canada) located at the University of Saskatchewan.  The 
cells received differing doses of exposure ranging from 2,000 rad for DC, 20,000 rad for 
Tg1-1 cells; 1,000 rad for EG7 cells and 5,000 rad for MCA cells.  
 
3.18.  Analysis of DC phagocytosis  
Apoptotic tumor cells were labeled with CFSE as previously described (Xiang et 
al. 2005).  To evaluate DC phagocytosis of apoptotic tumor cells, DC were cultivated 
with CFSE-labeled apoptotic tumor cells at a ratio of 3:1 in the culture medium 
containing GM-CSF (10 ng/ml) and IL-4 (10 ng/ml) at 37oC overnight. DCs were 
harvested, purified with Ficoll-Paque gradient, and then analyzed by flow cytometry and 
electron microscopy. 
  
3.19.  Generation and analysis of apoptotic tumor cells:       
Apoptosis of EG7, MCA and MCA/HSP tumor cells were generated by in vitro 
irradiation with 1,000 and 5,000 rad, respectively, cultured in DMEM plus 10% FCS for 
12 and 48 hr, and then harvested for electron microscopy and flow cytometric analysis 
or for DC phagocytosis. For flow cytometric analysis, the apoptotic tumor cells were 
analyzed using anti-HSP70 antibody and Annexin V-FITC (Pharmingen) by flow 
cytometry. The apoptotic tumor cells in early and late phase of apoptosis, which 
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expressed Annexin V (early apoptosis marker) and HSP70 (late apoptosis marker) (Chen 
et al. 2001c; Chen et al. 2005) were termed EG7-E, EG7-L, MCA-E, MCA-L, 
MCA/HSP-E and MCA/HSP-L, respectively.   
 
3.20.  Electron microscopy 
Samples were sent to the Department of Pathology at the University of 
Saskatchewan to prepare the specimen for electron microscopy. 
   
3.21.  Vaccination of mice 
 
3.21.1. DCneu and DNA vaccine 
We selected to immunize mice with s.c. and i.m. routes for administration of 
DCs and DNA, since they induced more efficient immune responses than intravenous 
(i.v.) or intraperitoneal (i.p.) administration of DC (Fong et al. 2001b; Okada et al. 
2001a) and s.c. injection of DNA, (Davis et al. 1994; Gramzinski et al. 1998) 
respectively.  To evaluate tumor immunity, FVB/N and BALB/c mice were vaccinated 
s.c. with 1x106 DCneu  cells and i.m. with 100 µg pcDNAneu DNA twice with a 14 day 
interval, respectively.  Ten days subsequent to the last vaccination, the FVB/N and 
BALB/c mice (n = 4-10 per group) were challenged by s.c injection of 3x105 Tg1-1 and 
MCA-26neu tumor cells, respectively.  Animal mortality and tumor growth were 
monitored daily for up to 60 days; mice with an average tumor diameters greater than 12 
mm were euthanized for humanitarian reasons.   
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For evaluation of tumor prevention, FVBneuN Tg mice (n = 10 per group) at age 
of two and four months were vaccinated s.c. with 1x106 DCneu cells or i.m. with 100 µg 
pcDNAneu DNA at a one month interval, for a total of three vaccinations, respectively.  
Aged-matched FVBneuN left either untreated or injected with PBS were used as 
controls.  Spontaneous breast tumor development was monitored weekly for up to 12 
months.  Tumor free time curves were recorded when the first tumor of each mouse 
reached a palpable size of greater than 3 mm in diameter.    
 
3.21.2. DCHER2mut vaccine 
FVBneuN Tg mice were immunized with DCHER2mut in a similar fashion as used 
in the immunization of these mice using DCneu.  Briefly, for the protection study, mice 
(n=8) were immunized twice with PBS, DCneu or DCHER2mut two weeks apart then 
challenged with 3x105 Tg1-1 cells injected s.c. ten days later.  Tumor growth was 
monitored daily and mice were culled when tumors exceeded 12 mm in diameter for 
humane reasons.   
In the prevention assay, FVBneuN mice (n=15) at 8 weeks of age were 
immunized with DCHER2mut a total of 3 times at 4-week intervals or treated with PBS to 
serve as the control group.  Spontaneous breast tumor development was monitored 
weekly by palpitating the glands and the appearance of a tumor greater than 3 mm was 
recorded as a tumor. 
 
3.21.3. DC with phagocytosis of apoptotic cells vaccine 
For evaluation of antitumor immunity, mice were vaccinated twice s.c. with 
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5x105 DC with phagocytosis of apoptotic MCA, MCA/HSP or EG7 tumor cells (DCMCA, 
DCMCA/HSP, DCEG7, respectively).  Ten days after the final immunization, mice (n = 10 
per group) were challenged by s.c injection of 5x105 MCA or EG7 tumor cells.  Animal 
mortality and tumor growth were monitored daily for up to 10 weeks; for humanitarian 
reasons, all mice with tumors that achieved a size of 15 mm in diameter were sacrificed.  
 
3.22.  Lymph node cell culture 
To evaluate the type of immune response induced, mice were immunized either 
twice s.c. with 1x106 DCneu or i.m. with 100 µg DNA vector.  The draining inguinal and 
popliteal LN were harvested 3 days after the last immunization and a single cell 
suspension prepared by pressing the LN through a mesh screen.  A million LN T cells 
were cultured with 5x104 irradiated Tg1-1 tumor cells in DMEM plus 10% FCS with 20 
U/ml interleukin-2 (IL-2) for 1 to 3 days.  Both the LN T cells as well as the DC culture 
supernatants were assayed for the expression of IL-4, IL-6, TNF-α and IFN-γ using the 
cytokine ELISA kits, as mentioned in previous sections. 
  
3.23.  Statistical Analysis 
Statistical analyses were done using Prism software (GraphPad Software, Inc., San 
Diego, CA) to form Kaplan-Meier survival chart and to perform Logrank test to 
compare mouse survival and tumor development between groups.  Student t tests were 
performed to determine the significance of differences between groups.  P values <0.05 
were considered statistically significant.    
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4.0 RESULTS AND DISCUSSION 
 
4.1 Part A – Adenovirus mediated transfer of the Rat neu gene into DC as a 
breast cancer vaccine 
 
4.1.1 Adenovirus generation and verification 
AdV vectors have proven to be beneficial and results in highly efficient method 
for gene transfer.  We first began by creating a replication deficient AdV containing the 
full-length rat neu gene, AdVneu.  This was accomplished using the AdEasy system and 
AdV stocks were purified and tested to ensure the rat neu gene was still present within 
the viral vector construct.  Previous first hand experience in Dr. Xiang’s lab found some 
stability issues when inserting larger genes into the AdV.  A PCR analysis was 
performed utilizing neu-specific PCR primer pairs to detect the presence of rat neu 
within the AdV construct during the amplification stages and in the final purified AdV.  
This method allows for rapid identification and guarantees the purified virus contains the 
transgene within the construct.  From the analytical gel shown in Figure 4.1, we 
observed a 488 bp band, representing the presence of the neu gene within the AdV 
construct, from virus infected 293 cells (D), the culture media from infected cells (E) 
and most importantly, the purified virus (F).  The positive control used was the shuttle 
vector, pShuttleCMVneu while both the negative controls resulted in no bands produced.    
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 M             A            B             C               D           E              F     CR analysis of the adenoviral vector, AdVneu, from the AdEasy system to 
sence of the rat neu gene within the construct.  After 30 cycles, 10µl of the 
electrophoresed on a 1% agarose gel.  The samples were loaded into each 
s: water control (A), the backbone vector, pAdEasy-1 (B); the shuttle 
tle-CMV/neu (C); crude viral lysate from infected 293 cells (D); infected 
 (E) and the purified AdVneu (F). M is the DNA marker loaded.  The 
488 bp band represents the neu gene. 
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This showed the specificity of the PCR reaction and confirmed the presence of the gene 
within our final purified product. 
 
4.1.2 Examining neu expression in tumor and DC cells: 
Tumor cell lines were chosen based upon their expression or lack thereof for neu, 
as detected by both flow cytometry and western blotting (Figure 4.2).  This allowed us to 
select cell lines for developing our animal models.  The mouse breast cancer cell line 
Tg1-1 was derived from a spontaneous breast tumor derived from FVBneuN Tg mice 
that overexpresses the neu Ag, as detected by flow cytometry using the anti-neu Ab.  In 
contrast, another mammary cell line CaD1 and mouse colon cancer cell line, MCA26, 
did not to express neu.  We also generated the transfected MCA-26neu tumor cell line, 
using the pCDNAneu vector.  This clone was selected by employing positive screening 
methods using antibiotic resistance and gene expression selection, as detected by flow 
cytometry (Figure 4.2A).  DC themselves did not express neu; however, 24-36 hours 
after AdVneu transduction, neu expression was detected on the cell surface of DCneu.  
Obviously, the expression of neu was mediated by DC transduction with AdVneu. 
Furthermore, to confirm the expression of neu within the various cells, Western 
blot analysis using protein extracts from the above six types of cells were examined for 
neu expression.  As shown in Figure 4.2B, Tg1-1, MCA-26neu and DCneu cells 
displayed significant amount of neu Ag expression, as detected by the presence of a 185 
kD band, whereas CaD1, MCA-26 and DC did not express any neu molecule.  These 
results are in accordance with the data obtained from flow cytometry.  
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Figure 4.2  Analysis of neu expression.  (A) The expression of cell surface neu on 
CaD1, MCA26, DC, Tg1-1, MCA26neu and DCneu (solid lines) as analyzed by flow 
cytometry using the mouse anti-neu (Ab-4) and FITC-conjugated got anti-mouse IgG 
Abs.  Isotype-matched mAbs (dashed lines) were used as controls.  (B)   Western blot 
analysis.  Protein extracts were obtained from the above cell lines/preparations and 
loaded to each well of a polyacrylamide gel under reducing conditions.  The transferred 
nitrocellulose blot was incubated with mouse anti-neu Ab (Ab-3) followed by 
peroxidase-conjugated goat anti-mouse IgG Ab.  Enhanced chemiluminescence reagent 
was used to detect expression of neu. 
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4.1.3 DCneu cells up-regulate expression of immunologically important molecules, 
cytokines and chemokines  
Previous studies have shown following AdV transduction, DC often undergo 
changes in their maturational status (Chen et al. 2002c; Molinier-Frenkel et al. 2003).  
Increases in cell expression of MHC class II, CD40, CD80, CD86 are associated with 
DC maturation.  We therefore used flow cytometry to examine levels of commonly 
expressed cell surface markers on DC using a panel of anti-MHC class II, CD40, CD54, 
CD80 and CD86 Abs against both nontransduced DC and DCneu.  As shown in Figure 
4.3, we found that DC cultured under normal conditions were relatively mature as 
evidenced by expression of high levels of both MHC class II, CD54, CD80 and CD86.  
CD40 levels were very low in DC.  These results are consistent with the protocol used in 
culturing BM-derived DC in our lab, requiring both GM-CSF and IL-4, to produce 
relatively mature DC (Chen et al. 2001b).  However, after AdV transduction, we found 
DCneu underwent a further increase in the maturation level.  This was evidenced by 
increased expression, relative to DC alone; in MHC class II, CD40, CD54 and CD80.  
The expression of CD86, the B7-2 costimulatory molecule, did not result in significantly 
altered expression levels upon AdV transduction.  Transduction with the control 
AdVpLpA also led to a mild to moderate up-regulation of MHC class II, CD40, CD54 
and CD80 expression on DCpLpA cells that were similar to DCneu.  This data indicated 
that the up-regulation of MHC class II, CD40, CD54 and CD80 expression was derived 
from AdV transduction of DC itself and phenotypically suggested enhanced DC 
maturation. 
The maturational process regulates the expression of cytokines, chemokines and 
chemokine receptors, either increasing or decreasing them.  Each different cytokine, 
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Figure 4.3  Phenotypic analysis of DC.  A comparison of the phenotypic changes 
between non-transduced DC and AdVneu-mediated transgene expression in DC (DCneu), 
as measured by flow cytometry.  The expression of rat neu, MHC class II, CD40, CD54, 
CD80 and CD86 molecules were analyzed. 
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chemokine and the respective receptor can be analyzed and quantitated individually; 
however, this is time consuming especially when there is a large set to analyze.  The use 
of RNAse protection assay (RPA) offers the advantage of using isolated RNA from cells 
hybridized with protection probes specific for characteristic genes then digested with 
RNAse enzyme.  Formed RNA-probe complexes are resistant to enzyme digestion and 
easily identified by running on an acrylamide gel, followed by densitometry to 
quantifying gene expression levels.  This method allows for examining multiple sets of 
relevant genes at a single time.   
As shown in Figure 4.4A, the results from the RPA showed nontransduced DC 
expressed minimal amounts of TNF-α, IL-1β, IL-6, MIP-1β while IP-10 was the most 
abundantly expressed cytokine.  After AdV transduction, increased expression of all of 
the cytokines examined was seen in DCneu.  Both IL-6 and MIP-1β were the most 
dominantly expressed in DCneu compared to DC.  The increased levels of cytokine 
expression seen in DCneu compared to DC ranged from a 5-fold increase for IP-10, to 
over 300-fold level for IL-6.  The same banding intensity seen for the housekeeping 
gene, GAPDH, indicated that similar amounts of RNA were loaded and the differences 
seen in the cytokine expression levels are a result from AdV transduction. 
In addition, to confirm the results observed in the RPA, cytokine-based ELISAs 
were performed for IL-6 and TNF-α only.  In DC, both of these cytokines expressed 
minimal amounts and were either below or just above the level of detection.  On the 
other hand, DCneu was found to express ~650 pg/ml IL-6 and ~400 pg/ml TNF-α (Figure 
4.4B).  These results are in concordance with the expression pattern detected using RPA. 
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Figure 4.4  RNAse protection assay and cytokine ELISA from DC.  A.  DCneu and DC 
were assessed by RNAse protection assay for their expression of various cytokines, as 
indicated.  Autoradiograph of the RNAse protection assay gels is shown for each DC 
population and graphic presentation of the data showing the relative expression levels of 
each transcript for DCneu and DC.  B.  The supernatant of DC cultured cells were 
measured for the expression of IL-6 and TNF-α using cytokine ELISA kits.    
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4.1.4 DCneu partially convert CD4+25+ Tr-suppression by IL-6 secretion: 
It has recently been reported that the inflammatory cytokine IL-6 is required for 
T cell activation in vivo and can convert Tr-mediated immune tolerance (Pasare and 
Medzhitov 2003).  Since we found that DCneu expressed abundant levels of IL-6, we 
next examined whether DCneu could also convert the CD4+25+ Tr-mediated immune 
suppression.  To examine this, we conducted a T cell proliferation assay by using DCneu 
in the presence of Tr cells.  As shown in Figure 4.5, CD4+25+ Tr cells resulted in almost 
complete inhibition of T cell proliferation using DC stimulation contrasting the high 
proliferation activity with naïve T cells (Figure 4.5 A and B), whereas the Tr inhibition 
of T cell proliferation was reduced to only 45% when DCneu was used as stimulators 
(Figure 4.5B).  This indicated that DCneu could partially convert Tr-mediated 
suppression.  Furthermore, this partial inhibition was abrogated by the addition of anti-
IL-6 Ab, but not by an irrelevant control Ab, thus indicating that the partial conversion 
of Tr suppression by DCneu was mediated by IL-6 secretion.      
 
4.1.5 DCneu mounts an effective protective antitumor immune response in 
wildtype but is ineffective in Tg mice 
As a proof of principle study, we set out to determine if the DCneu vaccine 
provided protection in mice from challenge with Tg1-1 cells, derived from a 
spontaneous tumor in FVBneuN Tg mice and endogenously overexpresses neu (Chen et 
al. 1998).  This cell line is highly tumorigenic as wildtype mice easily formed tumors 
with a minimal dose of 1x105 tumor cells injected s.c. for tumor formation.  We first 
started by immunizing wildtype parental FVB mice twice with a total of 1x106 DCneu 
(n=5) s.c. into both legs two weeks apart or with PBS (n=4).  Ten days later, mice were  
 128
  
 
 
 
 
Figure 4.5  T cell proliferation assay.  (A) Irradiated (4,000 rad) DCs (0.2x105 
cells/well) and its dilutions were co-cultured with a constant number of naïve T cells 
(0.1x106 cells/well) in the absence (●) or presence (▲) of CD4+CD25+ Tr cells (0.1x106 
cells/well) in RPMI plus 10% FCS for 2 days.  T cell proliferation was measured using 
an overnight 3H-thymidine (1µCi/well) uptake assay.  (B)  Irradiated AdV-transfected 
DC (DCneu and the control DCpLpA) were used in a T cell proliferation assay in the 
presence of Tr cells and anti-IL-6 or control antibody.  One representative experiment of 
three is shown. 
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challenged with 0.4x106 Tg1-1 cells in the right flank s.c then monitored for tumor 
growth.  The Kaplan-Meier survival curve is shown in Figure 4.6, showing control mice 
mice treated with PBS alone failed to provide any protective antitumor effects as all of 
the mice developed tumors.  On the other hand, mice immunized with DCneu remained 
completely protected from Tg1-1 tumor challenge.  This protection lasted greater than 
two months and suggested that DCneu provided complete protection against a neu-
expressing tumor.    
These results were encouraging, however the tumor model employed above does 
not closely mimic the clinical situation seen in humans, in regards to tolerance.  
Wildtype FVB mice are not tolerized to rat neu protein whereas the FVBneuN Tg mice 
are tolerized to suggest that overcoming self-tolerance is required for effective 
protection (Reilly et al. 2000; Reilly et al. 2001).  In previous studies by that group, 
immunization of wildtype FVB mice resulted in complete protection using an irradiated 
whole cell alone or combined with recombinant vaccinia virus vaccinations whereas 
FVBneuN Tg immunized mice provided only a delay in tumor growth.  Therefore, we 
evaluated the ability of the DCneu vaccine to protect these Tg mice using the same 
vaccination protocol as previously used in our above protection study for the wildtype 
mice.  Ten days after the second immunization, Tg mice were challenged with varying 
doses of Tg1-1 cells.  The doses ranged from 3x104 cells to 3x106 cells and mice were 
continuously examined for tumor growth.  In all of the three doses of Tg1-1 cells used 
for tumor challenge, tumors developed in all of the mice, albeit not at the same time.  
Mice challenged with the lower doses took longer to reach a similar tumor size with that 
formed using a higher tumor cell dose before killing.  For DCneu immunized mice 
challenged at the high dose of Tg1-1 cells of 3x106 cells (Figure 4.7A), tumors  
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Figure 4.6  Vaccination of mice with DCneu induced protective antitumor immunity 
against tumor challenge.  Wildtype FVB/N mice (n=5) were vaccinated twice with 1x106 
DCneu cells s.c. then challenged with 4x105 Tg1-1 cells injected s.c. in the right flank.  
Control mice (n=4) were treated with PBS then challenged with Tg1-1 cells.  Mice were 
monitored for tumor growth and survival.   
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Figure 4.7 Kaplan-Meier survival curves for DCneu immunized FVBneuN transgenic 
mice challenged with Tg1-1 cells.  The transgenic mice (n=4 for each group) were 
immunized twice with 1x106 DCneu (■) s.c. or control mice (PBS; ▲) then challenged 
with Tg1-1 cells ranging from 3x106 cells (A), 0.3x106 cells (B) and 0.03x106 cells (C), 
given subcutaneously in the right thigh.  Mice were continually monitored for tumor 
growth and mice survival recorded. 
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developed at a similar rate as the control, whereas a ten-fold decrease in tumor dose 
resulted in a slight delay with one mouse being protected (Figure 4.7B).  On the other 
hand, a further 10-fold decrease in Tg1-1 cell challenge (3x104 cells) still failed to 
provide complete protection; however, a significant delay in tumor growth was observed 
(Figure 4.7C).  These results reconfirmed data obtained from Reilly’s group in respect to 
wildtype FVB/N mice being able to mount a strong protective immunity that resisted 
tumor growth upon tumor cell challenge whereas FVBneuN Tg lacked the protective 
ability (Reilly et al. 2000).  
 
4.1.6 DCneu induced much stronger Th1 type immune response than pcDNAneu 
Tumor rejection and growth has been shown to be associated with IFN-γ and 
IgG2a dominant Th1 and IL-4 and IgG1 dominant Th2 type immune response, 
respectively (Xiang and Moyana 2000).  To investigate the type of immune response 
derived from using DCneu and DNA vaccines, the supernatants of LN T cells from 
immunized mice were examined for cytokine secretion using cytokine ELISA kits.  In 
response to irradiated Tg1-1 cells, the regional LN T cells derived from mice immunized 
with DCneu or pcDNAneu predominantly secreted IFN-γ (Figure 4.8).  This indicated the 
induction of mainly a Th1 type immune response.  However, differing levels were seen 
with the former one secreting significantly higher levels of IFN-γ (1,050 pg/ml) than the 
latter one (200 pg/ml).  This indicated that the DCneu vaccine induced a much stronger 
Th1 type immune response than DNA vaccine.  In contrast, the expressed levels of IL-4 
were minimal, with the detected levels in both DCneu and DNA immunized mice above 
or below the sensitivity of the assay used (<17 pg/ml), respectively.   Based upon these 
levels, it seemed that DCneu immunization favored a stronger Th1 response in  
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Figure 4.8  DCneu induces strong expression of interferon gamma (IFN-γ) compared to 
DNA.  FVB/N mice were immunized twice with the respective vaccine.  Single cell 
suspensions of the inguinal and popliteal lymph nodes were removed from immunized 
mice three days after the last immunization and cocultured with irradiated Tg1-1 cells 
(20,000 rads) for 3 days.  Supernatants were analyzed for the presence of IFN-γ and IL-
4, characteristic cytokines of Th1 and Th2 responses, respectively.  For DCneu 
immunized mice, the level of IFNγ is 1050 pg/ml and 17 pg/ml for IL-4.  Meanwhile, 
DNA immunized mice had only 200 pg/ml of IFNγ and undetectable amounts of IL-4 
produced. 
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comparison to that of DNA vaccination. 
 
4.1.7 DCneu vaccine stimulates stronger HER-2/neu-specific humoral response 
than DNA vaccine 
Previous vaccines targeting HER-2/neu have shown the presence of anti-neu 
Abs, especially the induction of IgG, both IgG1 and IgG2a, Abs in the sera of 
immunized animals (Chen et al. 1998; Rovero et al. 2000; Cappello et al. 2003; Sakai et 
al. 2004).  To examine whether these neu-targeted vaccines induced a neu-specific 
humoral response, FVB/N mice were vaccinated twice with DCneu and pcDNAneu 
DNA, and the sera collected two weeks after each vaccination.  The presence of HER-
2/neu-specific IgG1 and IgG2a Abs, indicative of a Th2 and Th1 response, respectively, 
was first assessed by flow cytometric analysis on Tg1-1 cells.  Tg1-1 cells were 
incubated with mouse sera (1:50) from the respective groups, followed by FITC-
conjugated goat anti-mouse IgG1 and IgG2a Abs, respectively.  As shown in Figure 
4.9A, neu-specific IgG2a but not IgG1 response was detected in mice vaccinated with 
DCneu after one immunization.  This indicated induction of a neu-specific Th1 type 
response.  After the second immunization, increasing levels of both IgG1 and IgG2a 
were detected in the sera of the same mice, with significantly higher levels of IgG2a 
detected.  This indicated that both Th1 and Th2 type responses were stimulated after the 
boost and involved antibody isotype class switching (Coffman et al. 1989).  In contrast, 
we were only able to detect a minimal increase of the IgG2a Ab in the sera of DNA 
immunized mice, confirming a mild induction of a Th1 type response.  No neu-specific 
Abs were detected in the sera of unvaccinated mice and this served as our control for 
this analysis.   
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Figure 4.9  The presence of IgG1 and IgG2a anti-neu antibodies in immunized mice.  
Flow cytometric analysis (A) using serum from DCneu and DNA immunized mice.  Mice 
were immunized twice with serum collected 2 weeks after each immunization.  Tg1-1 
cells were stained with serum (1:50) followed by goat anti-mouse IgG1 and IgG2a-FITC 
conjugated antibodies to detect presence of IgG1 and IgG2a antibodies, respectively 
(solid line).  Sera from naïve mice were used as controls (dashed line). (B) An ELISA 
based method of serum IgG subtype.  Sera from immunized mice (1:80) were incubated 
with Tg1-1 cells fixed in 96-well plates followed by peroxidase-conjugated antibodies 
specific for IgG1 and IgG2a antibodies, respectively.  Samples were developed with 
substrate and absorbances read at 450 nm.  Each bar represents mean ± SEM.  
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 To reconfirm the above results, an indirect cell-based ELISA using Tg1-1 cells 
grown in 96-well plates was used to assess the presence of neu-specific IgG1 and IgG2a 
Abs.  Serum samples (1:80) were incubated on the plates, followed by peroxidase-
conjugated goat anti-mouse IgG1 and IgG2a Abs, respectively.  As shown in Figure 4-
9B, mice immunized twice with DCneu induced higher levels of neu-specific IgG2a and 
IgG1 Ab responses, whereas vaccination of mice with pcDNAneu twice only stimulated 
a mild HER-2/neu-specific IgG2a Ab response.  We also confirmed that the second 
immunization aids in further boosting the presence of neu-Abs in the sera of immunized 
mice whereas Abs in the sera of control mice remained undetected.  Taken together, 
both of these two methods confirmed the presence of anti-neu Abs with DCneu 
significantly producing a vast amount compared to pcDNAneu DNA immunization.  As 
well, DCneu immunization generated a strong Th1/Th2 response while only a minor 
induction of a Th1 response was observed with DNA immunization. 
 
4.1.8 DCneu-derived neu-specific antibody induces down-regulation of HER-2/neu 
expression and inhibits growth of Tg1-1 tumor cells 
 Previous studies have shown that the Abs recognizing neu induced neu receptor 
down-regulation and resulted in growth inhibition of tumor cells (Rovero et al. 2000; 
Yip et al. 2001).  As shown in Figure 4.10A, an overnight incubation of Tg1-1 cells with 
sera from DCneu immunized mice resulted in an apparent down-regulation of HER-2/neu 
expression in Tg1-1 cells to almost 50%, when directly compared to the expression level 
of Tg1-1 cells not cultured in the presence of sera.  The sera from DNA immunized mice 
also showed a slight but not a significant decrease in neu-receptor expression on the cell 
surface.   
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Figure 4.10  Analysis of anti-HER-2/neu IgG Ab response on tumor cells. (A) The anti-
HER-2/neu IgG Ab down-regulated HER-2/neu expression. Tg1-1 tumor cells were 
incubated in the medium with or without sera (1:50) from mice immunized with DNA 
(a) or DCneu (b) overnight. Cells were washed with PBS, stained with the anti-neu Ab 
and FITC-anti-mouse IgG Ab then analyzed by flow cytometry.  Cells incubated with 
sera from immunized mice are seen as solid lines in the histogram and non-sera 
incubated cells are shown as a dashed line.  (B) The presence of anti-neu Ab inhibits 
growth of Tg1-1, as determined by MTT assay after five days of culture.  Sera from 
respective groups were diluted 1:50 and anti-neu Ab used as a positive control.  
Student’s t test, * P<0.005 when compared to sera from PBS immunized mice and ** 
P<0.005 when comparing sera from DCneu immunized mice to DNA immunized mice.   
(C) On the other hand, the presence of these Abs caused CaD1 tumor cell proliferation, 
as determined by MTT assay.  Each bar represents the mean ± SEM 
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Since HER-2/neu expression is related to tumor cell growth, especially within 
breast cancer, we next examined whether the presence of anti-neu Abs affected cell 
proliferation of Tg1-1 cells in vitro using MTT assays.  The use of the MTT assay 
provided a quantitative, non-radioactive based method for measuring cell viability based 
upon the ability of mitochondrial dehydrogenase enzyme activity to cleave the 
tetrazolium rings and form formazen crystals in viable cells only.  As shown in Figure 
4.10B, the sera from DCneu immunized mice clearly inhibited ~73% of TG1-1 cell 
growth in vitro after five days, compared to cells incubated with sera from PBS 
vaccinated mice (P<0.0001; Student’s t test).  In fact, proliferation and not inhibition of 
Tg1-1 cells cultured with the sera from PBS immunized mice was observed.  Sera from 
DNA immunized mice also resulted in ~38% inhibition of Tg1-1 proliferation (P<0.005 
in comparison to PBS; Student’s t test) but the sera from DCneu immunized mice clearly 
had a greater growth inhibitory effect (P<0.005 between DCneu and DNA sera, Student’s 
t test).  In addition, culturing the tumor cells in the presence of the neu mAb (clone 
7.16.4) (Drebin et al. 1985; Drebin et al. 1986) also resulted in a significant growth 
inhibition of Tg1-1 cells (~58%).   Meanwhile, sera from the respective groups of 
immunized mice did not contribute to any inhibited growth of neu-negative CaD1 tumor 
cells (Figure 4.10C).  This indicated that the growth inhibition was neu-specific. 
 
4.1.9 DCneu vaccine stimulates stronger HER-2/neu-specific CTL response than 
DNA vaccine: 
Next, we addressed the specific anti-tumor effector function induced by 
vaccination of mice with DCneu and pcDNAneu DNA.  Spleen lymphocytes from 
immunized mice were cocultivated with irradiated Tg1-1 tumor cells for 3 days followed 
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by harvesting activated T cells.  To assess the cytotoxic activity, we conducted a 
chromium release assay using activated T cells as effector cells and 51Cr-labeled Tg1-1 
tumor cells as target cells.  As shown in Figure 4.11A, the activated T cells from mice 
vaccinated with DCneu showed significantly higher cell killing activity towards Tg1-1 
cells.  At an effector:target (E:T) ratio of 50, the specific killing activity for activated T 
cells from mice vaccinated with DCneu was 36%, which was significantly higher 
compared to the 12% killing activity using activated T cells derived from DNA 
vaccinated mice.  The specificity of cell killing towards neu was also demonstrated by 
the inability of activated T cells derived from DCneu mice to lyse CaD1 cells.   
Results from the in vitro study were also confirmed using an in vivo cytotoxicity 
assay (Figure 4.11B).  This assay involved differentially CFSE-labeled peptide-pulsed 
splenocytes, using CFSEhigh (neu peptide pulsed; PDSLRDLSVF) and CFSElow 
(irrelevant peptide, LCM N protein peptide-pulsed) labeled cells, transferred i.v. into 
recipient DNA and DCneu immunized mice.  These labeled splenocytes acted as target 
cells with the disappearance of the cells resulting mainly from cell killing mechanisms 
involving T cells.  Flow cytometry analysis was used to examine the elimination of 
labeled cells by determining the amount of labeled cells remaining.  Levels of CFSElow 
cells remained relatively unaffected; indicating the cell killing was specifically geared 
towards neu, whereas the CFSEhigh level in DNA immunized mice decreased minimally 
by 8%.  However, a greater degree of loss of CFSEhigh cells (~38%) was observed in 
DCneu immunized mice.  This indicated that DCneu immunization produced a stronger 
CTL response compared to DNA immunization. 
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Figure 4.11  DCneu immunizations induce a higher degree of neu-specific CTLs 
compared to DNA immunizations.  (A) In vitro cytotoxicity assays.  Splenic 
lymphocytes were harvested from mice vaccinated with DCneu (■) and pcDNAneu (∆) 
and co-cultured with irradiated Tg1-1 cells (20,000 rad) for 4 days, then used as effector 
cells in a chromium release assay with 51Cr-labeled Tg1-1 tumor cells.  To confirm that 
T cell cytotoxicity was neu tumor specific, we also included neu-negative CaD1 tumor 
cells (▼) as a target control and activated T cells from DCneu-immunized mice as 
effector cells. Each point represents the mean of triplicates.  (B) In vivo cytotoxicity 
assay.  Differentially labeled CFSEhigh and CFSElow naïve FVB/N splenocytes were 
pulsed with the neu peptide and an irrelevant peptide, respectively, then i.v. injected into  
PBS, DNA and DCneu immunized mice.  Sixteen hours later, the spleens’ of mice were 
harvested to determine the remaining CFSEhigh and CFSElow cells remaining, as 
determined by flow cytometry.  The value in each panel represents the percentage of 
CFSElow (L) versus CFSEhigh (H) cells remaining in the spleen.  
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4.1.10 DCneu vaccine induces more efficient protective tumor-specific immunity 
than DNA vaccine in wild-type mouse models: 
To examine whether the neu-targeted vaccines were capable of inducing 
antitumor immunity in vivo, we vaccinated wild-type FVB/N mice twice with DCneu and 
pcDNAneu DNA, then challenged 10 days later with 3x105 Tg1-1 tumor cells.  As 
shown in Figure 4.12A, Tg1-1 tumor cell challenges were invariably lethal within 6 
weeks post-implantation for PBS and DCpLpA vaccinated mice.  Nevertheless, 
vaccination of mice with DCneu (n=8) twice induced stronger antitumor immunity, 
resulting in protection of all of the mice from challenge with 3x105 Tg1-1 tumor cells 
and remaining tumor free at the end of the study, whereas only half of the mice (4/8) 
mice given two DNA vaccinations remained tumor free (P<0.05; log-rank test).  This 
data indicated that DCneu vaccination induced a more efficient protective tumor-specific 
immunity in vivo in comparison to DNA vaccination. 
To confirm the above finding, we repeated the study using a MCA26-neu animal 
model.  We vaccinated BALB/c mice (n=10) twice with DCneu s.c. and pcDNAneu DNA 
i.m. then challenged the mice 10 days later with 3x105 MCA-26neu tumor cells 
expressing the neu Ag.  As shown in Figure 4.12B, DCneu vaccination showed stronger 
antitumor immunity resulting in 100% complete protection in mice when challenged 
against MCA-26neu tumor cells, whereas pcDNAneu DNA immunization failed to 
protect mice from tumor growth (P<0.05; log-rank test).  This confirmed that DCneu 
vaccination induced more efficient and effective protective tumor-specific immunity in 
vivo than DNA vaccination.  On the other hand, immunization of mice with DCpLpA 
failed to induce protective immunity in mice when challenged with either Tg1-1 or 
MCA-26neu tumor cells (Figure 4.12A and B), further indicating that the specificity of 
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Figure 4.12  Vaccination of mice with DCneu induces stronger anti-tumor immunity. (A) 
FVB/N and (B) BALB/c mice (n = 10) were vaccinated twice with DCneu and 
pcDNAneu, respectively. Ten days later, the immunized mice were then s.c. challenged 
with 3x105 neu-positive Tg1-1 (A) and MCA-26neu (B) tumor cells. Mice were 
monitored twice weekly up to 60 days.  Survival of the DCneu-immunized group of mice 
(*) was significantly longer than that of the pcDNAneu-immunized group (Log rank test, 
P<0.05) in both (A) and (B) experiments. One representative experiment of two 
independent experiments is shown. 
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the protective immunity derived in DCneu immunized mice is neu specific. 
 
4.1.11 DCneu vaccine delays breast cancer development significantly longer than 
DNA vaccine in transgenic mouse model: 
A variety of studies have previously shown the ability for DNA vaccines to 
prevent spontaneous tumor formation in the aggressive breast tumor forming BALB-
neuT model with varying efficacies (Rovero et al. 2001; Cappello et al. 2003; Quaglino 
et al. 2004a).  However, there are limited studies to date examining the ability to prevent 
tumor formation in the FVBneuN Tg mice, containing the wildtype neu gene.  These 
mice spontaneously develop mammary tumors in a stochastic fashion beginning around 
4-5 months of age up until 8 months of age (Figure 4.13).  Therefore, to determine 
whether the antitumor immunity derived from HER-2/neu-targeted vaccines would be 
able to inhibit carcinogenesis, thereby preventing tumor formation, we vaccinated 
FVBneuN Tg mice beginning at two and four months of age.  These time points 
represent periods of observed atypical hyperplasia and infiltrating ductal carcinomas, 
respectively (Cardiff and Wellings 1999).  Mice were immunized with 1x106 DCneu cells 
s.c. and 100 µg pcDNAneu plasmid DNA  i.m. every four weeks for a total of three 
times, respectively.  Age matched controls were also used to monitor the development of 
spontaneous breast tumor development along, as seen in Figure 4.14A and B, in the ten 
mammary glands.  In Figure 4.14C, the photograph of the various spontaneous tumors 
derived from the Tg mice over a time period ranging from four months to the end of the 
study or when tumors reached a maximum size of 1.5 cm in diameter is shown.   
Tumor free curves were calculated based upon the first appearance of a 
mammary tumor detected.  As shown in Figure 4.15, Tg mice immunized with DCneu 
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beginning at the age of 2 months (A) but not at the age of 4 months (B), significantly 
delayed tumor development compared to that of the DNA-immunized mice (P<0.05; 
Log-rank test).  Overall, our data indicated that DCneu-based vaccination induced 
stronger neu-specific preventive immunity in Tg mice than DNA vaccination and 
provided a significant delay in tumor formation. 
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Figure 4.13  Spontaneous tumor development in FVBneuN Tg mice.  A total of 61 
FVBneuN Tg mice were monitored closely with palpitations of mammary glands twice a 
week for signs of tumor developments.  Detection of the first nodule greater than 3 mm 
was considered as a tumor.  The data presented as Kaplan-Meier survival curves 
indicates the percentage of tumor free animals as a function of age (weeks) in forming 
spontaneous tumors.  The appearance of the first tumor was detected as early as 20 
weeks of age but as late as 48 weeks of age. 
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e 4.14  Spontaneous tumors detected in FVBneuN transgenic mice.  (A) Both 
es show the same mice, but taken from different views.  The mouse on the left has 
le tumor (as shown with the arrow heads) located on its right hand side.  The 
e on the left has two tumors present, both of which are located on the right side.  
 transgenic mice formed spontaneous breast tumors at approximately 7 months of 
owever, the time varied, as tumors may be seen as early as 4 months or later on 
 months in untreated mice. (B) Diagram of the ten mammary glands located on a 
e.  (C).  Photograph of a representative sample of spontaneous forming tumors 
 from FVBneuN Tg mice at various time points ranging from 4-10 months of age 
rdered in progressing size and time frame. 
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Figure 4.15  Vaccination of mice with DCneu delays tumor development in transgenic 
mice.  FVBneuN transgenic mice (n = 15) were left untreated or vaccinated with DCneu 
and pcDNAneu for a total of three times (arrows) beginning at the age of two (A) and 
four months (B), respectively.  Spontaneous-forming breast tumors were monitored 
weekly.  The tumor free time of the DCneu-immunized group of mice (*) was 
significantly longer than that of the pcDNAneu-immunized group (Log rank test, 
P<0.05).  
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4.1.12 Discussion 
HER-2/neu is an attractive target for the development of immunotherapeutic 
strategies against breast cancers.  HER-2 is commonly overexpressed in 30% of breast 
cancer cases and its cell surface expression would make it amenable to both Abs and 
CTL immune responses.  This is just one of many reasons for developing HER-2/neu 
targeted therapies.  Although the humanized mAb, Herceptin, has shown incredible 
clinical efficacy in treating metastatic breast cancers as well as in an adjuvant setting, 
patients do eventually become resistant to therapy and tumors begin to grow again 
(Nahta and Esteva 2006).  Active immunotherapy strategies such DNA and DC-based 
vaccines are being created to rapidly induce an immune reaction against tumor cells.  
Such an approach may also be immunopreventative to provide lifelong protective 
immunity (Lollini and Forni 2003).   
The form of the Ag is important in the context of Ag processing and ultimately 
the loading of epitope peptides onto MHC class molecules.  HER-2 encodes for a 1255 
aa protein and neu encodes for a 1260 aa protein; therefore, these proteins should posses 
several MHC class I and class II epitopes to induce an effective immune response.  It 
was originally reported that plasmid DNA encoding a truncated rat neu possessing only 
the ECD and TM domain but lacking the ICD could induce antitumor immunity that was 
as strong as the one induced by a plasmid encoding the full-length HER-2/neu (Weiner 
1999).  This indicated that there is no beneficial advantage for incorporating the ICD to 
induce protective immunity.  Several other groups have shown the ability to induce a 
strong, protective immunity when using only the ECD and TM domains of HER-2/neu 
in a DNA vaccine (Rovero et al. 2000; Piechocki et al. 2001; Pilon et al. 2001; Lee et al. 
2003).  The rationale for using only the ECD and TM is to address safety issues in 
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regards to the possibility of unwanted signaling that may occur if the ICD included an 
active tyrosine kinase domain or the potential cross reactivity with the other highly 
homologous HER family members.  Evidence from clinical trials, however, have 
demonstrated that CD4+ T cells derived from peptide vaccination recognized peptide 
epitopes from both the ECD and the ICD of HER-2/neu, (Disis et al. 1997; Disis et al. 
1999; Kobayashi et al. 2000).  This suggested the ICD may represent a better immune 
target given (i) its limited exposure to the external environment, (ii) possession of 
additional helper epitopes and (iii) the lack of tolerogenic epitopes within the ECD due 
to ECD shedding, as observed in the sera of patients, leading to tolerance (Disis and 
Cheever 1998; Foy et al. 2002).  In support of this assumption, it has been shown that 
vaccination with plasmid DNA encoding the ICD (full length) or using the ICD protein 
of HER-2/neu elicited antitumor immunity, but not with plasmid DNA encoding the 
ECD or ECD protein (Wei et al. 1999; Foy et al. 2001).  More recently, it has also been 
reported that the antitumor immunity derived from vaccination with plasmid DNA 
encoding the ICD of HER-2/neu was mainly mediated by HER-2/neu-specific CTL, but 
not by a humoral response (Piechocki et al. 2001; Pilon et al. 2001).   Pupa et al has also 
recently demonstrated using a xenogeneic immunization strategy that FVBneuN mice 
immunized with a DNA vector encoding human HER-2 ECD-TM was less efficient at 
preventing tumor formation, contrary to results observed using the full-length human 
HER-2 (Pupa et al. 2005).  Conceptually, vaccination with plasmid DNA encoding the 
full-length of HER-2/neu or with full-length of HER-2/neu protein should have the 
advantage of presenting both MHC class I and class II epitopes and therefore, induce 
enhanced anti-HER-2/neu immune responses.  In this study, we constructed an 
expression vector pcDNAneu and a recombinant adenoviral vector AdVneu containing 
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the cDNA fragment encoding the full-length of HER-2/neu for DNA-based and 
engineered DC-based vaccines, respectively.  The gene-transfer method presented here 
allowed us to compare the efficacy of anti-HER-2/neu immunity elicited by a gene-
modified DC-based vaccine versus a plasmid DNA-based vaccine.  
It is also important to mention the rationale for choosing to use AdV-mediated 
transduction of DC.  In this comparison study, we chose not to use the pcDNAneu 
plasmid DNA mediated gene transfer into DC based upon the fact that nonviral DNA 
transfection methods are rather inefficient, particularly in nondividing cells.  This would 
limit the DNA trafficking into the nucleus for transcription to occur (Luo and Saltzman 
2000).  Furthermore, it has been reported that the transfection efficiency of DNA into 
well-differentiated BM-derived DC via electroporation is limited and generally toxic to 
the cells with a reduction in cell viability (Arthur et al. 1997; Van Tendeloo et al. 2001; 
Lundqvist et al. 2002).  Viral vectors, especially AdV vectors, are more commonly used 
for high efficiency gene transfer into DC (Wu et al. 2005).  AdV-mediated gene transfer 
has been demonstrated to be more efficient than plasmid DNA-mediated gene transfer 
via liposomes and electroporation (Arthur et al. 1997; Frolkis et al. 2003).  Therefore, 
AdVneu was selected instead of using pcDNAneu for gene transfer into DC in this study.   
We have shown that the BM-derived DC are amenable to AdV transduction and 
shown there is a perturbation in the maturation status.  Previous reports have also shown 
that AdV transduction itself can mature DC (Dietz et al. 2001; Miller et al. 2002; 
Molinier-Frenkel et al. 2003; Okada et al. 2003a; Schumacher et al. 2004).  In this study, 
our data also showed that transduced DCneu upregulated the expression of 
immunologically important molecules (MHC class II, CD40, CD54 and CD80) and 
inflammatory cytokines (IL-6, TNF-α, IL-1β, MIP-β and IP-10), compared to 
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nontransduced DC.  This indicated that AdV-transduced DC are a more immunogenic 
form of DC with high immunostimulatory properties and capability in stimulating both 
NK cells and CTL (Miller et al. 2002).  For example, IL-6 is required for T cell 
activation and can convert Tr-mediated immune suppression (Pasare and Medzhitov 
2003).  TNF-α is an immunoregulatory cytokine with the ability to activate both T cells 
(Robinet et al. 1990) and DC (Brunner et al. 2000) and to ameliorate IL-10-mediated DC 
inhibition (Brossart et al. 2000b).  The chemokines MIP-β and IP-10, expressed by 
DCneu, are each chemotactic for T cells and DC (Sozzani et al. 1996).  Therefore, the up-
regulation of the above cytokines and chemokines play a role in DCneu-induced anti-
HER-2/neu immunity. 
In this study, we have also demonstrated that mice immunized with DCneu and 
pcDNAneu DNA predominantly secreted IFN-γ, but not IL-4, indicating induction of 
mainly a Th1 cellular immune response.  However, the T cells from DCneu immunized 
mice secreted larger quantities of IFN-γ, which allowed for Ig class switching, compared 
to the T cells from pcDNAneu-immunized mice.  On the other hand, we also found the 
presence of neu-specific Abs in the sera of immunized mice.  The higher IFN-γ seen in 
DCneu immunized mice may account for higher levels of HER-2/neu-specific IgG2a than 
IgG1 Ab seen in DCneu immunized mice.  This confirmed that DCneu induced a mixed 
Th1/Th2 response rather than a strict Th1 type response while DNA immunized mice 
seemed to favor a mild Th1 response.  Moreover, we showed the immune sera 
containing anti-neu Ab from mice immunized with DCneu led to down-regulated HER-
2/neu expression. This mechanism has been reported with the use of Herceptin (Cuello 
et al. 2001) and other HER-2/neu Abs (Drebin et al. 1986; Rovero et al. 2000).  The Abs 
from the sera of DCneu immunized mice also inhibited the growth of Tg1-1 tumor cells 
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to a greater degree than the sera from DNA immunized mice, whereas CaD1 cell 
proliferation remained relatively unaffected when cultured in the presence of immune 
sera.  In addition, DCneu vaccination stimulated stronger neu-specific CTL responses 
than pcDNAneu DNA vaccination.  Activated T cells from mice vaccinated with DCneu 
showed significant neu-specific killing of 36% (at E:T of 50) to Tg1-1 cells, compared 
with only 12% killing activity derived from activated T cells of mice with vaccination of 
pcDNAneu DNA.  This CTL activity was immunologically specific, as minimal 
cytotoxic activity was found against the neu-negative CaD1 tumor cells.  Similar degree 
of cytotoxicity was observed in the in vivo cytotoxicity assays.  Based upon these 
mechanistic studies, it suggested that DCneu immunization induced a mixed cellular and 
humoral response that was of a greater magnitude than that observed using the DNA 
vaccine.   
Neu-specific Abs have previously been identified in mice immunized with 
peptides (Jasinska et al. 2003), HER-2/neu allogeneic cell expressing IL-12 (Cefai et al. 
1999; Nanni et al. 2001; De Giovanni et al. 2004), protein (Esserman et al. 1999; Renard 
et al. 2003), DNA (Chen et al. 1998; Amici et al. 2000; Lachman et al. 2001; Renard et 
al. 2003; Quaglino et al. 2004a) and DC (Chen et al. 2001a; Sakai et al. 2004).  These 
Abs may target a series of different epitopes that can have an inhibitory or a stimulatory 
effect on tumor cell growth (Yip et al. 2001).  This may explain some conflicting results 
in the literature.  Some groups have stated that despite the presence of neu-specific Abs, 
they are not directly involved with the antitumor protection (Chen et al. 1998; Foy et al. 
2001; Lindencrona et al. 2004).  Contradicting this, other groups have found that Abs are 
an important component, along with the typical cellular response involving the 
generation of CD8+ CTL and CD4+ Th cells, for antitumor immune protection (Rovero 
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et al. 2000; Penichet et al. 2001; Reilly et al. 2001; Wolpoe et al. 2003; Dela Cruz et al. 
2005).   
Another possible reason for this discrepancy between the actual roles of B cells, 
therefore Abs, is the tumor model used.  There may be some other functional differences 
between the parental wildtype and Tg mice besides immune tolerance to neu.  It has 
been demonstrated that both a humoral and cellular response was required to reject 
tumors in mice (Reilly et al. 2000; Reilly et al. 2001) .  Furthermore, stronger Ab 
responses were seen in parental FVB/N mice compared to the corresponding FVBneuN 
Tg counterpart (Reilly et al. 2001).   More recently, B cell deficient knock out mice have 
allowed for further dissection of the immune response to show B cell deficient mice 
failing to produce anti-neu Abs and developing tumors (Nanni et al. 2004; Quaglino et 
al. 2004a; Quaglino et al. 2004b; Park et al. 2005).  Interestingly, one study showed that 
even in these B cell deficient mice, approximately two-thirds of the mice were still able 
to form Abs of different subclasses and continued to provide a higher level of antitumor 
protection (Nanni et al. 2004).  However, majority of these reported studies stressed the 
importance of B cells, thus the presence of anti-neu Abs, with IgG2a subset being the 
most important, and T cell-derived cytokines (i.e. IFN-γ) produced by CD4+ Th1 cells 
playing an important role in inhibiting tumor formation (Cappello et al. 2003; Curcio et 
al. 2003; De Giovanni et al. 2004; Dela Cruz et al. 2005; Lo Iacono et al. 2005; Park et 
al. 2005).  It has also been demonstrated that the use of a mixture of IgG1 anti-HER-
2/neu mAb recognizing different epitopes also provided significant protection in 
FVBneuN mice upon tumor challenge (Wolpoe et al. 2003) and reduced growth of 
human xenografts (Spiridon et al. 2002).  Overall, some of the effects of the anti-neu 
Abs (both IgG1 and IgG2a) may range from blocking p185 receptor function and 
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inducing receptor down-regulation that will affect cell survival, proliferation, 
angiogenesis and metastasis (Katsumata et al. 1995; Yarden and Sliwkowski 2001; 
Spiridon et al. 2004).  The Abs may also prevent the formation of heterodimers, leading 
to cell growth inhibition through G1 cell cycle arrest and p27 induction, prevent the 
cleavage of the ECD and inhibit angiogenesis.  Immune mediated mechanisms may also 
play a role such as CDC and ADCC via the Fcγ receptor on leukocyte membranes 
(Baselga and Albanell 2001).  In vivo, these Abs have been also been shown to mediate 
receptor down-modulation and diminished proliferation with decreased proliferating cell 
nuclear Ag (PCNA) detected, halting the progression of preneoplastic lesions (Quaglino 
et al. 2004a; Quaglino et al. 2004b). 
More importantly, the in vivo animal studies showed the generation of antitumor 
immunity offered complete protection in DCneu immunized mice compared to the 
moderate protection seen in plasmid DNA immunized mice, when challenged with neu-
expressing tumor cells using two different wildtype models.  FVB/N mice given the 
DCneu vaccine were completely protected from a challenge of Tg1-1 cells whereas the 
DNA vaccine only protected 50% of the mice.  When taken into account the general 
pattern observed when studying the antitumor mechanisms, the fact that DNA 
immunized mice were only partially protected was not surprising, since we have clearly 
shown that DCneu immunized mice stimulated both a stronger neu-specific cellular and 
humoral immunity compared to their counterparts.  This conclusion was further 
solidified using another wild-type mouse MCA-26neu tumor model to examine the 
induction of antitumor immune responses with prophylactic immunizations.  
Vaccination of DCneu cells also resulted in tumor protection in 8 out of 8 mice, whereas 
none of the mice vaccinated with pcDNAneu rejected a tumor challenge with MCA-
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26neu expressing the neu Ag.  Renard et al reported similar in vivo findings in a 
different animal model system with 50%-80% protection seen in DNA immunized mice 
(Renard et al. 2003).  These results indicated that immunization of both FVB/N and 
BALB/c mice with two rounds of DCneu vaccine provided significant amount of 
antitumor protection against neu-expressing tumor cell challenge. 
The FVBneuN Tg mice were derived from the parental FVB/N strain and 
expressed the wild-type rat neu cDNA under the control of a mouse mammary tumor 
virus promoter (Guy et al. 1992).  Female mice stochastically develop spontaneous 
mammary tumors in situ and small mammary tumors beginning at 2 and 4 months of 
age, respectively (Cifaldi et al. 2001).  Because the HER-2/neu tumor Ag is endogenous 
to the host, this allows for development of self-tolerance to the HER-2/neu Ag, as 
evidenced by the poor ability of these mice to develop HER-2/neu-specific antitumor 
immunity following vaccination as compared with the parental FVB/N mice (Reilly et 
al. 2000; Renard et al. 2003).  This finding was highlighted in our study whereby 
FVBneuN immunized with DCneu twice failed to reject the highly tumorigenic Tg1-1 
tumors, even when challenged with a 100-fold lower dose (0.03x106 cells) typically used 
for inducing tumor growth in FVB/N mice.  Therefore, this mouse model of breast 
cancer that closely mimics immune tolerance that exists in some patients with cancer 
becomes a suitable model for evaluating HER-2/neu-targeted vaccines (Pupa et al. 
2001).  In this study, we demonstrated that DCneu vaccinations starting at two months of 
age delayed breast cancer development significantly longer in Tg mice than DNA 
vaccine, indicating that AdV-mediated neu-gene-engineered DC vaccine was superior to 
DNA vaccination in breast cancer prevention of Tg mice predestined to form mammary 
tumors.  However, there were no cases of complete prevention of breast cancer 
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development observed in DCneu immunized Tg mice.  The neu-specific self tolerance 
observed in Tg mice may account for the relatively low efficacy observed in DCneu 
immunized FVBneuN, despite expression of IL-6 that allows for partial suppression of 
Tr-mediated immune tolerance. Furthermore, regardless of the vaccine used to 
immunize mice beginning at four months of age, negligible effects were seen on the 
ability to hamper spontaneous tumor development in DCneu immunized compared to 
both DNA immunized and age-matched control mice.   
The delay observed when immunizing mice with DCneu at the younger age may 
be a result in the early generation of an effective immune response against neu but over 
time, the immune response declines in the presence of clinical tumors overexpressing 
neu (Takeuchi et al. 2004; Lo Iacono et al. 2005).  This may imply that additional 
boosters are required later on in life to maintain the immune response or perhaps alter 
the vaccination schedule for life-long administration (Astolfi et al. 2005).  By increasing 
the number of immunizations, it may activate low-avidity T cells to further stimulate 
more T cells after tolerization and elimination or to allow for the formation of a memory 
response (Lustgarten et al. 2004).  Moreover, the immune response generated at an 
earlier age and the resulting preventative effects may also reflect the histopathologic 
status of the mammary glands within these mice during the time of immunization with 
atypical hyperplasia seen at 2 months of age whereas at 4 months of age, infiltrating 
ductal carcinomas are seen (Pupa et al. 2001).  The decline in the immunopreventative 
effects of the cancer vaccine has been demonstrated by others that the age at which 
vaccinations were started could determine the overall protective effects (Cappello et al. 
2003; Provinciali et al. 2003; Sakai et al. 2004; Pupa et al. 2005).    At an older age, the 
immune system is less able to respond with impaired T cell proliferation and CTL 
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generation, cytokine secretion and Ab production (Provinciali et al. 2003).  In FVBneuN 
mice, vaccinations started at 28 weeks of age was ineffective at preventing tumors from 
forming whereas vaccinations beginning at 6 weeks followed by continuous booster 
every 4 weeks offered the greatest degree of prevention (Boggio et al. 2000).  A similar 
pattern was also confirmed in BALB-neuT immunized mice at a younger age offering a 
greater degree of protection and prevention compared to older aged mice (Boggio et al. 
1998; Boggio et al. 2000).   
Upon inducing a protective immune response, multifocal preneoplastic cells are 
inhibited (Quaglino et al. 2004a; Quaglino et al. 2004b); however, there may be some 
dormant tumor cells remaining.  Depending upon the condition, these remaining cells 
may develop into neu-negative expressing tumor cells (Knutson et al. 2004), or 
decreased MHC class I neu-positive expressing tumor cells (Lollini et al. 1998).  It may 
also, in the face of decreasing protective response allow for the neu expressing tumors to 
regrow.  Also, as the tumors begin to progress, alterations in hematopoiesis may 
generate larger amounts of immunosuppressive immature myeloid cells (Melani et al. 
2003), CD4+ T cell dysregulation and the generation of increasing number of Tr cells 
(Manjili et al. 2003; Ercolini et al. 2005) as seen in both mice and humans.  Other 
factors may also include further induction of tolerance or development of immunological 
escape of tumor cells through the secretion of immunosuppressive cytokines such as 
vascular endothelial growth factor (VEGF) and transforming growth factor β (TGF-β).  
These factors may directly impact the function of T cells or indirectly on DC (Takeuchi 
et al. 2004).  The expression of Fas-L by tumors may also induce T cell apoptosis (Cefai 
et al. 2001). 
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Overall, the results from both of our in vivo studies showed that FVBneuN mice 
are tolerant to neu but DCneu immunization was able to partially overcome this tolerance.  
Our results were similar in comparison to those obtained by Reilly et al (Reilly et al. 
2000; Reilly et al. 2001).  However, the failure to completely protect and prevent tumors 
from forming in these mice indicated that the efficiency of HER-2/neu-targeted DC-
based vaccination needs further improvement.  The addition of immunostimulatory 
cytokines may be one avenue that deserves attention.  Vaccination of DC engineered by 
two different AdV to simultaneously express a TAA such as HER-2/neu or gp100 along 
with cytokines such as TNF-α (Chen et al. 2002c), IL-12 (Chen et al. 2001a; Okada et al. 
2005) or GM-CSF (Nakamura et al. 2002) has shown augmented immunity compared to 
DC engineered to express either the TAA or cytokine alone.  Therefore, DC engineered 
to express both tumor Ag and cytokine gene may represent a new powerful direction in 
DC-based vaccine to improve and strengthen antitumor immunity.   
The reduced efficacy of pcDNAneu DNA vaccine in generating anti-HER-2/neu 
immunity compared to DCneu vaccine may be derived from the following reasons.  As 
indicated above, immunization using naked DNA relied on the uptake of DNA by host 
APC (Condon et al. 1996; Akbari et al. 1999).   Defective APC function in situ has been 
documented in tumor-bearing mice and may in part explain the failure in induction of 
effective immunity using plasmid DNA in these studies (Chaux et al. 1997; Troy et al. 
1998).  Secondly, it has also been reported that DNA vaccination induced low level of 
CTL activity and often failed in breaking immune tolerance in animal models (Rovero et 
al. 2000).  Another important factor may stem from the reduced number of 
immunizations/boosters with the DNA plasmid used in our study compared to other 
reports that have varying immunization protocols ranging from a total of 3 
 159
immunizations to continuous boosting throughout the entire study period for the rest of 
their life (Amici et al. 1998; Chen et al. 1998).   The number of injections may be a 
critical factor, as noted by Bellone et al. whereby mice immunized 3 times with an 
OVA-DNA vector provided a similar level of protection just as effective as a single dose 
of OVA I peptide pulsed DC vaccine (Bellone et al. 2000), clearly supporting the 
strength of DC-based vaccinations. 
Taken together, we have demonstrated that AdV-mediated HER-2/neu-gene-
modified DC vaccine is more potent than DNA vaccine in both protective and 
preventive animal tumor models in our side-by-side comparison study.  Therefore, DC 
genetically engineered to express tumor Ag such as HER-2/neu are likely representative 
of a new direction in DC-based vaccine of breast cancer. 
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4.2 Xenogeneic approach utilizing adenovirus mediated transfer of human HER-
2 into dendritic cells to overcome self tolerance to rat neu 
 
4.2.1 HER-2 adenovirus creation and DC expression 
Previous studies have utilized the human HER-2 gene for DNA-based 
immunization against neu-expressing tumors in both normal and Tg mouse models (Wei 
et al. 1999; Pilon et al. 2001).  More recently, the use of human HER-2 DNA-based 
vaccine was shown to prevent the formation of spontaneous tumors in FVBneuN Tg 
mice, thus acting as a form of xenogeneic immunization (Pupa et al. 2005).  Therefore, 
we employed similar methods in the previous section to create a recombinant AdV 
containing human HER-2 and subsequently used the AdV for transduction of DC.  The 
full length HER-2 gene was cloned from cDNA obtained from a HER-2 expressing 
breast tumor cell line.  To address the potential safety issue, site directed mutagenesis 
was performed to inactivate ATPase activity within the kinase domain (Ben-Levy et al. 
1994; Wei et al. 1999), rendering the expressed gene kinase deficient.  The recombinant 
adenovirus was amplified, purified by two-rounds of CsCl ultracentrifugations and 
dialyzed.  PCR analysis was performed to verify the resulting AdV construct contained 
the appropriate transgene.   
As shown in Figure 4.16A, the analytical gel from PCR analysis revealed that the 
final purified product (lane F) does indeed contain the transgene with the generation of a 
2,277 bp product.  Both water and plasmid backbone vector served as negative controls 
(lane A and B, respectively) and the shuttle vector containing the transgene as the 
positive control (lane C).  Both the crude viral lysate (lane D) and culture media (lane E) 
from 293 infected cells produced similar bands, which supported the detection of HER-2 
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within the final purified AdV preparation.  As well, expression of the HER-2mut 
transgene product was clearly detected in AdVHER-2mut transduced DCs (DCHER-2mut) 
using the anti-HER-2 specific antibody (Herceptin), generously supplied by Dr. Sami 
from the Saskatoon Cancer Centre, while no expression of HER-2 was detected in 
nontransduced DC (Figure 4.16B). 
 
4.2.2  Examination of DCHER2mut ability to induce protective and preventive 
antitumor immunity in mice 
To examine the utility of a xenogeneic DC vaccine expressing HER-2mut against 
neu expressing tumors, a proof of principle study was performed.  This allowed us to 
determine whether prophylactic immunization of mice with a DCHER2mut vaccine induced 
immunoprotective effects by protecting the mice from developing tumors upon tumor 
challenge.  Previous immunizations with DCneu in wildtype mice provided strong 
antitumor protective responses (Section 4.1.5; Figure 4.6) but failed to do so in the 
FVBneuN Tg mice (Figure 4.7), so FVBneuN Tg mice were used to determine if 
tolerance could be overcome against neu.  We found that FVBneuN mice (n=10/group) 
immunized with DCHER2mut followed by a boost two weeks later showed the greatest 
potential with significantly enhanced survival by delaying tumor growth compared to 
mice injected with only PBS (P <0.0001; Log-rank).  As a comparison, immunization of 
FVBneuN Tg mice with DCneu saw only a minimal, but still a significant delay in tumor 
growth compared to mice injected with PBS only (P <0.05; Log-rank). Albeit, prolonged 
tumor free survival was observed in all of the vaccinated mice but all of the mice 
eventually developed progressively growing tumors.  This suggested that the tolerance 
to rat neu was not completely overcome.   
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Figure 4.16  AdVHER2mut construction and gene expression verification.  A.  PCR gene 
analysis.  The samples were loaded onto a 1% agarose gel after 30 cycling reactions.  
Controls include a water control (A); the backbone vector, pAdEasy-1 (B); the 
recombinant vector, pAdEasyHER2mut (C).  Samples include the crude viral lysate from 
infected cells (D), the infected culture media (E) and the purified AdVHER2mut (F).  The 
presence of the 2.1 kb band indicated the presence of the HER2 gene within the viral 
vectors.  B.  Flow cytometric analysis of HER-2 expression.  The expression of HER-2 
on the cell surface of DC and DCHER2mut was analyzed by staining the cells with human 
anti-HER-2 Ab followed by incubation with anti-human IgG-FTIC Ab (dark line).  
Isotype matched mAb (faint band). 
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Figure 4.17  Vaccination of FVBneuN mice with DCHER2mut improves survival.  
FVBneuN mice (10 per group) were immunized twice with 1x106 DCneu (▲) or 
DCHER2mut (■) s.c. or with PBS (▼).  Mice were challenged with 0.3x106 Tg1-1 cells 
and survival was monitored closely for tumor development and survival.  A Kaplan 
Meier plot of survival is shown and log-rank tests performed to compare survival 
between the different groups.  * P<0.05, ** P<0.0001; note that between DCHER2mut and 
DCneu P=0.003. 
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With the encouraging results seen from the previous animal study, we moved on 
to examine the effects of vaccinating FVBneuN Tg mice (n=15-20/group) with DCHER-
2mut or PBS alone.  The Tg mice were immunized with 1x106 DCHER-2mut cells beginning 
at two months of age and every 4 weeks thereafter, for a total of 3 times.  The 
development of spontaneous tumors was closely monitored with all mammary glands 
palpitated weekly.  We found the age-matched control mice, injected with only PBS, all 
developed tumors within 5 to 7 months of age (Figure 4.18A), which was within the 
range normally observed in our previous Tg animal study (Figure 4.13 and 4.15). Mice 
vaccinated with DCHER2mut showed a significant delay in the development of its first 
detectable spontaneous breast tumor (P<0.0001; Log-rank).  In addition, DCHER2mut 
immunized mice developed less mammary tumors on average (2.1 mammary tumors at 
38 weeks) compared to the PBS age-matched controls with 3.6 mammary tumors during 
the same period (Figure 4.18B).  However, this alone was not sufficient to successfully 
prevent tumors from growing as all of the mice eventually developed spontaneous 
tumors.   
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Figure 4.18  The effect of vaccination on tumor development in transgenic mice.  (A).  
FVBneuN mice (8 weeks old; n=15-20/group) were given three injections of 1x106 
DCHER2mut (▲) s.c. at 4-week intervals (indicated by arrows) or with PBS (■) then 
continually monitored for development of spontaneous tumors.  Mice with at least one 
mammary tumor were classified as tumor bearing.  Tumor incidence was significantly 
delayed in DCHER2mut immunized mice (*, P<0.0001, log-rank test).  (B), The mean 
tumor multiplicity (mean number of tumors per mouse) in both PBS and DCHER2mut 
immunized mice was recorded throughout the same time. *, P<0.0001 (Student’s t test). 
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4.2.3 Discussion 
The use of xenogeneic approach in cancer vaccines attempts to utilize the 
“foreignness” of an Ag to overcome tolerance and mount a protective immune response 
against a “self” Ag (Wei 2002).  Xenogeneic immunization strategies have mainly been 
associated with the use of DNA or protein based vaccines.  Some of the Ags previously 
used included human gp100 (Gold et al. 2003; Yamanaka and Xanthopoulos 2005), 
tyrosinase related protein-1 TRP-1/gp75 (Naftzger et al. 1996; Weber et al. 1998) and 
EGFR (Lu et al. 2003) to overcome self-tolerance and reject syngeneic tumors in  mouse 
animal models.   
Recently, xenogeneic immunization strategies have been examined for use to 
target HER-2/neu.  Protein immunization of rats utilizing human ICD generated 
significantly higher titer levels of HER-2 and neu-specific Abs as well as T cell 
responses compared to respective controls (Disis et al. 1998).  Further studies by Pupa 
have shown the ability of DNA xenoimmunization in BALB-neuT Tg mice with either 
the full-length or the ECD-TM portion of human HER-2 to induce antitumor immune 
responses that delayed tumor growth (Pupa et al. 2001; Pupa et al. 2005).  When the full 
length of HER-2 was used in the vector, VR1012/HER-2-FL, a significant delay in the 
formation of spontaneous tumors with over 60% remaining tumor free at 50 weeks of 
age was seen (Pupa et al. 2001).  All of the control mice developed tumors by the 36th 
week of age.  When only the ECD-TM portion was used in the vector, VR1012-ECD-
TM, only 25% of the Tg mice remained tumor free (Pupa et al. 2005).  This suggested 
that the inclusion of the ICD may contain additional helper epitopes to generate 
protective immune responses and provided a basis for us to create an AdV containing 
the full length HER-2 gene, AdVHER2mut, for use in a DC-based vaccine.  In a recent 
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report, an AdV containing the full-length HER-2 gene created by another group was 
used to directly immunize BALB-neuT Tg mice.  This immunization strategy led to the 
induction of a humoral and cellular response that slightly delayed the onset of 
spontaneous tumors (Gallo et al. 2005). 
 The initial in vivo studies utilizing AdV mediated transfer of HER-2 into BM 
derived DC (DCHER2mut) provided proof that prophylactic immunization of neu-tolerized 
FVBneuN mice at high risk of developing breast tumors provided a benefit to some 
degree.  When mice were challenged with a lethal dose of 3x105 Tg1-1 tumor cells, 
DCHER2mut immunization significantly delayed the formation of tumors and increased 
their overall survival whereas PBS immunized mice all succumbed to large tumors by 
day 27.  Furthermore, we found that immunization of mice with DCHER-2mut was more 
effective at delaying tumor growth when compared to mice immunized with DCneu.  This 
suggested DCHER2mut was able to break the tolerance in FVBneuN Tg mice to rat neu.  
From this animal study, it showed that the use of the human HER-2 gene provided 
stronger protective immunity than using the syngeneic neu gene in a DC vaccine.  For 
the prevention of spontaneous tumors from forming, immunization of mice with 
DCHER2mut delayed the formation of mammary tumors and significantly reduced the 
number of mammary tumors formed to an average of 2.1 tumors compared to an average 
of 3.6 tumors seen in control group mice.  Although there was a significant delay 
observed in DCHER-2mut immunized mice, all of the mice eventually developed tumors.  
Our results contrasts the results obtained by Pupa et al whereby they found 70% of their 
vaccinated mice remained tumor free (Pupa et al. 2005).  However, it is rather difficult 
to compare their model system with our model system, as we did not perform DNA 
vaccination in our study.  As well, the number of vaccinations/boosts may be an 
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indicator since we only used three monthly immunizations, while Pupas’ study in Tg 
mice received a total of 10 monthly vaccinations.  It is also extremely difficult to assess 
the differences without determining the actual immune mechanisms involved as well as 
determining the role that the endogenous murine neu Ag has with autoimmunity and 
cross-reactivity (Concetti et al. 1996; Lin et al. 2004; Pupa et al. 2005).  These immune 
mechanisms will need to be further analyzed to fully understand and compare the data.  
 Xenogeneic HER-2 immunization provides a source of Ag that not only encodes 
for peptides that are identical but may also be completely different from that of rat neu 
throughout the protein.  One mechanism of action may arise from slight alterations 
within known peptide epitopes, acting in a heteroclitic peptide fashion.  This heteroclitic 
peptide may have several AA residues altered that would increase the binding efficacy 
on MHC class molecules therefore acting as a better agonist than the native peptide in 
inducing immune responses (Scardino et al. 2002; Gold et al. 2003).  The recently 
identified immunodominant MHC class I neu peptide in FVB mice is PDSLRDLSVF 
(RNEU420-429).  This peptide was altered to become PASLRDLSVF (RNEU420-429A2), as 
determined by alanine substitution, resulting in increased T cell stimulatory activity.  
The modified peptide used in a DC-peptide vaccine revealed enhanced protection in 
FVB/N and FVBneuN mice (Ercolini et al. 2003).  In comparing the HER-2 aa sequence 
with neu for the same region (Figure 1.1), only a single aa change (PDSLPDLSVF) is 
found, which may potentially increase the binding affinity to MHC class I molecules to 
account for the overall improved survival seen in our experiments.  The use of these 
heteroclitic peptide may stimulate T cells specifically recognizing not only the 
heteroclitic peptide sequence but also activate T cells against the native peptide (Trojan 
et al. 2001).  It has also been recently documented that FVBneuN mice are already 
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tolerized to the immunodominant T cell epitope, thus failing to induce a response, 
(Ercolini et al. 2003; Murata et al. 2006) and this may account for the lack of overall 
effective protection.  However, it cannot be ruled out that epitope spreading or the 
generation of cryptic and subdominant epitopes may also be involved with the enhanced 
protection observed, as previously observed when using Listeriolysin O with rat neu 
(Singh et al. 2005).  It is also interesting to note that the aa sequences between the rat 
and mouse protein is 94.8% homologous (Nagata et al. 1997) and within the defined 
dominant epitope, there is a difference of 3 aa (PESFQDLSVF).  These xenogeneic 
immunization strategies may potentially form cross-reactive Abs against the mouse form 
of neu, which remains endogenously expressed at low levels on adult mouse epithelial 
cells (Quaglino et al. 2004a; Pupa et al. 2005). 
Overall, this strategy attempts to develop cross-reactive immune responses 
against a self-Ag and detailed immune protective mechanisms involved will need to be 
examined.  Xenogeneic immunization strategies have previously been utilized 
successfully in DC-based vaccines.  In a recent report utilizing murine BM DC 
transfected with DNA plasmid vectors encoding the human survivin gene, a substantial 
protective immunity in a C57BL/6 model of glioma was observed (Ciesielski et al. 
2006).  Furthermore, patients with metastatic prostate cancer were immunized with DC 
expressing murine prostatic acid phosphatase (PAP) in a clinical study and 11 out of 21 
patients developed T cell proliferative responses (Fong et al. 2001a).  More importantly, 
six of these patients developed clinically stabilized disease and the immune responses 
generated cross-reacted with the human PAP.  Therefore, by combining the 
powerfulness of DC-based vaccines loaded with xenogeneic Ags or “altered self”, 
another arsenal weapon is available as a candidate for a cancer vaccine. 
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4.3 PART B – Enhancement of T cell immunity induced by DC phagocytosis of 
HSP70-transfected tumor cells on antitumor immunity 
 
4.3.1 Tumor cell apoptosis induced by in vitro irradiation 
 To study the potential effect of HSP70 in DC-mediated antitumor immunity, we 
selected two tumor cells lines EG7 and MCA-26 (MCA) based upon their expression of 
HSP70 (Figure 4.19A) in this study.  EG7 cells expressed HSP70 while MCA cells 
lacked the expression of HSP70.  In addition, we constructed an expression vector 
pcDNA-HSP70 and further transfected MCA-26 tumor cells with this vector. As shown 
in Figure 4.19A, the transfected tumor cell line MCA-26/HSP70 (MCA/HSP) expressed 
HSP70 after vector transfection.  Next, MCA, MCA/HSP and EG7 tumor cells were 
irradiated with 5,000 and 1,000 rad, respectively, to induce tumor cell apoptosis.  MCA 
tumor cell apoptosis occurred in two phases, an early and late phase, in relation to time.  
The early phase was characterized by expression of PS on the cell membrane as detected 
by Annexin V-FITC and the late phase characterized by expression of HSP70 detected 
by anti-HSP70 antibody (Chen et al. 2001c), at 12 and 48 hr after irradiation, 
respectively (Figure 4.19B and C, respectively).  These cells were termed MCA-E for 
cells during the early apoptotic phase and MCA-L for cells in the late apoptotic phase.  
Both MCA/HSP and EG7 tumor cells expressed HSP70 before irradiation, but not PS.  
After irradiating and in the early phase of apoptosis, these cells expressed PS and 
HSP70, whereas, in the late phase of apoptosis, enhanced expression of both PS and 
HSP70 was detected (Figure 4-19 B and C).  Based upon the different stages of 
apoptosis, these tumor cells were termed MCA/HSP-E, MCA/HSP-L, EG7-E and EG7-
L, respectively.  
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Figure 4.19  Induction of tumor cell apoptosis by irradiation.  A.  HSP70 expression in 
tumor cells.  Non-treated tumor cells were stained with anti-HSP70 antibody and 
expression detected by flow cytometry.  Next, the MCA, MCA/HSP and EG7 tumor 
cells were irradiated in vitro with 5,000 and 1,000 rad, respectively, cultured in DMEM 
plus 10% FCS for 12 and 48 hr, and then harvested. The original (dotted lines) and 
apoptotic (solid lines) tumor cells were then analyzed using Annexin V-FITC (B) and 
anti-HSP70 antibody (C) by flow cytometry. One representative experiment of two is 
shown. 
 172
4.3.2 Enhanced maturation of DC with phagocytosis of apoptotic tumor cells 
expressing HSP70 
DC used in this study were derived from mouse bone marrow cells cultivated in 
culture medium in the presence of IL-4 and GM-CSF. These DC showed (i) typical 
morphologic characteristic of DC with numerous dendrites and (ii) the expression of 
MHC II, CD54 (ICAM-1), CD80 and CD86 (Figure 4.20), indicating that they were 
relatively mature DC (Chen et al. 2002b). After physical contact with apoptotic MCA 
tumor cells in culture, DC displayed phagocytosed apoptotic tumor cell in the 
cytoplasm, as shown by electron microscopy (Figure 4.21).  To quantify the amount of 
apoptotic cells phagocytosed by DC, CFSE-labeled apoptotic MCA-E and MCA/HSP-E 
tumor cells (in early phase of apoptosis) or apoptotic MCA-L tumor cells (in late phase 
of apoptosis) were used for physical contact with DC in culture followed by flow 
cytometric analysis.  Approximately 44-48 % of DC displayed the phagocytosed CFSE-
apoptotic tumor cells in their cytoplasm by flow cytometric analysis (Figure 4.22), 
indicating that BM-derived DC phagocytosed an equal amount of apoptotic cells in both 
the early and late phases of apoptosis, irregardless of HSP70 expression.  
To verify whether further DC maturation was accompanied by phagocytosis of 
apoptotic tumor cells expressing HSP70, DC were further subjected to flow cytometric 
analysis.  DCMCA-E with phagocytosis of MCA-E tumor cells without expression of 
HSP70 expressed similar amount of MHC II, ICAM-1, CD80 and CD86 as DC without 
phagocytosis, when comparing the levels in Figure 4.23 with Figure 4.20.  Both DCMCA-
L and DCMCA/HSP-E, which had phagocytosed apoptotic MCA-L or MCA/HSP-E tumor 
cells expressing HSP70, respectively, displayed an upregulated expression of the above 
molecules, compared to DCMCA-E with phagocytosis of apoptotic MCA-E tumor cells  
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Figure 4.20  Phenotypic analysis of cultured dendritic cell.  Bone-marrow derived DC 
were cultured in the presence of GM-CSF and IL-4.  Flow cytometric analysis was 
performed to examine the cell surface expression of MHC class II (Iab), CD54 (ICAM), 
CD80 and CD86.  Irrelevant isotype-matched antibodies were used as controls (light 
shaded dotted line).  One representative experiment of two is shown. 
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Figure 4.21  Ultrastructural observation of apoptotic tumor cells and dendritic cells 
(DC). (A) Apoptotic MCA tumor cells were induced by irradiation (5,000 rad) 
treatment. Note the marked cytoplasmic condensation and blebs that form apoptotic 
bodies (arrow). (B) The apoptotic tumor cell (arrow) within the cytoplasm of DC that 
was co-cultured with apoptotic tumor cells overnight.    
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Figure 4.22  Flow cytometric analysis of apoptotic tumor cells phagocytosed by 
dendritic cells.  DC (solid lines) were incubated with CFSE-labeled apoptotic tumor 
cells for 24 hr at 37oC, purified with Ficoll-Paque gradient then analyzed by flow 
cytometry.  DC alone were used as the control (dotted lines).  
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without HSP70 expression (Figure 4.23).  In fact, DCMCA/HSP-E had a more significant 
increase in the expression of these molecules compared to DCMCA-L and DCMCA-E.   
DCMCA/HSP-L, DCEG7-E and DCEG7-L with phagocytosis of apoptotic MCA/HSP-L, EG7-E 
and EG7-L tumor cells expressing HSP70 all displayed an up-regulation of the above 
molecules (similar to the data seen in Figure 4.23), indicating that the expression of 
HSP70 on apoptotic tumor cells further stimulated DC maturation after DC 
phagocytosis.  Interestingly, DCEG7-E displayed more OVA peptide-MHC class I 
complex (pMHC I) expression than DCEG7-L, as detected by flow cytometry using anti-
pMHC Ab obtained from Dr. Germain from National Institutes of Health (NIH; 
Bethesda MD), even though they expressed similar amounts of MHC I Ag (Figure 4.24).  
This may be indicative of the ability for DCEG7-E to cross-present OVA more efficiently 
to T cells than DCEG7-L as there would be more peptide-bound to the grooves of MHC 
molecules to activate T cells.  
 
4.3.3 Enhanced CD8+ T cell proliferation induced by DC with phagocytosis of 
HSP70-expressing tumor cells in early phase of apoptosis 
 DC are known to be potent stimulators of primary mixed lymphocyte reaction 
(MLR) and induce the proliferation of allogeneic CD8+ T cells in vitro (Inaba et al. 
1987).  To assess this function, we compared DC which had phagocytosed apoptotic 
tumor cells with or without HSP70 expression in regards to their effect on primary 
allogeneic MLR.  As shown in Figure 4.25A, both DCMCA-L which had phagocytosed 
apoptotic MCA-L and DCMCA/HSP-E which had phagocytosed MCA/HSP-E tumor cells 
expressing HSP70 more strongly stimulated allogeneic C57BL/6 T cell proliferation in 
comparison to DCMCA-E with phagocytosis of MCA-E lacking HSP70 
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Figure 4.23:  Phenotypic analysis of DC which had phagocytosed apoptotic tumor cells 
by flow cytometry. DC with phagocytosis of apoptotic MCA-E (early phase of 
apoptosis), MCA-L  (late phase of apoptosis), MCA/HSP-E (early phase of apoptosis) 
were termed DCMCA-E, DCMCA-L, and DCMCA/HSP-E and analyzed to measure surface 
expression (solid lines) of MHC class II antigen, ICAM-1, CD80 and CD86 molecules 
by flow cytometry.  Irrelevant isotype-matched antibodies were used as controls (dotted 
lines). One representative experiment of two is shown.  
 178
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.24  pMHC I complex expression. DC with phagocytosis of apoptotic EG7 
tumor cells in early or late phase of apoptosis (solid lines) were analyzed using anti-
MHC I and pMHC I antibodies, respectively, by flow cytometry. Irrelevant isotype-
matched antibodies were used as controls (dotted lines). One representative experiment 
of two is shown. 
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Figure 4.25  Mixed lymphocyte reaction. (A) Irradiated DCMCA-E, DCMCA-L, DCMCA/HSP-
E and DCMCA/HSP-L which had phagocytosed apoptotic MCA and MCA/HSP tumor cells 
starting with 0.4x105 cells/well and its reciprocal dilutions were added to 1X105 
allogeneic C57BL/6 T cells. Irradiated DCEG7-E and DCEG7-L which had phagocytosed 
apoptotic EG7 tumor cells starting with 0.4x105 cells/well) and its reciprocal dilutions 
were added to  (B) allogeneic T cells or (C) CD8+ T cells (1x105 cells/well) derived 
from BALB/c or OTI mice, respectively. Cells were co-cultured for 3 days. [3H]-
thymidine uptake after overnight incubation is expressed as the mean of three 
determinations. *, P<0.05 versus cohorts of DCMCA-E or DCEG7-L (Student’s t test). One 
representative experiment of three is shown. 
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expression (P<0.05; Student’s t test).  In addition, DCMCA/HSP-L was also shown to 
efficiently stimulate T cells just as effectively as DCMCA/HSP-E did.  This suggested that 
DC with phagocytosis of apoptotic MCA tumor cells in the late phase of apoptosis are 
more immunogenic than DC with phagocytosis of apoptotic tumor cells in early phase of 
apoptosis, when MCA tumor cells lack the induced endogenous expression of HSP70.  It 
also showed that when increasing levels of HSP70 expression was present, as seen in 
DC phagocytosis of the MCA-HSP-E and –L cells, allogeneic T cell stimulatory activity 
was comparable to each other.   
Another MLR assay was performed to assess the stimulatory effect of DCEG7-E 
and DCEG7-L on allogeneic BALB/c T cells.  As shown in Figure 4.25B, both DCEG7-E 
and DCEG7-L with phagocytosis of endogenous HSP70-expressing apoptotic EG7 tumor 
cells stimulated allogeneic T cell proliferation to a similar extent.  Furthermore, to assess 
the stimulatory effect of DCEG7-E and DCEG7-L on OVA-specific CD8+ T cells, we further 
performed OVA-specific T cell proliferation assay using CD8+ T cells derived from 
OVA-specific TCR-Tg OTI mice.  As shown in Figure 4.25C, DCEG7-E significantly 
enhanced OVA-specific T cell proliferation in vitro in comparison to DCEG7-L (P<0.05; 
Student’s t test).   To further confirm this, we conducted an in vivo T cell proliferation 
experiment using OVA-specific tetramer staining to enumerate the number of OVA-
specific T cells.  As shown in Figure 4.26, vaccination of mice with DCEG7-E and DCEG7-
L stimulated 2.5 % and 1.5 % OVA-specific CD8+ T cells of the total CD8+ T cell 
population using OVA-specific tetramer staining.  This indicated that DC with 
phagocytosis of apoptotic EG7 tumor cells endogenously expressing HSP70 during the 
early phase of apoptosis is more immunogenic than DC with phagocytosis of apoptotic 
EG7 tumor cells in the late phase of apoptosis. 
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Figure 4.26  In vivo T cell proliferation assay. C57BL/6 mice were also i.v. immunized 
with irradiated DCFG7-E and DCEG7-L (5x105 cells) which had phagocytosed apoptotic 
EG7 tumor cells. Six days subsequent to immunizations, tail blood samples were 
incubated with PE-H-2Kb/OVAI tetramer and FITC-anti-CD8 Ab according to the 
company’s protocol and samples were analyzed by flow cytometry. One representative 
experiment of three is shown. 
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4.3.4 Enhanced CD8+ CTL responses induced by DC with phagocytosis of HSP70-
expressing tumor cells in early phase of apoptosis 
To examine the cytotoxic effect of CTL responses, we performed chromium 
release assays.  Splenocytes from mice immunized with either DCMCA-E, DCMCA-L, 
DCMCA/HSP-E, DCMCA/HSP-L, DCEG7-E and DCEG7-L were co-cultured with irradiated MCA 
or EG7 tumor cells, respectively.  After 4 days in culture, T lymphocytes were harvested 
and analyzed by flow cytometry.  These T lymphocytes, which consisted mainly of 
CD8+ T cells were used as effector cells in a chromium release assay.  As shown in 
Figure 4.27A, T lymphocytes derived from mice vaccinated with DCMCA-L which had 
phagocytosed apoptotic MCA tumor cells expressing HSP70 significantly displayed 
stronger cytotoxicity to MCA tumor cells (34 % specific killing at an E:T cell ratio of 
50) than those of mice vaccinated with DCMCA-E that phagocytosed early phase HSP70-
negative expressing apoptotic MCA  tumor cells (20 % specific killing at an E:T cell 
ratio of 50) (P<0.05; Student’s t test).  On the other hand, T lymphocytes derived from 
mice vaccinated with DCMCA/HSP-E had a slight but still a significantly stronger 
cytotoxicity to MCA tumor cells than DCMCA/HSP-L (P<0.05; Student’s t test) (Figure 
4.27B).  As shown in Figure 4.27C, DCEG7-E also induced significantly more efficient T 
cell cytotoxic activity towards EG7 tumor cells (47% specific killing at an E:T cell ratio 
of 25) compared to than DCEG7-L (33% specific killing at an E:T cell ratio of 25) 
(P<0.05; Student’s t test).  Overall, our data indicated that vaccination of DC which had 
phagocytosed HSP70-expressing apoptotic tumor cells in early phase of apoptosis can 
induce more efficient tumor-specific CTL responses than DC with phagocytosis of 
HSP70-expressing apoptotic tumor cells in the late phase of apoptosis or apoptotic 
tumor cells in early phase of apoptosis lacking the endogenous induced HSP70  
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Figure 4.27  Cytotoxicity assay. Spleen lymphocytes were harvested from mice one 
week subsequent to immunization of (A) DCMCA-E and DCMCA-L, (B) DCMCA/HSP-E and 
DCMCA/HSP-L, (C) DCEG7-E and DCEG7-L, and cultured with irradiated MCA and EG7 
tumor cells for 4 days, respectively. T cells were then harvested and used as effector 
cells, whereas [51Cr]-chromate radiolabeled MCA and EG7 tumor cells were used as 
target cells. To confirm MCA and EG7 tumor specific T cell cytotoxicity, [51Cr]-labeled 
A20 and EL4 cells were used as target controls. Each point represents the mean of 
triplicates. *, P<0.05 versus cohorts of DCMCA-E, DCMCA/HSP-L or DCEG7-L (Student’s t 
test). The experiment was repeated once with similar results.     
 184
expression.  The above CTL responses were specifically against MCA and EG7 tumor 
cells with minimal cell cross reactivity with A20 and EL4 tumor cells, respectively, 
(Figure 4.27 A, B &C). 
 
4.3.5 Enhanced antitumor immunity induced by vaccination of DC with 
phagocytosis of HSP70-expressing tumor cells in early phase of apoptosis 
To examine whether DC which had phagocytosed HSP70-expressing apoptotic 
tumor cells were capable of inducing enhanced antitumor immunity in vivo, mice were 
vaccinated twice s.c. with the above DC then challenged with MCA or EG7 tumor cells.  
As shown in Figure 4.28A, 5 out of 10 mice vaccinated with DCMCA-L which had 
phagocytosed apoptotic MCA-L tumor cells, were protected against MCA tumor cell 
challenge, compared to 20% (2 out of 10 mice) vaccinated with vaccination of DCMCA-E.  
However, mice vaccinated with DCMCA/HSP-E that phagocytosed HSP70-expressing 
apoptotic tumor cells protected 90% of mice from MCA tumor cell challenge, in 
comparison to the modest 60% protection seen in mice vaccinated with DCMCA/HSP-L 
(Figure 4.28B).  Interestingly, similar results were obtained from groups of mice 
vaccinated with DCEG7-E and DCEG7-L.  As shown in Figure 4.28 C, DCEG7-E vaccination 
provided complete protection [10 out of 10 mice (100%)] from EG7 tumor challenge, 
whereas DCEG7-L vaccination resulted in only 70% (7 out of 10) protection.  This clearly 
indicated that the vaccination of DCs that had phagocytosed HSP70-expressing 
apoptotic tumor cells in early phase of apoptosis induced the strongest protective 
antitumor immunity in both MCA and EG7 tumor models.   
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Figure 4.28  Vaccination of mice with DC with phagocytosis of apoptotic tumor cells. 
Mice (n = 10 per group) were vaccinated s.c. with irradiated (A) DCMCA-E and DCMCA-L, 
(B) DCMCA/HSP-E and DCMCA/HSP-L, (C) DCEG7-E and DCEG7-L, which had phagocytosed 
apoptotic MCA, MCA/HSP and EG7 tumor cells in early or late phase of apoptosis.  
Mice injected with PBS were used as controls.  Ten days after final immunization, mice 
were challenged by s.c injection of 5x105 MCA or EG7 tumor cells.  Animal mortality 
and tumor growth were monitored daily for up to 8 weeks. One representative 
experiment of three is shown. 
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4.3.6 Discussion 
Radiation has been found to induce tumor cell apoptosis through both the death 
receptor and the mitochondrial pathways (Guan et al. 2001; Schumacher et al. 2001; 
Friedman 2002), which is one of the methods favored for tumor Ag release.  There has 
been several phases characterized in programmed cell death (Medzhitov and Janeway 
1997; Somersan et al. 2001).  This ranges from early phase apoptosis with PS exposure 
on the cell surfaces to late phase apoptosis, also defined as secondary necrosis, 
characterized by DNA damage revealed by using PI staining (Somersan et al. 2001) and 
the expression of  HSP (Feng et al. 2001).  HSPs belong to a family of inducible 
intracellular molecular chaperone proteins that act as key elements in the protein-folding 
machinery of the cells and are involved with crucial immunological functions (Castelli 
et al. 2004).  
 Srivastava and Amato first identified HSP as the component in tumor lysates, 
which protected mice from a subsequent tumor challenge (DeLeo and Srivastava 1985). 
Initial studies focused on vaccination with endogenous HSP purified from tumor cells. 
Despite encouraging results with this strategy in mouse models (Tamura et al. 1997; 
Kovalchin et al. 2001) and in humans (Janetzki et al. 2000; Belli et al. 2002), 
purification of HSP from tumor cells is a labor-intensive and time-consuming procedure. 
Other strategies involve purification of recombinant HSP from bacterial or mammalian 
cells (Roman and Moreno 1996; Blachere et al. 1997). There are, however, some 
drawbacks to these strategies including the requirement for known tumor Ags to be 
associated with HSP and the contamination of preparations with immunogenic bacterial 
products (Bausinger et al. 2002; Gao and Tsan 2003).  Vaccination of tumor cells 
engineered to express or secrete HSP preserves the primary advantage of purified HSP 
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(i.e., the broad spectrum of chaperoned tumor peptides that includes unknown tumor Ag) 
without the cumbersome process of physically purifying HSP samples.  However, 
transfection of tumor cells with plasmids coding for HSP sequences has given 
contradictory results.  In some experimental models, the immunogenicity of transfected 
tumor cells is increased upon exogenous overexpression of HSP leading to enhanced 
antitumor immune responses (Todryk et al. 1999; Wang et al. 2002; Massa et al. 2004; 
Wang et al. 2004b), whereas in other models, the opposite is noted with increased cell 
tumorigenicity  (Jaattela 1995; Gurbuxani et al. 2001).  This discrepancy may be 
explained by the protective activity of HSP, which helps to prevent cells from triggering 
apoptosis in response to stressful stimuli (Jaattela 1999).  To avoid the possible 
protumorigenic activity of transfected HSP, modifications have been made to alter the 
intracellular localization of HSPs.  The cytosolic HSP70 and ER-resident HSP family 
member, gp96, have been converted into transmembrane proteins (Zheng et al. 2001; 
Chen et al. 2002a).  Secretable HSP70 from tumor cells has been shown to improve 
immunogenicity (Massa et al. 2004).  These modified HSP forms continued to maintain 
their ability to activate the immune responses against parental tumor cells.  Moreover, in 
all of these strategies the tumor antigens are taken-up by DC and cross-presented to T 
cells resulting in the generation of antitumor immune responses.  
An alternative to the previous strategy is to directly use a DC-based antitumor 
vaccine and incorporating HSP70 expression in tumor cells.  In vitro-generated DC can 
phagocytose apoptotic tumor cells via specific cellular receptors when culturing DC in 
the presence of apoptotic tumor cells.  DC that phagocytose the apoptotic tumor cells 
would thus be able to present tumor antigens to T cells and induce antitumor immunity. 
We have previously demonstrated that apoptotic tumor cells with secondary necrosis 
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induced DC maturation and subsequent vaccination of DC with phagocytosis of these 
apoptotic tumor cells in late phase of apoptosis stimulated efficient antitumor immunity 
in comparison to phagocytosis of early phase apoptotic tumors (Chen et al. 2001c).  This 
finding has been confirmed by Ip and Lau, which demonstrated that DC that 
phagocytose early and late phase apoptotic cells retain their homing ability to LN.  
However, DC that take up late phase apoptotic cells are more functionally mature 
resulting in T cell responses whereas the uptake of early apoptotic cells may result in T 
cell tolerance (Ip and Lau 2004).  Taken this into consideration, the potential critical role 
of HSP70 expression in our model system has not been fully investigated.  Reports in 
the literature have shown necrotic tumor cells expressing HSP70 can promote DC 
maturation whereas apoptotic cells cannot (Basu et al. 2000; Sauter et al. 2000).  This 
leaves the possibility that the effects of dying tumor cells on DC maturation and function 
may not only be dependent on the type of cell death (apoptosis versus necrosis), but also 
on the phase of tumor cell apoptosis (early apoptosis versus secondary necrosis) as well 
as the association of HSP70 expression.   
In this study, we demonstrated that (i) apoptotic tumor cells expressing HSP70 
and late phase apoptotic tumor cells stimulated DC maturation after DC phagocytosis of 
these apoptotic tumor cells, and (ii) DC with phagocytosis of apoptotic tumor cells 
expressing HSP70 and late phase apoptotic tumor cells induced stronger antitumor 
immunity compared to DC that phagocytose early phase apoptotic tumor cells.  In both 
of our tumor models, MCA cells expressed endogenous HSP70 only during the late 
phase of apoptosis whereas EG7 tumor cells endogenously expressed HSP70 and 
MCA/HSP overexpressed HSP70.  DC that phagocytosed MCA/HSP-E tumor cells 
resulted in a more mature DC phenotype in comparison to MCA-L and resulted in 
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similar levels of T cell proliferation observed in the MLR assays.  Also, higher levels of 
pMHC I molecules were detected on the cell surface of DCEG7-E that led to higher T cell 
proliferation of CD8+ OT I T cells both in vitro and in vivo.  These results were 
consistent with recent findings from our group using a combined radiation therapy and 
DC-based vaccine in a J558 mouse myeloma tumor model (Chen et al. 2005).  
Interestingly, we also demonstrated that our DC-based vaccine using apoptotic tumor 
cells expressing HSP70 in the early phase of apoptosis induced tumor-specific CTL 
responses more efficiently that specifically recognized the appropriate target cells.  
Furthermore, the vaccine using DC that phagocytose early phase apoptotic tumor cells 
expressing HSP70 improved vaccine efficacy in vivo compared to using DC with late 
phase apoptotic tumor cells in two MCA/HSP and EG7 tumor model systems by 
providing a higher level of protective antitumor immunity when given prophylactic 
immunization followed by tumor cell challenge.   
The results from our study may be explained based upon the immunogenic 
properties of HSP70.  It is known that HSP70 is able to trigger a “danger signal” by 
binding to DC receptors such as TLR4 (Asea et al. 2002; Vabulas et al. 2002) and CD14 
(Asea et al. 2000) through inducing NFκB activity to up-regulate costimulatory 
molecules of DC and induce secretion of proinflammatory cytokines (Basu et al. 2000).  
In addition, HSP70 inherently possess a cytokine/chemokine immunostimulatory 
sequence within the peptide binding domain that allows for the production of TNF-α, IL-
12 and CCL5 by DC, which also further enhances DC maturation (Wang et al. 2005b).  
The dual role of HSP70 as an antigenic peptide chaperone (Chandawarkar et al. 1999) 
and as a danger signal (Basu et al. 2000) makes HSP70 especially important in DC-
based vaccination for inducing antitumor immune responses.  Secondly, DC with 
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phagocytosis of apoptotic EG7 tumor cells expressing HSP70 in early phase of apoptosis 
can present more pMHC I complexes to T cells, as shown in this study.  
There have been numerous controversial reports in the literature that has shown 
necrotic tumor cells induced stronger tumor-specific CTL responses compared to 
apoptotic tumor cells in some reports (Basu et al. 2000; Sauter et al. 2000), whereas, in 
some other tumor models,  DC charged with apoptotic, but not necrotic tumor cells 
induced efficient vaccines in vivo (Goldszmid et al. 2003).  The discordance between the 
previous studies does not provide a clear distinction as to the optimal source of tumor 
Ag for DC phagocytosis of tumor cells.  It is perhaps that the discrepancies between 
these controversial findings may be derived from the different tumor models used in 
these studies, in which tumor cells may or may not express HSP70, and the levels of 
HSP70 expression in early and late phase of apoptosis may vary throughout the different 
types of tumor cell model systems.  As well, the amount of HSP70 induced may be 
variable based upon the methods used to induce necrosis and apoptosis..  .   
Taken together, our data demonstrated that HSP70 expression in apoptotic tumor 
cells further stimulated DC maturation.  Furthermore, DC with phagocytosis of apoptotic 
tumor cells expressing HSP70 in the early phase of apoptosis more efficiently induced 
tumor-specific CTL responses and immunity than DC with phagocytosis of apoptotic 
tumor cells in late phase of apoptosis.  These results may have an important impact in 
designing DC-based antitumor vaccines. 
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5.0 CONCLUSIONS AND FUTURE DIRECTIONS 
DC are the most powerful APC in the initiation and activation of immune 
responses.  To date, DC have been widely utilized in cancer vaccines to generate an 
effective antitumor immune response both in murine models and in human clinical 
studies.  We have shown in this thesis the multitude of tumor Ag sources loaded onto 
DC including the use of replication-deficient adenovirus expressing tumor Ag for 
transduction of DC and the use of DC with phagocytosis of apoptotic tumor cells 
expressing HSP70.  We demonstrated both types of tumor Ag sources in our DC-based 
vaccines were able to stimulate protective and preventive antitumor immune responses.   
HER-2/neu has proven to be an attractive Ag for immunotherapeutic targeting.  
In our study, we found that the use of AdVneu-transduced DC induced DC maturation by 
up-regulating the expression of MHC class II, costimulatory, adhesion molecules as well 
as a variety of pro-inflammatory cytokines.  DC engineered to express neu induced a 
mixed Th1/Th2 response; whereas, immunization of naked DNA plasmid expressing neu 
resulted in a low to mild induction of a Th1 response.  Moreover, immunization of 
parental FVB/N and Tg FVBneuN mice twice with DCneu afforded the greatest 
protection upon tumor challenge in contrast to DNA immunization that only resulted in 
partial to no protection in tumor challenged mice.  In Tg FVBneuN mice, immunization 
with DCneu in younger mice provided a greater delay in the formation of spontaneous 
tumors when compared to aged match control and mice immunized with DNA.    Both 
DCneu- and DNA-immunized mice, when immunized at an older age, failed to delay the 
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spontaneous tumor development in FVBneuN Tg mice.  The reduced therapeutic 
efficacy of DCneu seen in FVBneuN Tg mice may be due to the neu-specific self immune 
tolerance developed in the mice.  
 The issue of self-immune tolerance has become a critical avenue of exploration 
in determining the reasons for why the promising results obtained from animal models 
often fail in being repeatable when studies are performed in humans.  This problem can 
be addressed through development of Tg mice (both knock-in and knock-outs) that 
allow for expression of a “foreign” Ag as an endogenous Ag, and development of Ag-
specific self-immune tolerance.  We demonstrated that DCneu was only able to partially 
overcome the neu-specific tolerance within the Tg mice.  To improve the vaccine and 
address the role of Tr cells, a combination of immune modulating agents may be used 
that would act synergistically for overcoming the tolerance factors derived from Tr cells 
and potentially maximizing the antitumor immune responses of the combinational 
immunotherapies (Emens et al. 2005).  One simple method may be to delete Tr cells 
using a mAb for CD25 in combination with the immunotherapy strategy (Li et al. 2003; 
Comes et al. 2006).  Another method may be a combinatorial therapy using 
immunotherapy combining chemotherapeutic agents such as paclitaxel, doxorubicin and 
Cy (Machiels et al. 2001; Eralp et al. 2004).  It has been demonstrated that low doses of 
Cy reduces the number of Tr cells and suppresses the function of Tr (Ercolini et al. 
2005; Lutsiak et al. 2005).  Reports by Jaffee’s group have previously shown that low 
doses of Cy with allogeneic 3T3/neu cells expressing GM-CSF enhanced the efficacy of 
the vaccine and delayed tumor growth in FVBneuN mice (Machiels et al. 2001).  More 
recently, they have also shown Cy treatment increases the number of high avidity T cells 
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recognizing the immunodominant neu epitope RNEU420-429 in FVBneuN mice (Ercolini 
et al. 2005).   
  In our study, we showed that plasmid DNA vaccination provided minimal 
protection and preventative effect in the tumor models used.  However, alternative 
strategies could be used to increase the effectiveness of DNA vaccines.  One method is 
the use of a prime-boost strategy that involves priming with a DNA vaccine followed by 
the use of a viral vector to generate high levels of CD8+ effector and memory T cells 
(Woodland 2004).  This approach has been recently applied in a therapeutic model of 
neu expressing tumor cells resulting in high levels of cellular and humoral immunity 
(Wang et al. 2005a).  There are also different alternatives to the classical prime boost 
strategy such as the use of DC with or without a viral boost (Badovinac et al. 2005) or 
initially priming with AdV transduced DCs followed by peptide-pulsed DCs 
(Tuettenberg et al. 2003).  All of these methods have shown the ability to generate 
higher number of CD8+ T cells and to provide protection in the in vivo animal studies.  
Moreover, the number of boost required is also an important factor as it may assist in 
expansion of long-lived tumor specific immunity, especially in face of short-lived 
immune responses (Knutson et al. 2002; Palucka et al. 2005) 
 Another method to enhance the overall effectiveness of DC vaccines is the 
inclusion of cytokines and chemokines to act as adjuvants.  Typically, Th1 promoting 
cytokines can be used to directly transduce DCs by adenovirus-mediated gene transfer.  
On the other hand, it has also been demonstrated that injection of soluble cytokines also 
provide adjuvant effects (Disis et al. 2003).  The most commonly used cytokines for co-
immunization is IL-12 and GM-CSF that results in augmentation of the Ag-specific 
induced immune response.  Other cytokines and chemokines have also been used in 
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conjunction with DC vaccines with success in various model systems.  These cytokines 
include TNF-α (Chen et al. 2002c; Liu et al. 2004), IL-18 (Xia et al. 2004), Flt-3L (Liu 
et al. 2003) and SLC/CCL21 (Yang et al. 2004).  Interestingly, higher transduction 
efficiency can be achieved using RGD fiber modified AdV (Okada et al. 2001b; Okada 
et al. 2005) and this may allow for dual AdV transduction of DC.  This area warrants 
further consideration to further improve the DCneu vaccine to be able to overcome the 
self-tolerance found in FVBneuN mice.        
 In the case of HSP70, it truly plays a dynamic role in DC maturation and DC-
based vaccines.  Based upon the collective results from the presented studies, one may 
potentially include the use of both HSP70 and rat neu for use in a cancer vaccine.  
Another DC based vaccine could be made using a neu-expressing tumor cell line (e.g. 
Tg1-1) modified to overexpress HSP70 for enhancement of neu Ag loading.  Another 
method is based upon a recent report demonstrating that a DNA based vaccine encoding 
a fusion protein consisting of human HSP70 linked to the ECD of rat neu (forming 
NeuEDhsp70) increased the survival and reduced the metastatic potential of tumor cells 
in neu Tg mice (Kim et al. 2005a).  Alternatively, this fusion protein could also be 
utilized in a DC-based vaccine. 
 Overall, we have examined variations in designing a DC-based cancer vaccine to 
provide an effective antitumor immunity in our various tumor animal models.  Our 
results continue to validate the concept of a DC-based vaccine and will have an 
important impact on the design of future of DC-based vaccines.  This will play an 
important role for future development of immunotherapeutics in a clinical setting.  
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